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Appendix 1. Vital Statistics Terms Defined 
 
Fetal death: means death prior to the complete expulsion or extraction from its mother of a 
product of human conception, irrespective of the duration of pregnancy. Death is indicated by the 
fact that after expulsion or extraction the fetus does not breathe or show any other evidence of 
life such as beating of the heart, pulsation of the umbilical cord, or definite movement of 
voluntary muscles. In determining a fetal death, heartbeats shall be distinguished from transient 
cardiac contractions, and respirations shall be distinguished from fleeting respiratory efforts or 
gasps.
1 (Commonly referred to as “stillbirth”) 
 
Infant death: death of a liveborn infant under one year of age; includes both neonatal and 
postneonatal deaths
 3
   
 
Live birth: means the complete expulsion or extraction from its mother of a product of human 
conception, irrespective of the duration of pregnancy, which, after such expulsion or extraction, 
breathes or shows any other evidence of life such as beating of the heart, pulsation of the 
umbilical cord, or definite movement of voluntary muscles, whether or not the umbilical cord has 
been cut or the placenta is attached. In determining a live birth, heartbeats shall be distinguished 
from transient cardiac contractions, and respirations shall be distinguished from fleeting 
respiratory efforts or gasps.
1
   
 
Maternal Death: A maternal death is any death occurring while a woman is pregnant or of a 
woman within one year after delivery. This includes but is not limited to deaths resulting from 
abortions, ectopic pregnancies and all deaths during pregnancy, childbirth, puerperium or deaths 
from complications of childbirth. In the event of a maternal death, the certifying physician shall 
indicate that circumstance on the certificate of death.
2
  
 
Neonatal death:  death of a liveborn infant occurring within the first 27 days of life
3
   
 
Perinatal death:  death of a fetus of greater than 20 weeks’ gestation or death of a liveborn 
infant under 28 days of life
3
 
 
Postneonatal death:  death of a liveborn infant after the first 27 days of life, but before one year 
of age
3
   
 
 
1. Iowa Code 144.1/Title IV Public Health/Subtitle 2 Health-Related Activities Definitions  
 641.4—IAC/Genetics/Definitions 
 
2.641—5.1(135) Iowa Administrative Code 
 
3. 2005 Vital Statistics of Iowa, Iowa Department of Public Health, Center for Health Statistics. Available at: 
http://www.idph.state.ia.us/apl/common/pdf/health_statistics/2005/vital_stats_2005.   Accessed June 4, 
2013. 
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Appendix 2. Maternal—Fetal Transport 
 
Maternal-fetal transport is an essential component of modern perinatal care. All facilities in the 
state providing obstetrics need to be familiar with their own resources and capabilities in dealing 
with obstetrical and neonatal complications.  In most instances, maternal-fetal transport is 
preferable to neonatal transport. Each hospital, when transporting or accepting a transport, needs 
a system in place to facilitate a smooth transition of care in the most expeditious manner 
possible. The majority of maternal-fetal transports can be carried out by ground transportation. It 
is important for ambulance services to be equipped for maternal-fetal transport and have 
appropriately trained staff.   
 
Maternal-fetal transports must be conducted and accomplished in compliance with EMTALA 
rules and regulations; see the EMTALA reference on page 3 of these guidelines. Particular 
attention must be given to areas regarding appropriate medical screening as it relates to women 
in labor and transfer requirements. EMTALA rules do not preclude appropriate transfer of 
women in labor with careful documentation of the need for transport.   
 
The transferring hospital and physician must ensure that the skills and equipment available 
during transport will meet the anticipated needs of the maternal-fetal dyad rather than assume 
that everyone onboard an ambulance or aircraft is adequately trained. Specific attention should 
be placed on neonatal resuscitation skills. If the referring hospital chooses to set up its own 
transport for the purpose of “saving time” and getting the patient to the receiving hospital sooner, 
it must understand that it is fully responsible for the patient until arrival at the receiving 
institution. It is important that when a referring hospital refuses a transport team after it has been 
recommended, the receiving hospital document the refusal in writing.   
 
Communication between the referring and accepting physicians is critical to ensure safe 
maternal-fetal transport. Record keeping and transfer of records is also an important element of 
maternal-fetal transport. Centers for Medicare and Medicaid Services (CMS) requires that “the 
transferring hospital send to the receiving facility all medical records (or copies thereof) related 
to the emergency condition which the individual has presented that are available at the time of 
the transfer…other records (e.g., test results not yet available or historical records not readily 
available from the hospital’s files) must be sent as soon as practicable after transfer.”1  
 
Although hospitals designated as Level II and higher are expected to accept patient referrals, 
Level II Regional Centers, Level II Regional Neonatology Centers, and Level III Centers are 
expected to provide transportation services. A critical function of providers at Level II 
designated and higher hospitals is to communicate with the providers at Level I Hospitals in 
deciding whether a particular patient should be transported to the Level II Hospital, Level II 
Regional Center, Level II Regional Neonatology Center or directly to a Level III Center. Careful 
assessment of the hospital’s capabilities for perinatal management will be critical in these 
decisions. This information will need to be disseminated among the hospital staff. Providers of 
obstetric care need to know the critical gestational age limitations for their particular nursery.  
Below this gestational age, maternal-fetal transport should be utilized if delivery is anticipated 
and the circumstances permit.   
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Level III Centers are capable of providing ground and air transportation with fully staffed crews.  
Important decisions to be made jointly will include the appropriateness of transport, the best 
mode of transportation, the need for additional personnel accompanying the transport, and 
appropriate medical management to initiate prior to transport.   
 
 
1. American Academy of Pediatrics and American College of Obstetricians and Gynecologists (2012). 
Guidelines for Perinatal Care (7
th
 Edition). Chapter 4. Elk Grove Village, IL. 
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Appendix 3. Antenatal Administration of Steroids  
 
The American College of Obstetricians and Gynecologists, (ACOG), Committee on Obstetric 
Practice issued an updated ACOG Committee Opinion on antenatal administration of 
corticosteroids in 2011.
1
 
 
The Committee on Obstetric Practice makes the following recommendations regarding the use of 
corticosteroid therapy for fetal maturation during pregnancy: 
 Treatment should consist of one of the following corticosteroid courses: 
Betamethasone 12 mg given intramuscularly 24 hours apart for two doses  
     OR 
Dexamethasone 6 mg given intramuscularly 12 hours apart for four doses 
 A single course of corticosteroids is recommended for pregnant women between 24 and 34 
weeks of gestation who are at risk of preterm delivery within 7 days. 
 A single course of antenatal corticosteroids should be administered to women with PROM 
before 32 weeks of gestation to reduce the risks of respiratory distress syndrome, perinatal 
mortality, and other morbidities. 
 The efficacy of corticosteroid use at 32–33 completed weeks of gestation for preterm PROM 
is unclear based on available evidence, but treatment may be beneficial, particularly if 
pulmonary immaturity is documented. 
 There are no data regarding the efficacy of corticosteroid use before viability, and it is not 
recommended. 
 A single rescue course of antenatal corticosteroids may be considered if the antecedent 
treatment was given more than 2 weeks prior, the gestational age is less than 32 6/7 weeks, 
and the women are judged by the clinician to be likely to give birth within the next week. 
 Regularly scheduled repeat courses or multiple courses (more than two) are not currently 
recommended. 
 Further research regarding the risks and benefits, optimal dose, and timing of a single rescue 
course of steroid treatment is needed. 
 
Since infants born at 22-24 weeks are now surviving, it follows that there is no contraindication 
for antenatal steroid use in this population based on gestational age. Although the use of 
antenatal steroids for infants between 22-24 weeks gestation has been controversial in the past, 
this therapy should  be strongly considered based upon a recent study suggesting improvements 
in the survival of these infants.
2 
 
 
1. American College of Obstetricians and Gynecologists (2011).  (Practice Bulletin No. 130). Washington 
D.C. Available at: 
http://www.acog.org/Resources_And_Publications/Committee_Opinions/Committee_on_Obstetric_Practic
e/Antenatal_Corticosteroid_Therapy_for_Fetal_Maturation. Accessed June 4, 2013. 
2. Muri R, Kusuda S, Fujimura M, Neonatal Research Network Japan. Antenatal Corticosteroids Promote 
Survival of Extremely Preterm Infants Born at 22 to 23 Weeks of Gestation. J Pediatr. 2011; 159(1):110-114.
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Appendix 4. Maternal—Fetal Vital Signs in Labor 
 
After the patient in labor has been admitted and her status evaluated, ongoing intrapartum 
surveillance is necessary. The level of surveillance may vary according to predetermined risk 
factors. General care during labor should provide optimal patient comfort in addition to optimal 
fetal and maternal safety. There is no comparative data that supports optimal time intervals for 
maternal-fetal assessments for low risk clients. Therefore, determining frequency of assessments 
is based on individual clinical situations, guidelines and standards from professional 
organizations and unit policies.  
 Assessment of the quality of uterine contractions is recommend to occur at the same time 
intervals as fetal heart rate (FHR) assessment intervals defined below, in conjunction with 
vaginal examinations: this should be adequate to monitor the progress of labor and to detect 
abnormalities.   
 Maternal temperature, pulse and blood pressure should be assessed and recorded every four 
hours until membranes have ruptured and then every 1-2 hours thereafter (Ricci & Kyle, 
2008 p.335).  
 Maternal pain and interventions for pain should be assessed and recorded regularly.   
 The frequency and method (intermittent auscultation or continuous electronic fetal 
monitoring) of fetal heart rate monitoring used during labor should be based on risk factors 
and delineated by departmental policy. 
 If there are no risk factors at the time of the patient’s admission, a standard approach to 
intermittent auscultation of the fetal heart rate is to determine and record the auscultated FHR 
just after a contraction at least every 15-30 minutes in active phase, of the first stage of labor 
and at least every 5-15 minutes in the second stage of labor. Intermittent auscultation may not 
be appropriate for all pregnancies. Most of the clinical trials that compare electronic fetal 
monitoring (EFM) with intermittent auscultation have excluded subjects at high risk for 
adverse outcomes, and the relative safety of intermittent auscultation in such cases is 
uncertain.  
 When using electronic fetal monitoring during the active phase of the first stage of labor, the 
fetal heart rate should be assessed at 15-30 minute intervals and during the active pushing 
phase of the second stage of labor, at 5-15 minute intervals. 
 Interpretations of the fetal heart rate patterns during labor cannot occur without the 
evaluation of uterine contractions. Assessment of the intensity, duration, frequency and 
resting tone of uterine contractions is recommended to occur at the same time intervals as 
fetal heart rate (FHR) assessments intervals. 
 If risk factors are present on admission or appear during labor continuous electronic fetal 
monitoring is recommended. 
► During the active phase of the first stage of labor, the FHR should be determined and 
recorded at least every 15 minutes.  
► During the second stage of labor, the FHR should be determined and recorded and 
documented at least every 5 minutes if auscultation is used. If continuous fetal 
monitoring is used the fetal heart rate tracing should be evaluated at least every 5 
minutes.   
 Intermittent auscultation may not be appropriate for all pregnancies. Most of the clinical 
trials that compare electronic fetal monitoring (EFM) with intermittent auscultation have 
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excluded subjects at high risk for adverse outcomes, and the relative safety of intermittent 
auscultation in such cases is uncertain. 
 When electronic fetal heart rate monitoring is selected as the method of fetal assessment, the 
physician and obstetric personnel attending the patient should be qualified to identify  and 
assess the fetal monitor tracing.  
 When interpreting the FHR pattern consider the gestational age, prior fetal assessment, 
medications and obstetric and medical conditions (e.g. suspected intrauterine growth 
restriction, preeclampsia, and diabetes).  
 A detailed and graphic documentation of the course of events during labor should be noted, 
such as: physician or nurse presence, the patient’s position in the bed, cervical status, oxygen 
or drug administration, hypertension or hypotension, fever, amniotomy, color of the amniotic 
fluid, and maternal pushing.   
 Laboring down or delayed pushing is an approach to second stage management of labor that 
allows for passive descent of the fetus with no maternal effort despite complete 
dilation. Usually this technique is initiated with women who have regional 
anesthesia. Typically this is two hours for the nulliparous woman or until the urge to push 
(also known as the Ferguson reflex) and one hour for the multiparous woman. Delayed 
pushing has been associated with preventing negative fetal effects, a decrease in instrumental 
deliveries, a decrease in maternal fatigue, and a decrease in third and fourth degree 
lacerations and episiotomies. There is no standard guideline for the frequency of FHR 
assessment for the patient who is complete but not actively pushing, this should be defined in 
your hospital policy. 
 Tachysystole is defined as greater than 5 contractions in 10 minutes, contractions that last 
longer than 90 seconds, or increase in baseline uterine tone.   
 
Electronic Fetal Monitoring (EFM) Nomenclature Update  
The National Institute of Child Health and Human Development (NICHD) held workshops in 
2008 for the specific purpose of developing standardized and clear-cut definitions for fetal heart 
rate (FHR) tracings. The definitions that came from these workshops have now been adopted by 
the American College of Obstetricians and Gynecologists (ACOG)
2
 and the Association of 
Women’s Health, Obstetric and Neonatal Nurses (AWHONN). The Joint Commission (TJC), 
formerly called the Joint Commission on Accreditation of Healthcare Organizations (JACHO), 
also recommended standardized terminology for fetal monitoring in the July 2004 Sentinel Event 
Alert #30.
5
 The purpose for this adoption is to have all care providers using the same 
terminology for interpretation of fetal monitor strips to ensure safe and consistent patient care. 
The new definitions are listed in the tables that follow.  
   
Three Tier Fetal Heart Rate Interpretation System 
Category I FHR tracings include all of the following: 
 Baseline rate: 110-160 beats per minute 
 Baseline  FHR variability: moderate 
 Late or variable decelerations: absent 
 Accelerations: present or absent  
 
Appendix 4 
Guidelines for Perinatal Services, Eighth Edition, Appendices Updated August 2013  7 
Category II FHR tracings include all FHR tracings not categorized as category I or category  III.  
Category II tracings may represent an appreciable amount of those encountered in clinical care.  
Examples of Category II FHR tracings include any of the following: 
Baseline rate- 
 Bradycardia not accompanied by absent variability 
 Tachycardia 
Baseline FHR variability- 
 Minimal baseline variability 
 Absent baseline variability not accompanied by recurrent decelerations 
 Marked baseline variability 
Accelerations- 
 Absence of induced accelerations after fetal stimulation 
Periodic or episodic decelerations- 
 Recurrent variable decelerations accompanied by minimal or moderate baseline 
variability 
 Prolonged deceleration>2 minutes but<10 minutes 
 Recurrent late decelerations with moderate baseline variability 
 Variable decelerations with other characteristics, such as slow return to baseline, 
“overshoots,” or “shoulders” 
 
Category III FHR tracings include either: 
 Absent baseline FHR variability and any of the following 
                   -Recurrent late decelerations 
                   - Recurrent variable decelerations 
                   - Bradycardia 
   OR 
 Sinusoidal pattern 
 
 
1. American Academy of Pediatrics and American College of Obstetricians and Gynecologists (2012). 
Guidelines for Perinatal Care (7
th
 Edition) Chapter 6. Elk Grove Village, IL. 
2. American College of Obstetricians and Gynecologists, Practice Bulletin. Intrapartum Fetal Heart Rate 
Monitoring. Vol.116, No.5, November 2010. 
3. Mayberry LJ, Hammer R, Kelly C, True-Driver B, De A. Use of Delayed Pushing with Epidural 
Anesthesia:  Findings from a Randomized Controlled Trial. J Perinatol. 1999; 19(1):26-30. 
4. Ricci S, Kyle T. Nursing management during labor and birth. Maternity and Pediatric Nursing. New York, 
NY: Lippincott, Williams & Wilkins, Ch.14, p.335. 
5.    Joint Commission on Accreditation of Healthcare Organizations. Preventing Infant Death and Injury 
during Delivery. Sentinel Event Alert No. 30. Oakbrook Terrace, IL: Joint Commission on Accreditation of 
Healthcare Organizations; 2004:1-3. 
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Table 1. Definitions of Fetal Heart Rate Patterns 
 
 
Pattern 
 
                                                              Definition 
Baseline  The mean FHR rounded to increments of 5 beats per min during a 10 min 
segment, excluding: 
        – Periodic or episodic changes 
        – Periods of marked FHR variability 
        – Segments of baseline that differ by more than 25 beats per min 
 The baseline must be for a minimum of 2 min in any 10 min segment 
Baseline variability  Fluctuations in the FHR of two cycles per min or greater 
 Variability is visually quantitated as the amplitude of peak-to-trough in beats 
per min 
        – Absent–amplitude range undetectable 
        – Minimal–amplitude range detectable but 5 beats per min or fewer 
        – Moderate (normal)–amplitude range 6-25 beats per min 
        – Marked–amplitude range greater than 25 beats per min 
Acceleration  A visually apparent increase (onset to peak in less than 30 sec) in the FHR 
from the most recently calculated baseline 
 The duration of an acceleration is defined as the time from the initial change 
in FHR from the baseline to the return of the FHR to the baseline 
 At 32 weeks of gestation and beyond, an acceleration has an acme of 15 
beats per min or more above baseline, with a duration of 15 sec or more but 
less than 2 min 
 Before 32 weeks of gestation, an acceleration has an acme of 10 beats per 
min or more above baseline, with a duration of 10 sec or more but less than 2 
min 
 Prolonged acceleration lasts 2 min or more but less than 10 min 
 If an acceleration lasts 10 min or longer, it is a baseline change 
Bradycardia  Baseline FHR less than 110 beats per min 
Early deceleration  In association with a uterine contraction, a visually apparent, gradual (onset 
to nadir 30 sec or more) decrease in FHR with return to baseline 
 Nadir of the deceleration occurs at the same time as the peak of the 
contraction 
Late deceleration  In association with a uterine contraction, a visually apparent, gradual (onset 
to nadir 30 sec or more) decrease in FHR with return to baseline 
 Onset, nadir, and recovery of the deceleration occur after the beginning, 
peak, and end of the contraction, respectively 
Tachycardia  Baseline FHR greater than 160 beats per min 
Variable 
deceleration 
 An abrupt (onset to nadir less than 30 sec), visually apparent decrease in the 
FHR below the baseline 
 The decrease in FHR is 15 beats per min or more, with a duration of 15 sec 
or more but less than 2 min 
Prolonged 
deceleration 
 Visually apparent decrease in the FHR below the baseline 
 The deceleration is 15 beats per min or more, lasting 2 min or more but less 
than 10 min from onset to return to baseline 
 
Appendix 5 
Guidelines for Perinatal Services, Eighth Edition, Appendices Updated August 2013  9 
Appendix 5.   Vaginal Birth after Cesarean and Trial of Labor after Cesarean 
 
The changing views in the US related to VBAC over the past decade have been considered in 
The Iowa Perinatal Letter (“VBAC Revisited: Déjà Vu All Over Again,” vol. XIX, no. 3, p. 11, 
1998 and “VBAC: The Pendulum Swings,” vol. XXI, no. 1, p. 4, 2000) and by the American 
College of Obstetricians and Gynecologists (ACOG) in the Practice Bulletin #5 published in 
July, 1999, “Vaginal Birth After Previous Cesarean Delivery.”1 On July 10, 2010 new guidelines 
were released by ACOG. These guidelines are less restrictive than those previously issued. 
 
The following recommendations are based on good and consistent scientific evidence (Level 
A): 
 Most women with one previous cesarean delivery with a low-transverse incision are 
candidates for trial of labor after cesarean (TOLAC). They should be counseled about vaginal 
birth after cesarean (VBAC) and offered a trial of labor. 
 Epidural anesthesia may be used for TOLAC.  
 Misoprostol (Cytotec) should not be used for third trimester cervical ripening or labor 
induction in patients who have had a cesarean delivery or major uterine surgery. 
 A previous uterine incision extending into the fundus is a contraindication for TOLAC. 
 
The following recommendations are based on limited or inconsistent scientific evidence 
(Level B): 
 Women with two previous low-transverse cesarean deliveries and no contraindications who 
wish to attempt VBAC may be allowed a trial of labor. They should be advised that the risk 
of uterine rupture increases as the number of cesarean deliveries increases. 
 Use of oxytocin or prostaglandin gel for TOLAC requires close patient monitoring. 
 Women with a vertical incision within the lower uterine segment that does not extend into 
the fundus are candidates for TOLAC. 
 Women with one previous cesarean delivery with a low transverse incision, who are 
otherwise appropriate candidates for twin delivery, may be considered candidates for 
TOLAC. 
 External cephalic version for breech presentation is not contraindicated in women with a 
prior low transverse uterine incision who are not at risk for adverse maternal or neonatal 
outcomes from external cephalic version and TOLAC. 
 Those at high risk for complications (e.g. those with previous classical or T-incision, prior 
uterine rupture, or extensive transfundal uterine surgery) and those in whom vaginal delivery 
is otherwise contraindicated (e.g., those with placenta previa) are not generally candidates for 
planned TOLAC. 
 Induction of labor for maternal or fetal indications remains an option in women undergoing 
TOLAC. 
 TOLAC is not contraindicated for women with previous cesarean delivery with an unknown 
uterine scar type unless there is a high clinical suspicion of a previous classical uterine 
incision. 
 
The following recommendations are based primarily on consensus and expert opinion 
(Level C): 
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 Because uterine rupture may be catastrophic, TOLAC/VBAC should only be attempted in 
institutions equipped to respond to emergencies with physicians immediately available to 
provide emergency care. 
 After thorough counseling that weighs the individual benefits and risks of TOLAC, the 
ultimate decision to attempt this procedure or undergo a repeat cesarean delivery should be 
made by the patient and her physician. Documentation of counseling and the management 
plan should be included in the medical record. 
 
 
Other considerations: 
 The statement that physicians should be “immediately available to provide emergency 
care”1 for the woman undergoing TOLAC has had very significant implications for Iowa 
hospitals. ACOG points out that, as opposed to other obstetric complications which may 
arise without warning, TOLAC attempts represent elective procedures. If a service plans 
on offering TOLAC to its patients, surgical, anesthetic, and nursing support should be 
available when a woman attempting TOLAC is in active labor so that prompt cesarean 
delivery can be undertaken should it be required. 
 
 In making plans for delivery, physicians and patients should consider a woman’s chance 
of a successful VBAC as well as the risk of complications from trail of labor, all viewed 
in the context of her future reproductive plans. 
 
 Approximately 60-80% of appropriate candidates who attempt VBAC will be successful. 
A VBAC avoids major abdominal surgery, lowers a woman’s risk from having multiple 
cesarean deliveries such as hysterectomy, bowel and bladder injury, transfusion, 
infection, placenta previa and placenta accreta. 
 
 There are trade-offs here as a woman desiring VBAC may have to travel from her local 
facility to a center hospital in order to be afforded this opportunity. The delays inherent in 
additional travel time to the hospital for the woman in labor may present additional risks. 
As ACOG states in the last statement in the summary, the ultimate decision to attempt 
VBAC or undergo a repeat cesarean delivery is an individual one made by the patient and 
her physician based on individual risks, benefits, and values. 
 
 Prostaglandins, especially misoprostol (Cytotec), are not recommended in any woman 
with a prior uterine scar, regardless of gestational age or clinical situation due to the 
increased risk of uterine rupture. 
 
 
1. American College of Obstetricians and Gynecologists, Practice Bulletin. Vaginal Birth After a Previous 
Cesarean Delivery. Vol.116, No.2, Part 1, August 2010. 
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Appendix 6. Oxytocin for Induction and Augmentation of Labor 
 
Oxytocin is a synthetic hormone used to stimulate rhythmic contractions of the uterus that 
produce cervical changes and fetal descent, while avoiding uterine tachysystole and fetal 
intolerance to labor.  Complications from the use of oxytocics are ever present, especially when 
used in the antepartum and intrapartum phases of pregnancy. 
 
Labor may be induced or augmented with oxytocin only after a thorough examination of both 
mother and fetus and indications for and methods of induction or augmentation have been 
documented. A physician who has privileges to perform cesarean deliveries should be readily 
available to respond should problems arise. 
 
Prior to the initiation of oxytocin infusion: 
 A physician or qualified nurse should perform a vaginal exam on the patient to assure the 
adequacy of the maternal pelvis as well as the position of the fetus.   
 A 20-minute baseline fetal monitoring strip is recommended before initiation of oxytocin. 
 A primary line of intravenous solution is established. 
 Before an induction for any indication, ACOG (2009)2 recommends that the benefits of labor 
induction be weighed against the potential maternal and fetal risk. An induction of labor has 
merit as a therapeutic option when the benefits of delivery outweigh the risks of continuing 
the pregnancy.  
 Oxytocin following pre-induction cervical ripening agent appears to be more effective than 
oxytocin alone as a method of induction. 
 The likelihood of success of induction of labor is significantly increased in women with a 
Bishop score of six or more compared with women who have an unfavorable cervix. 
 Prepare oxytocin intravenous solutions using a physiologic electrolyte-containing solution to 
prevent water intoxication. Oxytocin is a high risk medication and should be prepared by 
pharmacy personnel. 
 Oxytocin is administered as a dilute solution intravenously via an infusion pump. The 
Oxytocin tubing should be inserted as close to the IV site as possible.  
 
During Oxytocin infusion: 
 Although there is no consensus in the literature on the ideal oxytocin dosage regimen, 
available data support a lower dosage rate of infusion. The Society of Obstetricians and 
Gynaecologists of Canada (SOGC) recommends “using the minimum dose to achieve active 
labor, increasing the dosage no more frequently than every 30 minutes and reevaluating the 
clinical situation if the oxytocin dosage rate reaches 20 mU/min.”5 The Statewide Perinatal 
Care Program supports a lower dosage approach to oxytocin use, e.g., 1-2 mU/min., 
increasing by 1-2 mU/min. every 30-40 minutes.  
 The exact half-life of oxytocin is unknown, but is thought to be 3-10 minutes. The 
physiological steady state is believed to be approximately 40 minutes, therefore advancing 
oxytocin in increments of less than 30 minutes is not recommended. 
 Continued increases in oxytocin rates over a prolonged period can result in oxytocin receptor 
desensitization or down regulation, making oxytocin less effective in producing uterine 
contractions. 
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 The uterus should relax for at least one minute between contractions.   
 The most common side effect of oxytocin is tachysystole and is dose related. Tachysystole is 
defined as greater than 5 contractions in 10 minutes, contractions that last longer than 90 
seconds, or increase in baseline uterine tone. Fifty percent of tachysystole cases will have 
nonreassuring fetal heart rate tracings. Therefore, when tachysystole is present, oxytocin 
should be discontinued (see tachysystole algorithm). 
 Physiologic doses (low dose) of oxytocin may be safer in patients at high risk for 
tachysystole, fetal distress, or both. Examples include: preeclampsia, chronic hypertension, 
oligohydramnios, multiple gestation, prematurity, fetal growth restriction, placental abruption 
or any fetus that is already compromised and has little reserve. 
 Fetal heart rate and uterine activity should be evaluated every 15 minutes in the first stage of 
labor and every 5 minutes in the second stage of labor while oxytocin is infusing. This is 
most easily accomplished with continuous electronic fetal monitoring but may be done by 
auscultation. Establish protocols for your institution and follow them.  
 Assess and document maternal pulse, respirations and blood pressure every 30 to 60 minutes 
depending on stage of labor and presence of associated complications and hospital protocol. 
 Assess and document maternal temperature every 4 hours or more often if indicated. 
 
Refer to American College of Obstetricians and Gynecologists’ (ACOG) Practice Bulletin on 
Induction of Labor and to recent literature when developing protocols and procedures.
2
  
 
Each hospital must have policies, procedures, and protocols developed by nursing and medical 
staff. These should be evaluated and revised on an ongoing basis. If the physician requests 
deviation from the institution's policy, procedures, or protocol, ensure that the physician writes 
the order.   
 
 
1. American Academy of Pediatrics and American College of Obstetricians and Gynecologists (2012). 
Guidelines for Perinatal Care (7
th
 Edition).Chapter 6.  Elk Grove Village, IL. 
2. American College of Obstetricians and Gynecologists, Practice Bulletin. Induction of Labor. Vol.114, 
No.2, Part 1, August 2009. 
3. Association of Women’s Health, Obstetric, and Neonatal Nurses, Practice Resource, 3rd Edition. Cervical 
Ripening and Induction and Augmentation of Labor.  Washington D.C. 2008. 
4. Simpson KR, Knox GE. Oxytocin as a High Alert Medication: Implications for Perinatal Patient Safety. 
MCN. 2009; 34(1):8-15. 
5. Society of Obstetricians and Gynaecoloigist of Canada. Induction of  labour at term. (Clinical Practice 
Guideline No. 107). Ottawa, Canada. 2001  
6. Miller L. Excessive Uterine Activity, and Patient Safety: Time for a Collaborative Approach. J Perinat 
Neonatal Nurs. 2009; 23(1):52-58. 
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Appendix 7. Neonatal Assessment 
 
At every delivery there should be at least one person whose primary responsibility is the neonate 
and who is certified in NRP and capable of initiating resuscitation. Either that person or someone 
else who is immediately available should have the skills required to perform a complete 
resuscitation including endotracheal intubation. During the stabilization period immediately 
following the delivery, temperature; heart and respiratory rates; skin color; adequacy of 
peripheral circulation; type of respiration; level of consciousness; tone and activity should be 
monitored and recorded at least once every 30 minutes until the neonate's condition has remained 
stable for two hours. For newborns with pallor or poor perfusion blood pressures should be 
obtained every 30 minutes until stable for two hours. Once the infant is determined clinically 
stable, and remains clinically stable, observations should be made and recorded according to the 
routine of the hospital nursery or at least every eight hours until discharge.   
 
The American Academy of Pediatrics (AAP) and the American College of Obstetricians and 
Gynecologists (ACOG) recommend that if the five minute Apgar score is less than seven, 
additional scores should be assigned every five minutes for up to 20 minutes.2 Any conditions 
that require special attention, such as vacuum assisted delivery; respiratory distress; 
hypoglycemia; temperature instability; change in activity (including poor feeding); unusual skin 
color; abnormal cardiac and respiratory findings, including abnormal blood pressure; 
delayed/abnormal voiding or stooling; or any degree of neonatal depression should be noted. 
Actions taken to correct the problem should be documented in the infant’s record. For infants 
awaiting transport, vital signs including temperature, heart and respiratory rates, blood pressure, 
oxygen saturation, and fraction of inspired oxygen should be documented at least every 30 
minutes. 
 
It is advisable to develop nursery guidelines to delineate those conditions that are associated with 
increased risk for neonatal illness and warrant close observation and frequent assessment. These 
include delivery prior to 37 weeks gestation, low birth weight, small for gestational age (SGA), 
large for gestational age (LGA), maternal drug abuse, maternal fever or infection, low Apgar 
scores, operative vaginal delivery (forceps or vacuum extraction), or any questionable clinical 
status. 
 
Gestational Age Classification 
In August 2001, the American Academy of Pediatrics published an article by Kramer et al 
entitled, “A New and Improved Canadian Reference for Birth Weight for Gestational Age.”3 
This reference provides sex-specific growth curves and percentile cutoffs for defining small- and 
large-for-gestational-age births that reflect the trend toward increasing birth weight at or near 
term. Data from each neonate should be plotted on a birth weight-gestational age chart that 
indicates whether the neonate is small, appropriate, or large for gestational age. 
 
The determination of gestational age and its relationship to weight can be used in the 
identification of neonates at risk for illness. For example, neonates who are either large or small 
for gestational age are at relatively increased risk for hypoglycemia and polycythemia, and 
appropriate tests are indicated. Newborn exam to determine gestational age should be done as 
soon as possible after birth or with in the first 12 hours of life using the New Ballard Score sheet. 
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Guidelines for performing the gestational age assessment are available at, 
http://www.ballardscore.com, accessed June 26, 2013.   
 
Risk for Hypoglycemia 
Neonatal hypoglycemia, a common metabolic disorder, may result in significant neurologic 
sequelae, especially in the symptomatic infant, if left untreated. In certain groups of high-risk 
infants who have a higher incidence of hypoglycemia than the normal population, neonatal 
glucose screening is highly recommended. These groups include the following infants: preterm 
infants; infants of diabetic mothers; infants who are small for gestational age (SGA) or large for 
gestation age (LGA); infants with a history of substance exposure; infants with limited or no 
prenatal care; infants with a five-minute Apgar score of six or less; infants with meconium 
staining or other symptoms of fetal distress; infants with polycythemia; and infants with severe 
erythroblastosis fetalis.  
 
In 2011, the AAP published a clinical report, “Postnatal Glucose Homeostasis in Late Preterm 
and Term Infants.”4 This guideline includes an algorithm for the screening and management of 
neonatal hypoglycemia (Fig 1). Hospitals are encouraged to refer to this clinical report when 
establishing their own written policy for screening and treatment of newborns at risk for 
hypoglycemia. Protocols should include specific guidelines for treatment with intravenous 
D10W, particularly for those infants with symptoms of hypoglycemia. Symptoms include 
irritability, tremors, jitteriness, exaggerated Moro reflex, high-pitched cry, seizures, lethargy, 
floppiness, cyanosis, apnea and poor feeding.  Blood glucose concentration should be measured 
as soon as possible (minutes, not hours) in any infant who manifests clinical signs of 
hypoglycemia. 
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Figure 1: Reprinted with permission from the American Academy of Pediatrics
4 
Screening for and management of postnatal glucose homeostasis in late-preterm (LPT 34-36 6/7 weeks) and term 
small-for-gestational age (SGA) infants and infants who were born to mothers with diabetes (IDM)/ large-for-
gestational age (LGA) infants. LPT and SGA (screen 0-24 hours), IDM and LGA >34 weeks (screen 0-12 hours). IV 
indicates intravenous.  
1. American Academy of Pediatrics and American College of Obstetricians and Gynecologists 
(2012).  Guidelines for Perinatal Care (7th Edition).  Chapter 8. Elk Grove Village, IL. 
2. American Academy of Pediatrics, Committee on Fetus and Newborn, American College of 
Obstetricians and Gynecologists, Committee on Obstetric Practice. Pediatrics. 2006; 117(4):1444-
1447. 
3. Kramer MS, Platt RW, Wen SW, Joseph KS, Allen A, Abrahamowicz M, Blondel B, Bréart G for 
the Fetal/Infant Health Study Group of the Canadian Perinatal Surveillance System. A New and 
Improved Population-Based Canadian Reference for Birth Weight for Gestational Age. Pediatrics. 
2001; 108(2):e35. Available at:  http://pediatrics.aappublications.org/content/108/2/e35.  Accessed 
June 9, 2013. 
4. American Academy of Pediatrics, Committee on Fetus and Newborn. Clinical report—Postnatal 
Glucose Homeostasis in Late Preterm and Term Infants. Pediatrics. 2011; 127(3):575-579. 
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Appendix 8. Statute and Rules for Ophthalmia Prophylactics 
 
Code of Iowa 139 A.38: Medical treatment of newly born  
Each physician attending the birth of a child, shall cause to be instilled into the eyes of the newly 
born infant a prophylactic solution approved by the Iowa department of public health. This 
section shall not be construed to require medical treatment of the child of any person who is a 
member of a church or religious denomination and whose religious convictions, in accordance 
with the tenets or principles of the person’s church or religious denomination, are against 
medical prophylaxis or treatment for disease.   
 
Iowa Administrative Code 641-1.7(139 A): Treatment of infant eyes   
The Iowa department of public health approves one percent silver nitrate solution in single-dose 
ampules or single-use tubes of an ophthalmic ointment containing one percent tetracycline or 0.5 
percent erythromycin in each conjunctival sac as an ophthalmia prophylactic for newborn 
infants’ eyes. Prophylaxis should be given after birth, but in no instance delayed for more than 
one hour after delivery. Once applied none of the above agents used for prophylaxis shall be 
flushed from the eyes following installation. 
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Appendix 9.  Center for Congenital and Inherited Disorders  
 
Code of Iowa 2004, Volume I, 136A.1: Purpose   
To reduce and avoid adverse health conditions of inhabitants of the state, the Iowa department of 
public health shall initiate, conduct, and supervise screening and health care programs in order to 
detect and predict congenital or inherited disorders. The department shall assist in the translation 
and integration of genetic and genomic advances into public health services to improve health 
outcomes throughout the life span of the inhabitants of the state. 
 
 
Iowa Administrative Code defines the responsibilities of the Center for Congenital and 
Inherited Disorders as follows: 
641—4.1(136A) Program overview. The center for congenital and inherited 
disorders within the department of public health provides administrative oversight to 
the following: Iowa newborn screening program, expanded maternal serum alpha-
fetoprotein screening program, regional genetic consultation service, neuromuscular 
and related genetic disease program and Iowa registry for congenital and inherited 
disorders. 
The Iowa Department of Public Health has designated the State Hygienic Laboratory (SHL) as 
the central testing laboratory for the Iowa Newborn Screening Program (INSP) and the Maternal 
Prenatal Screening Program (MPSP). The SHL is responsible for testing specimens submitted by 
providers and reporting the test results to the facility/provider of record.  
All newborn blood spot forms and maternal serum specimens for Iowa patients shall be 
submitted to the SHL for testing.   
The Center for Congenital and Inherited Disorders (CCID) also provides oversight for the Iowa 
Stillbirth Surveillance Project and the Family Health History initiative.  
Contact information:  Center for Congenital and Inherited Disorders 
Iowa Department of Public Health 
321 E. 12
th
 Street 
Lucas State Office Building 
Des Moines, IA 50319-0075 
1-800-383-3826 
Information about CCID programs, Iowa Code, Iowa Administrative Rules and genetics 
resources may be found on the Iowa Department of Public Health website, available at: 
www.idph.state.ia.us/genetics, accessed June 6, 2013.  
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Appendix 10. Newborn Hearing Screening 
 
Goal and Outcomes of Newborn Hearing Screening 
This protocol is intended to provide guidelines for personnel providing newborn hearing 
screening in order to be in compliance with 2003 Iowa Code and Iowa Administrative Rules, 
legislation mandating newborn hearing screening and reporting.
3
 It has long been recognized that 
unidentified hearing loss at birth can adversely affect speech and language development as well as 
academic achievement and social-emotional development.
1
 The goal of universal hearing screening 
of all newborns and infants in Iowa is early detection of hearing loss to allow children and their 
families the earliest possible opportunity to obtain appropriate early intervention services.  
 
National recommendations are to have infant’s hearing screened before one month of age, 
hearing loss identified by three months of age and early intervention services in place by six 
months of age. 
 
Goal of Iowa Newborn Hearing Screening Protocol 
This protocol is intended to provide guidelines to personnel providing newborn hearing 
screening in Iowa in accordance with 2003 Iowa Code and Iowa Administrative Rules, legislation 
mandating newborn hearing screening and reporting in Iowa.  
 
Personnel 
Every birth hospital or birth center shall designate an employee to be responsible for the 
newborn hearing screening program in that institution.   
 
Newborn hearing screen shall be performed by an audiologist, audiology assistant, audiometrist, 
registered nurse, licensed physician, or other person for whom newborn hearing screening is 
within the person’s scope of practice.  
 
Responsibility of Birth Facility 
If the infant is born in a birthing hospital, hearing screening shall be performed prior to 
discharge, except in the following circumstances: 
1. The newborn is transferred for acute care prior to completion of the hearing screening. 
2. The newborn is born with a condition that is incompatible with life.   
 
If the infant is born in a birthing center, that center shall refer the newborn to an audiologist, 
physician or hospital for newborn hearing screening. Before discharge of the newborn, the birth 
center shall arrange an appointment for the newborn hearing screening and report to the parent 
the appointment time, date and location. The newborn hearing screen should take place no later 
than one month of age. 
 
If the infant is born in a location other than a birthing hospital or birthing center, the physician or 
other health care professional who undertakes primary pediatric care of the newborn shall refer 
the newborn to an audiologist, physician, or other hospital for completion of the newborn hearing 
screen no later than one month of age. The health care professional who undertakes primary 
pediatric care of the newborn shall arrange an appointment for the newborn hearing screening 
and report the appointment time, date, and location to the parent.   
Appendix 10 
Guidelines for Perinatal Services, Eighth Edition, Appendices Updated August 2013  20 
 
Technology 
All newborns and infants born in Iowa, except those born with a condition that is incompatible 
with life, shall be screened for hearing loss using at least one of the following procedures: 
1. Automated or screening auditory brainstem response (ABR), or 
2. Evoked otoacoustic emissions (OAE) 
 
Test Parameters and Pass Criteria for DPOAE, TEOAE, and ABR 
 DPOAE 
 Collection Parameters 
Stimulus type: 2 primary pure tones, response measured at 2f1-f2 for each stimulus tone 
pair 
Stimulus intensity: L1 65 dB SPL, L2 55 dB SPL 
Frequency ratio (f2/f1): 1.22 
F2 Frequency region: 2-5 kHz  
 
Pass Criteria 
Response presence can be determined by examining response level or by examining the 
response level relative to the noise floor (SNR) (ASHA 2004). SNR should be at least 6 
dB, with a minimum response level of –5 to –8 dB SPL and an acceptably low noise floor 
(-4 dB SPL or less) at a minimum of 3 of 4 F2 frequencies. 
 
TEOAE 
Collection Parameters 
Stimulus type: click 
Click rate: 50-80 per second 
Stimulus intensity: 78-82 dB SPL 
Frequency region:  1-5 kHz 
 
Pass Criteria 
Common clinical practice defines presence of a response as a SNR of at least 6 dB, or an 
overall minimum amplitude (wideband) response of 6 dB, with a reproducibility of 50 
percent or greater.  
 
ABR 
Stimulus Parameters 
Stimulus type: 0.1 msec click 
Intensity: 35 dB HL 
 
Stopping Criteria for Newborn Hearing Screening 
Many factors influence the outcome of a hearing screen, such as technology used, skill of the 
screener, the state of the baby, the noise level in the room, the age at which the infant is tested, 
and the hearing sensitivity of the baby. To reduce the refer rate at the time of discharge, babies 
who refer on the first screen are often tested again. While this is a viable means of reducing the 
false positive rate (referring babies with normal hearing), excessive retesting can increase the 
false negative rate (passing babies with actual hearing loss).  
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No guidelines are currently available that address the number of times a hearing screen should be 
repeated on a baby before hospital discharge or at outpatient follow-up. The following guidelines 
can be used until published data are available. Because birthing debris in the ear canal is the 
primary cause of false positive results, the preferable age of initial testing is at least 24 hours of 
age in the well-baby nursery and no less than 12 hours unless the family is planning to leave. The 
recommended age for children in the NICU for a longer period of time is at least five days of 
age. Ear canal massage between tests is recommended.  
 
OAE Screening in the Well-baby Nursery 
Assuming that test conditions are adequate (quiet baby, quiet room, acceptable probe fit) two test 
sessions of no more than three tests per ear are recommended, for a total of six tests per ear. The 
test sessions should be conducted several hours apart.  
 
ABR Screening in the Well-baby Nursery 
Assuming that test conditions are adequate (quiet baby with little or no muscle movement, quiet 
room, acceptable electrode impedance and headphone placement), no more than two tests per ear 
are recommended. The tests should be conducted several hours apart.  
 
Two-stage Screening in the Well-baby Nursery (OAE followed by ABR) 
Assuming that test conditions are adequate (see above), no more than three OAE’s followed by 
one ABR per ear are recommended. Testing should be conducted in one to two sessions. If a 
child does not pass with ABR, the child must be referred to a hospital/audiology clinic that is 
able to rescreen the child with ABR as recommended by the Joint Committee for Infant Hearing 
Screening.
1
  
 
ABR Tests in the NICU 
It is recommended that all NICU babies be tested with ABR. The baby should be tested close to 
the time of discharge. If test conditions are adequate and the baby is at least five days of age, 
recommended stopping criteria are one test per ear. If the baby is less than five days old, follow 
the well-baby protocol.  
 
Outpatient Follow-up 
Outpatient follow-up screening can be accomplished at some birthing hospitals, Area Education 
Agency (AEA) offices, audiology clinics, or Child Health Specialty Clinics in Iowa. Assuming 
that the babies are at least five days of age and test conditions are adequate, recommended 
stopping criteria for OAE’s are three tests per ear. If a baby passes on the third attempt, the test 
should be immediately repeated. If the pass result cannot be replicated, the result should be 
recorded as “a refer.” Proceed to ABR. Scheduling a second outpatient OAE rescreen is not 
recommended. Stopping criteria for screening ABR is one test per ear. Scheduling a second 
outpatient screening ABR is not recommended. Instead, proceed to a comprehensive evaluation 
following Recommended Guidelines for Pediatric Audiologic Assessment. 
 
Guidelines for Children with Risk Factors for Delayed Onset or Progressive Hearing Loss  
Iowa’s Early Hearing Detection and Intervention (EHDI) program follows children who pass 
their birth screen and are identified with Risk factors for delayed onset or progressive hearing 
loss based on Joint Committee on Infant Hearing (JCIH) indicators. Known risk factors) (e.g. 
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cranio-facial anomalies, exchange transfusion for elevated bilirubin, family history of hearing 
loss, NICU > 5 days) are listed by JCIH at: 
http://pediatrics.aappublications.org/content/120/4/898.full.pdf+html, accessed June 26, 2013. 
Some risk factors are of greater concern for delayed onset hearing loss and require closer 
monitoring. Families and Primary Care Providers (PCPs) receive risk factor letters from EHDI 
when the child is 3 months old as a reminder that the child needs to have an audiological 
assessment by 6 or 24-30 months of age depending on risk indicated. An audiologist with skills 
and expertise in evaluating newborns and young infants with hearing loss should conduct the 
assessment. In addition, if caregiver or parental concerns arise about speech, hearing or 
communication development, the child should be referred for an audiology assessment. Staff at 
Child Health Specialty Clinics are available to answer questions about risk factors and can 
provide locations offering audiology assessment; call (319) 356-3570. 
 
Parental Notification 
If at the time of hearing screening a child is known to have risk factors for delayed onset hearing 
loss (as set forth in the recommendations of JCIH), the parents should be notified about the risk 
factors present along with the results of the birth screen. Although not required by law, it is 
strongly recommended that hospital staff discuss the results verbally in language the parents can 
understand and assist the family with scheduling recommended follow up screening. The parents 
and primary care provider will also be notified by written letter from EHDI about the risk factors 
present along with the results of the birth screen. 
 
Parental Refusal 
Although parental consent is not necessary to perform newborn hearing screening, parental 
objection to the screening is valid. If a parent refuses the newborn hearing screen, obtain a 
written refusal from the parent or guardian, the form is available at: 
http://www.idph.state.ia.us/IAEHDI/, accessed June 26, 2013. Maintain the original copy in the 
infant’s medical record. A copy of the refusal should be sent to the Iowa Department of Public 
Health within six days of the infant’s birth.  
 
Reporting Hearing Screening Results and Information to the Iowa Department of Public 
Health 
Iowa law provides that birthing hospitals, birth centers, physicians, any facility including Area 
Education Agencies (AEAs), audiologists and other health care professionals are legally required 
to report to the Iowa Department of Public Health (IDPH) the results of a hearing screen, re-
screen, or diagnostic assessment for any child under three years of age.
3  
 
The following information shall be reported to the Iowa Department of Public Health within six 
days of the birth of the newborn, utilizing the department’s designated reporting system:  
1. The name and date of the birth of the newborn. 
2. The name, address and telephone number, if available, of the mother of the newborn.  If 
the mother is not the person designated as legally responsible for the child’s care, the 
name address and telephone number of the guardian shall be reported.  
3. The name of the primary care provider for the newborn at the birthing hospital or birth 
center. 
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4. The results of the newborn hearing screening, either ‘pass’, ‘refer’, or ‘not screened’, for 
each ear separately.  
5. The results of any rescreening, either ‘pass’ or ‘refer’, and the diagnostic audiologic 
assessment procedures used for each ear separately.  
6. Known risk indicators for hearing loss of the newborn or infant. 
 
Confidentiality 
Reports, records, and other information collected by or provided to the Iowa Department of 
Public Health relating to a child’s newborn hearing screening, rescreen, and diagnostic 
audiologic assessment are confidential records.  The confidentiality of all the information and 
records used in its review shall be maintained by the personnel of the department.  No individual 
or organization providing information to the department in accordance with its rules shall be 
deemed to be or held liable for divulging confidential information.   
 
If you have questions about the Iowa EHDI system or where you can find hearing-related 
services for children, please contact: State EHDI Coordinator, Iowa Department of Public 
Health; phone: (515) 242-5639 or (800) 383-3826; EHDI website available at: 
http://www.idph.state.ia.us/iaehdi/default.asp, accessed June 26, 2013.   
      
1. American Academy of Pediatrics, Joint Committee on Infant Hearing. Policy Statement—Year 2007 
Position Statement: Principles and Guidelines for Early Hearing Detection and Intervention Programs. 
Pediatrics. 2007; 120(4):898-921. Available at: 
http://pediatrics.aappublications.org/cgi/content/full/120/4/898. Accessed June 5, 2013. 
2.    Iowa Administrative Code 641, Chapter 3. Early Hearing Detection and Intervention. 
3.    2003 Iowa Code, Chapter 135.131. Available at: 
http://www.idph.state.ia.us/iaehdi/common/pdf/iaehdi_law.pdf. Accessed June 9, 2013. 
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Appendix 11. Neonatal Transport-Medical and Legal Concerns  
 
Neonatal transport teams are involved in very high-risk transport situations; therefore, prior 
attention to potential legal problems is advisable. The institution that employs the team is 
responsible for its actions, and a physician at that institution directs the team’s activities. The 
goals of a neonatal transport team include stabilization of the neonate and initiation of advanced 
care at the referring hospital with continuation of critical care therapies and monitoring en route 
to the receiving facility.  Transport services should have detailed job descriptions, policies and 
procedures that guide transport personnel in the care of critically ill newborns. In 2007, the 
American Academy of Pediatrics’ Section on Transport Medicine published the “Guidelines for 
Air and Ground Transport of Neonatal and Pediatric Patients, 3
rd
 Edition.”1 This revised and 
updated resource provides comprehensive guidelines for health care professionals on emergency 
interfacility transport of neonates and children. 
 
The referring hospital is responsible for coordinating the transfer.  EMTALA requires the 
transferring physician to certify in writing that at the time of the transfer: 1) the benefits of the 
transfer outweigh the risks; 2) the patient (parent or surrogate) has given informed consent for 
the transfer; 3) and appropriate transfer has been arranged. If no parent or surrogate is available 
to provide consent, the transfer may proceed under implied consent. The physician should be as 
thorough as possible when documenting the benefits and risks of transfer. EMTALA does not 
require transporting services to obtain a separate consent. 
 
Before transport, the referring institution should understand the degree of its responsibility to the 
patient being transported. During a transport, there is a gradual shift in responsibility from the 
referring facility to the transport team and then to the receiving facility. The transport team 
should lead the process of preparing the patient for transfer. However, the referring physician 
and medical personnel share the responsibility for the patient’s medical care until the patient 
physically leaves the hospital. If the transferring physician disagrees with the plan of the 
transport team, the team must defer to the transferring physician while the patient is still in the 
referring hospital.  The departure of the transport team from the premises of the referring hospital 
may be considered the official point of transfer of responsibility from the referring physician to 
the transport team. The receiving facility and staff begin to acquire medical responsibility for a 
patient when the patient arrives at the hospital and they become aware of his presence, even if 
the patient is being attended to by the transport team.   
 
An institution should always perform within its capability and should not accept patients whose 
care exceeds that capability. Hospitals in each region should determine their level of 
commitment to emergency or specialty care.  They should operate within those boundaries and 
within their designated level of service in Iowa’s regionalized system of perinatal care. Hospitals 
that are designated as a Level II Regional, Level II Regional Neonatology and Level III referral 
center are required to maintain a functional neonatal transport team. In general, transport of 
neonates should not be done by Level I or Level II facilities. If a referring hospital refuses a 
transport team after it has been recommended, it is important for the receiving hospital to 
document the refusal in writing. 
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The medical control physician should make a decision regarding the acceptance of a neonatal 
transport promptly after the initial request. The availability of neonatal inter-facility transport 
services does not preclude the need to provide resuscitation and emergency care at the referring 
facility. The receiving facility and medical control physician must ensure that the skills and 
equipment available during transport will meet the anticipated needs of the patient. If the 
referring hospital chooses to perform its own transport for the purpose of “saving time” and 
getting the patient to the receiving hospital sooner, they must understand that they are fully 
responsible for the patient until arrival at the receiving institution. The referring physician and 
hospital may be held liable for using inappropriate transport services. 
 
An appropriate transfer occurs when the: 
 Transferring hospital has provided medical care within its capacity to minimize risk to 
the patient’s health (or to unborn child of a woman in labor) 
 Receiving hospital has agreed to accept the patient and has the space and resources 
available for treatment 
 Transferring hospital sends available medical records with the patient 
 Transfer is effected by qualified personnel and transportation equipment 
 
Transport Supervision 
The medical director should be a specialist in pediatrics and sub-specialist in pediatric critical 
care, pediatric emergency medicine or neonatology. The medical director should be available to 
the team 24 hours a day or should clearly designate an appropriate physician for alternative 
coverage. The transport coordinator is a registered nurse who coordinates the day-to-day 
activities of the transport team. This position is often the equivalent of a head nurse for the 
transport team. A designated medical control physician (MCP) should be available 24 hours a 
day and be able to respond promptly to transport or consultation requests. This person must be 
experienced in handling transport calls and in offering management suggestions for the period 
before the arrival of the transport team. The MCP should be knowledgeable about the availability 
or resources such as beds and transport teams, and must have authority to accept transferred 
patients without further consultation. The MCP must be able to triage and activate back-up 
systems when necessary and is responsible for team composition, selection of carrier, and the 
clinical care provided during transport. The MCP should communicate with the referring 
physician when necessary, especially in the period between the initial call and the arrival of the 
transport team at the referring institution. 
 
Experience and Background Training of Staff 
Each transport nurse will be currently licensed as a registered nurse by the Iowa Board of 
Nursing.  Specific training and experience in the care of critically ill neonates is necessary. This 
background should include a minimum of one year of full time staff nurse experience in a Level 
IIR, Level IIRN or Level III NICU. The transport nurse must be able to provide appropriate care 
for the patient being transported by air/ground from the time of arrival at the referring hospital, 
while the patient is loaded on the aircraft/ground transport vehicle and during the transport until 
the time the patient is admitted to the neonatal center.   
 
Guidelines for Training of Personnel Involved in Transport 
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Each transport nurse shall be able to provide care necessary for life support and/or stabilization 
of the patient during transport. Responsibilities shall include a working knowledge of all 
equipment used during transport. All transport nurses should have successfully completed and be 
current in Basic Life Support (BLS) and Neonatal Resuscitation Program (NRP).  Certification 
by the S.T.A.B.L.E. Program is highly recommended. Continuing education, training, 
competency and quality review should be documented to ensure that the team members remain 
qualified to perform necessary services and procedures. 
 
All transport nurses should be proficient in the following procedures: 
 Bag-mask ventilation 
 Intubation 
 Insertion of laryngeal mask airway (LMA) 
 Operation of transport ventilator (if available) 
 Use of oxygen therapy devices (e.g., masks, nasal cannula) 
 Intravenous line placement. 
 Umbilical catheter placement. 
 
The development of an effective neonatal inter-facility transport service requires multiple 
resources, but in particular, needs skilled healthcare professionals trained and experienced in 
neonatal transport. In order to maintain these resources in a cost-effective manner, a minimum 
volume of neonatal transport patients is required. Substantial commitment from hospital 
administration is necessary to provide a system that will meet the goal of safe, skilled neonatal 
transport.   
 
 
1. American Academy of Pediatrics (2007). Guidelines for Air and Ground transport of Neonatal and 
Pediatric Patients (3
rd 
Edition). Elk Grove Village, IL. 
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Appendix 12. Discharge Planning and Health Education  
 
The following are guidelines for minimum discharge education that should be provided to 
parents or care taker prior to discharge of mother and baby from the hospital: 
 
1. Umbilical cord care. Research has shown that umbilical cord drying time is decreased with 
as needed cleaning of the cord with water rather than alcohol. Parents should notify their 
physician if the cord or skin around the cord is reddened or has foul-smelling drainage. 
2. Voiding and stooling patterns. 
3. Breastfeeding education. Position, latch-on, and adequacy of swallowing. Breastfed babies 
should be fed every 1-1/2 to 3 hours to total 8-12 feedings in a 24-hour period. Parents 
should understand that 6-8 wet diapers/day indicate adequate oral intake. 
4. Formula preparation. 
5. Newborn skin care/rashes. 
6. Jaundice. Recent research has shown that even moderate degrees of hyperbilirubinemia are 
associated with an increase in minor neurologic dysfunction throughout the first year of life. 
Follow-up should be provided within two days of discharge for all neonates discharged < 48 
hours after birth. Early follow-up is particularly important for infants of < 38 weeks’ 
gestation. Parents should be taught to notify the baby’s physician if jaundice extends to the 
lower extremities, if the baby is not eating well, or if the baby is lethargic. 
7. Bathing. 
8. Positioning. To reduce the risk of SIDS, infants should be placed on their backs to sleep. All 
babysitters and daycare providers need this instruction as well. It is necessary to provide 
supervised “tummy time,” that is, time when the baby is awake and observed by the parents 
or caregivers at all times, to help prevent head-positioning deformities, and encourage 
development of upper body, trunk and neck strength. 
9. Smoking. Parents should be taught that smoking around their baby increases the risk of SIDS 
and some respiratory ailments. Parents who smoke should be provided with information on 
smoking cessation programs. One evidence based program free to all Iowans is Quitline 
Iowa, a toll free telephone tobacco cessation program that can be reached by dialing 1-800-
QUIT NOW (1-800-784-8669). Parents should be encouraged to leave the house to smoke, 
and to not smoke in the car. They should ask child care providers to not smoke around the 
baby as well. All children benefit from smoke free environments. For more information go to 
www.quitlineiowa.org. 
10. Bed-sharing. Parents should be aware that bed-sharing increases the risk of SUID/SIDS(for 
definition of these terms and more information see appendix X) and death from suffocation, 
overlying and entrapment. 
11. Warning signs for the infant. Parents should be encouraged to call their physician for any 
of the following signs in the newborn: 
 Breathing difficulties 
 Seizures, loss of consciousness 
 Lethargy, irritability 
 Decreased feeding for 24 hours 
 Vomiting more than one to two entire feeds in one day, or projectile vomiting 
 No urine output for more than 12 hours 
 Bowel movements that are black, watery, loose, or of increased frequency 
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 Reddened umbilical site 
 Redness, drainage, swelling, foul odor around circumcision site 
 Jaundice covering abdomen/extremities 
 Pustules/rashes other than normal newborn rashes 
 White patches on the mouth that remain after the mouth is gently wiped with a wet cloth 
or that cannot be removed with gentle scraping 
 Axillary temperature under 97.7ºF (36.4ºC) or over 100ºF (37.8ºC).  Demonstrate 
temperature taking and reading a thermometer 
 Any baby who appears “ill” 
12. Importance of regular medical checkups. The first newborn visit should be two to three 
days after discharge in infants discharged at < 48 hours of age. Those infants discharged at > 
48 hours should be seen at one to two weeks of life by a health care practitioner, unless 
conditions exist that require a visit sooner. 
13. Infant safety concerns. Includes the following:  
 Car seat safety5 
 Crib safety6 
 Sun safety 
 Infection control (limiting contact) 
14. Discharge follow-up. All infants discharged prior to 72 hours should be followed for 
newborn jaundice and weight check within 48 hours of discharge. 
15. Instruction in self-care for the mother. Includes the following:  
 Perineal self-care and hand washing 
 Involution, lochial flow and breast changes 
 Signs of hemorrhage 
 Recognition of signs of infection 
 Introduction to family planning  and contraception principles 
 Introduction to stress management and strategies for coping with parenting 
responsibilities 
 Maternal depression 
 Follow–up care 
16. Warning signs for the mother. Includes the following: 
 Fever over 100.4°F (38°C)   
 Reappearance of bright red color in lochia that has turned brownish 
 Vaginal discharge with a foul odor or accompanied by irritation 
 Excessive bleeding or large clots 
 Swelling of legs, particularly if this is painful, red, or warm to touch 
 Burning or painful sensation upon urination, frequent urination or inability to urinate  
 Pain in the pelvic or perineal area 
 Severe headache, blurred vision  
 Swelling in the face or around the eyes 
 Persistent or severe mood swings 
 Thoughts of harming herself or the baby 
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Early Discharge of the Mother and Infant  
The Newborns’ and Mothers’ Health Protection Act of 1996 provides minimum federal 
standards for health plan coverage for mothers and their newborns, including those who are 
discharged from the hospital in less than 24 hours.  Under the act all health plans are required to 
allow the new mother and newborn to remain in the hospital for a minimum of 48 hours after a 
normal vaginal birth and for 96 hours after a cesarean birth unless the attending provider, in 
consultation with the mother, decides upon and earlier discharge. Discharge planning should 
begin with the first contact with the health care provider.  
  
When discharge is considered before 48 hours, the American Academy of Pediatrics (AAP) 
recommends limiting this practice to singleton infants who are born between 38 and 42 weeks of 
gestation, who are birth-weight appropriate for gestational age, and who meet the following 
criteria:  
 Uncomplicated antepartum, intrapartum and postpartum course for both the mother and the 
infant 
 Physical exam completed by physician, nurse midwife, nurse practitioner, or physician’s 
assistant prior to discharge of both mother and the infant.  
 Vaginal birth 
 Newborn vital signs are documented as within normal limits and stable for 12 hours before 
release: 
► Respiratory rate below 60 breaths per minute 
► Heart rate of 100-160 beats per minute 
► Axillary temperature of 97.7° to 99.3° (36.5° C to 37.4°C) measured in an open 
crib with appropriate clothing 
 Newborn has spontaneously passed at least two successful feedings and can coordinate suck, 
swallow and breathing with feeding 
 Infant has voided and passed one stool  
 Evaluation of clinically significant jaundice, if present, has been completed and follow-up 
plans are in place 
 Physical assessment shows no abnormalities requiring continued hospitalization 
 Bleeding at circumcision site is not excessive for at least two hours post procedure 
 All immediately necessary vaccines have been administered, e.g., hepatitis B, according to 
current immunization schedules 
 Screening tests have been performed as required by state regulations, including HIV 
 Newborn hearing screening has been completed per state regulations 
 Cord or infant blood type and direct Coombs test results, as indicated, have been reviewed 
 Pulse-oximetry screening for Critical Congenital Heart Disease (CCHD) is complete, and 
baby has a negative (normal) screen. (See Appendix EE, Guidelines for Newborn Screening 
for Critical Congenital Heart Disease) 
 
In their compendium of postpartum care
 the Association of Women’s Health Obstetric and 
Neonatal Nurses (AWHONN) recommends the following for preparing the mother for 
discharge
8
:  
 Maternal vital signs are documented as within normal limits and stable: 
► Temperature less than 100.4°F (38°C)   Pulse less than 100 beats per minute 
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► Blood pressure more than 90/60 mmHg and less than 140/90 mmHg, and/or 
consistent with the prenatal course 
► Fundus firm without excessive bleeding 
► Able to void without difficulty 
► Rh status of mother determined and RhoGam given if indicated 
► Ambulation tolerated 
 Follow-up for medical care is documented. 
 Mother's knowledge, skill and confidence to provide adequate care for baby are documented 
by the fact that she has received education regarding the following: 
► Breastfeeding or bottle feeding  (The breastfeeding mother-infant dyad should be 
assessed by trained staff regarding nursing position, latch-on, feeding frequency, 
and adequacy of swallowing) 
► Knowledge of infant’s urine and stool frequency 
► Cord, skin and infant genital care 
► Recognition of signs of illness and common infant problems, particularly jaundice 
► Proper infant safety (i.e., proper use of a car seat and positioning for sleep) 
 Mother has received instruction in self-care about: 
► Perineal self-care and hand washing 
► Involution, lochial flow and breast changes 
► signs of hemorrhage 
► recognition of signs of infection 
► introduction to family planning  and contraception principles 
► introduction to stress management and strategies for coping with parenting 
responsibilities 
► maternal depression 
► Follow –up care 
 Laboratory data were available and reviewed, including: 
► Maternal syphilis and hepatitis B surface antigen status 
► Cord blood (Type, RH, direct Coombs’) 
► Other tests as clinically indicated 
 A source of continuing health care (Medical Home) for the mother and infant has been 
identified. 
 Family, environmental and social risk factors have been assessed. 
 Family members or other support person(s), including health care providers who are familiar 
with newborn care, are available to the mother and baby the first few days after discharge. 
 Prior to discharge from the hospital verify the identification tags of both mother and the 
infant.  
 
 
1. American Academy of Pediatrics and American College of Obstetricians and Gynecologists (2012). 
Guidelines for Perinatal Care (7th Edition). Chapter 8. Elk Grove Village, IL    
2. American Academy of Pediatrics, Subcommittee on Hyperbilirubinemia. Management of 
hyperbilirubinemia in the newborn infant 35 or more weeks of gestation [published correction appears 
in Pediatrics. 2004; 114(4):1138]. Pediatrics. 2004;114(1):297-316. Available at: 
http://pediatrics.aappublications.org/content/114/1/297. Accessed June 5, 2013.  
3. Dore S, Buchan D, Coulas S, Hamber L, Stewart M, Cowan D, Jamieson L. Alcohol Versus Natural 
Drying for Newborn Cord Care. JOGNN. 1998; 27(6):621-627. 
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4. Thureen P, Deacon J, O’Neill, Hernandez J (1999). Assessment and Care of the Well Newborn. 
Philadelphia, PA: W.B. Saunders Co. 
5. American Academy of Pediatrics, Committee on Injury, Violence, and Poison Prevention, Committee 
on Fetus and Newborn, Bull MJ, Engle WA. Clinical Report—Safe Transportation of Preterm and 
Low Birth Weight Infants at Hospital Discharge. Pediatrics. 2009; 123(5):1424-1429. Available at: 
http://pediatrics.aappublications.org/content/123/5/1424. Accessed June 11, 2013. 
6. US Consumer Product Safety Commission. Crib Information Center. Available at: 
http://www.cpsc.gov/info/cribs/index.html. Accessed June 11, 2013.  
7. American Academy of Pediatrics, Council on Environmental Health, Section on Dermatology, Balk 
SJ. Technical Report—Ultraviolet Radiation: A Hazard to Children and Adolescents. Pediatrics. 2011; 
127(3):e791-e817. Available at: http://pediatrics.aappublications.org/content/127/3/e791. Accessed 
June 11, 2013. 
8. Association of Women’s Health, Obstetric and Neonatal Nurses (2006). The Compendium of 
Postpartum Care, Washington D.C.: AWHONN. 
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Appendix 13. Iowa High Risk Infant Follow-up Program 
 
Iowa High Risk Infant Follow-up Program screening evaluations are recommended for high-risk 
NICU patients at ages 4, 9, and 18 and 30 months of age. The screening evaluation consists of a 
developmental, neurological and physical assessment performed by a physician or pediatric 
nurse practitioner that has had training in developmental assessment. See below for the 
admission criteria. 
 
Level II Regional Centers and higher-level perinatal services are expected to participate in the 
Iowa High Risk Infant Follow-up Program, or develop an independent high-risk infant follow-up 
program. Assistance with the program may be obtained from: 
Iowa High Risk Infant Follow-up Program 
The University of Iowa 
200 Hawkins Drive, 8900 JPP 
Iowa City, IA  52242-1011 
(319) 353-6880 
 
Admission criteria for the Iowa High Risk Infant Follow-up Program: 
1. Birth weight < 1500 grams or less than 33 weeks gestation 
2. Respiratory Distress Syndrome requiring mechanical ventilation for > 2 hours 
3. Other forms of respiratory distress requiring mechanical ventilation for > 2 hours 
4. Clinical diagnosis of central nervous system infection 
5. Perinatal depression as evidenced by a five-minute Apgar score of < 6 
6. Hypoglycemia as proven by two consecutive true blood glucose levels of < 30 mg/dl 
7. Neonatal seizures as documented by physician observation with concurrence of a staff 
neonatologist, or by an attending pediatrician in a Level II-Regional, Level II- Regional 
Neonatal, or Level III Center 
8. Infants demonstrating hypotonia on discharge examination 
9. Polycythemia - central hematocrit of > 65% or 60-64% with signs and partial exchange 
transfusion, with resolution of signs occurring within the first 24 hours of life 
10. Maternal substance abuse during pregnancy 
11. Infants not included in criteria 1-10, but felt to be at risk by an attending physician:  
 Examples include: 
a) Sepsis 
b) Small for gestational age (SGA) 
c) Severe hyperbilirubinemia (total bilirubin of 20mg/dl or greater) 
d) Chorioamnionitis 
e) Intraventricular hemorrhage 
f) Multiple birth, if one sibling meets criteria 
g) Intrauterine transfusion 
h) Babies entering living environments that present severe psychosocial concerns 
i) Other as defined locally 
j) Physician request 
 
Infants moving into Iowa from other states are accepted if one or more of the above criteria 
occurred within the neonatal period.
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Appendix 14. Outreach Education 
 
Each Level II Regional and higher hospital provides outreach education to the referral area it 
serves. The purpose of the outreach education is to meet the needs of the hospitals being served 
and is based on a needs assessment of those hospitals. It is recommended that Level II Regional, 
Level II Regional Neonatology Centers, and Level III Centers have contact at least once each 
year with each referring hospital. This contact may consist of: 
 direct visits 
 visits by referring hospital personnel 
 an annual regional program 
 written materials prepared by Level II Regional Center, Level II Regional Neonatology 
Center and Level III Center personnel with distribution to the referral area 
 
The Statewide Perinatal Care Program (SPCP), through the Iowa Regionalized System of 
Perinatal Health Care (IRSPHC) with oversight and funding from the Iowa Department of Public 
Health, provides outreach education to the state of Iowa. The content of the educational contacts 
is as outlined above.  
 
The Statewide Perinatal Program keeps a record of educational contacts with its surrounding 
areas and provides this record to the IRSPHC upon request. 
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Appendix 15. Pregnancy and HIV (Human Immunodeficiency Virus) 
 
Since 1994, the United States Public Health Service has recommended universal, voluntary 
testing of pregnant women. The decrease in mother-to-child (perinatal) HIV transmission is a 
public health achievement in HIV prevention in the United States. Nationally, the number of 
infants infected with HIV through perinatal transmission has decreased from 1,650 cases during 
the early- to mid-1990s to fewer than 240 cases in 2002. This decline is attributed to multiple 
interventions, including routine, voluntary HIV testing of pregnant women, the use of rapid HIV 
tests at delivery for women of unknown HIV status, and the use of antiretroviral therapy by HIV-
infected women during pregnancy and by infants after birth. 
While the need for pregnant women to know their HIV status was recognized early in the 
epidemic as a key step to preventing perinatal transmission, testing efforts to date have often 
focused on risk-based screening or voluntary, opt-in systems of testing. These types of systems 
have been shown to be only moderately successful at achieving testing of pregnant women, in 
part because they depend on the ability of a health care provider to discern potential risk 
behaviors and on the enthusiasm with which the provider recommends the testing.
1
 
In September 2006, the Centers for Disease Control and Prevention (CDC) released the Revised 
Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care 
Settings, available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5514a1.htm, accessed 
June 11, 2013. These new recommendations, which replace CDC's 1993 Recommendations for 
HIV Testing Services for Inpatients and Outpatients in Acute-Care Hospital Settings, advise 
universal, opt-out testing for pregnant women. The CDC recommendations include the 
following: 
 
 All pregnant women in the United States should be screened for HIV infection. 
 Health care providers should test women for HIV as early as possible in the pregnancy. 
 Screening should occur after the patient is notified that:  
a) HIV screening is recommended for all pregnant patients; and  
b) She will receive an HIV test as part of the routine panel of prenatal blood tests, unless 
she declines (i.e., opt-out screening). 
 HIV testing must be voluntary and free of coercion. 
 Pregnant women should receive oral or written information that includes an explanation 
of HIV infection, a description of interventions that can reduce HIV transmission from 
mother to infant, and the meanings of positive and negative results. 
 No additional process or written documentation of informed consent should be required 
for HIV tests beyond that for other routine prenatal tests.  
 Pregnant women should be given the opportunity to ask questions and to decline testing. 
If a patient declines testing, this decision should be documented in the medical record. 
 Health care providers should discuss and address reasons for declining an HIV test (e.g., 
lack of perceived risk, fear of the disease, and concerns regarding partner violence or 
potential stigma or discrimination). 
 Women who decline the test early in prenatal care should be encouraged to be tested at a 
subsequent visit. 
 A second HIV test during the third trimester, preferable <36 weeks of gestation may be 
considered for all pregnant women, and is recommended for women with risk factors 
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(e.g., injection drug users and their sex partners, women who exchange sex for money or 
drugs, women who are sex partners of HIV-infected persons, and women who have had a 
new or more than one sex partner during this pregnancy) or who have signs or symptoms 
consistent with acute HIV infection. 
 Any woman with an undocumented HIV status at the time of labor should be screened 
with a rapid HIV test unless she declines (opt-out screening). 
 When a woman’s HIV status is still unknown at time of delivery, she should be screened 
immediately postpartum with a rapid HIV test unless she declines (opt-out screening). 
 Immediate initiation of appropriate antiretroviral prophylaxis should be recommended to 
women on the basis of a reactive rapid test result without waiting for the result of a 
confirmatory test. 
 When the mother’s HIV status is unknown postpartum, rapid testing of the newborn as 
soon as possible after birth is recommended so antiretroviral prophylaxis can be offered 
to HIV-exposed infants. Women should be informed that identifying HIV antibodies in 
the newborn indicates that the mother is infected. 
 
 
IOWA REQUIREMENTS AND GUIDELINES FOR HIV TESTING DURING 
PREGNANCY 
 
Iowa Code Chapter 141A governs HIV testing. On July 1, 2007, new provisions took effect.  The 
following requirements and guidelines are consistent with Iowa Code. Requirements of Iowa 
Code are indicated by a code citation following the entry. 
 
A.  Pretest Education 
Required: 
 Information about HIV prevention, risk reduction, and treatment opportunities to reduce 
the possible transmission of HIV to a fetus shall be made available to all pregnant 
women. (141A.4) 
 Prior to undergoing an HIV test, information shall be available concerning testing and 
how to obtain additional information about HIV infection and risk reduction. (141A.6) 
Recommended: 
 All health care providers of pregnant women should be knowledgeable about HIV in 
pregnancy, the treatment needed to protect infants of HIV-positive mothers, how to 
discuss HIV and risk factors with patients, and how to refer HIV-positive and high-risk 
patients for other support services. 
 All pregnant women should receive the required information as early as possible during 
the prenatal period. 
 The opportunity for the woman to ask questions about HIV should be provided in a 
supportive manner by the health care provider. 
 
B.  Consent 
As part of routine prenatal testing: 
The State of Iowa deems consent for all pregnant women when tested as part of routine prenatal 
testing (Iowa Code 141A.4). No written or oral consent is required. However, special provisions 
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for minors apply. A pregnant minor must be informed by the health care provider that the 
minor’s legal guardian will be notified by the health care provider if the HIV test is confirmed as 
positive. Minors are not required to sign a separate consent to this effect. 
 
C.  Testing 
Required: 
 All pregnant women shall be tested for HIV infection as part of the routine panel of prenatal 
tests. (141A.4) 
 A pregnant woman shall be notified that HIV screening is recommended for all prenatal 
patients and that the pregnant woman will receive an HIV test as part of the routine panel of 
prenatal tests unless she objects to the test. (141A.4) 
 If a pregnant woman objects to and declines the test, the decision shall be documented in her 
medical record. (141A.4) 
Recommended: 
Testing should occur as early in the pregnancy as possible. 
 Health care providers should discuss and address reasons for declining an HIV test (e.g., 
lack of perceived risk, fear of the disease, and concerns regarding partner violence or 
potential stigma or discrimination), and encourage women who decline the test early in 
prenatal care to be tested at a subsequent visit. 
 A second HIV test during the third trimester, preferable <36 weeks of gestation may be 
considered for women with risk factors (e.g., injection drug users and their sex partners, 
women who exchange sex for money or drugs, women who are sex partners of HIV-
infected persons, and women who have had a new or more than one sex partner during 
this pregnancy) or who have signs or symptoms consistent with acute HIV infection. 
 
D.  Post-test Counseling 
Required: 
Post-test counseling is required only if the test is positive. 
 At any time that the subject of an HIV test is informed of confirmed positive test results, 
counseling concerning the emotional and physical health effects shall be initiated.  
Particular attention shall be given to explaining the need for the precautions necessary to 
avoid transmitting the virus.  The subject shall be given information concerning 
additional counseling. (141A.7) 
Recommended: 
 The HIV-positive patient should be referred to an HIV specialist for follow up. 
  Partner notification should be explained to the patient at this time.  Newly diagnosed 
persons will be contacted by a state or local health department disease prevention 
specialist to assist them in notifying partners who may also be infected with HIV. 
 
E.  Testing of the Newborn When the Mother’s HIV Status is Unknown 
Not Consistent with Iowa Code: 
The CDC recommends HIV testing of newborns immediately after birth when the HIV status of 
the mother has not been determined. However, testing of a newborn without the consent of a 
legal guardian is not consistent with Iowa Code 141A.6 unless the legal guardian cannot be 
located or is unavailable and the test results are necessary for diagnostic purposes to provide 
appropriate urgent medical care. 
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 RECOMMENDATIONS FOR PREGNANT HIV-INFECTED WOMEN 
 
The Public Health Service Task Force issued revised Recommendations for Use of Antiretroviral 
Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce 
Perinatal HIV-1 Transmission in the United States on October 12, 2006. It is emphasized that 
concepts relevant to HIV management evolve rapidly. The Task Force has a mechanism to 
update recommendations on a regular basis, and the most recent information is available on the 
AIDSinfo Web site, available at: http://AIDSinfo.nih.gov , accessed June 11, 2013.   
 
Resources 
For questions regarding the clinical management of HIV/AIDS, contact: 
 Iowa Department of Public Health 
Bureau of HIV, STD, and Hepatitis: (515) 242-5150  
HIV Partner Notification Assistance Program: (515) 242-5141  
 National Perinatal HIV Hotline 
(888) 448-8765  
 
1. Royce RA, Walter EB, Fernandez MI, Wilson TE, Ickovics JR, Simonds RJ.  Barriers to universal 
prenatal HIV testing in 4 US locations in 1997. Am J Public Health. 2001; 91:727-733. 
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Appendix 16. Group B Streptococcal Disease 
 
In November 2010, the CDC released updated guidelines for the prevention of early onset 
neonatal GBS infections.
1
 This update replaces the 2002 CDC guidelines. Due to efforts to 
decrease GBS related disease, the incidence of early-onset GBS disease in the newborn has 
decreased significantly from 1.7 cases per 1000 live births to 0.34-0.37 cases per 1000 live 
births. Because rates of maternal colonization remain unchanged since the 1970s, we need to 
continue to be vigilant in our efforts to prevent GBS disease. Therefore, the updated guidelines, 
endorsed by ACOG and AAP, continue to recommend screening of all pregnant women between 
35 and 37 weeks’ gestation but they clarify many issues that were left unaddressed in the 2002 
guidelines, including new methods for identifying GBS, a new definition of GBS bacteriuria, 
clarified screening and treatment algorithms for women with preterm labor and preterm 
premature rupture of membranes (PPROM), dosing information of penicillin, revised 
prophylaxis regimens for penicillin allergic women as well as a new algorithm for management 
of potentially affected newborns. We review these changes, as well as unchanged key aspects of 
the 2002 guidelines. 
 
Identifying GBS 
Proper identification of GBS first relies upon correct collection techniques. Specimens should be 
collected from the inside of the lower vagina (introitus) and through the anal sphincter. The same 
swab can be used, or 2 different swabs can be used, if desired. However, they should be treated 
as 1 sample.  A speculum should not be used during the collection. If lab processing is not 
immediately available, transport media can be used for samples. The highest specificity occurs if 
the sample is stored at 4
o
C and is processed within 24 hours of collection. Typically after 
enrichment, GBS is isolated on blood agar plates and then identified by the CAMP test or by a 
latex agglutination assay.  If chromogenic media is used, a negative result must be confirmed by 
subculturing to an appropriate agar plate or the media can be directly tested for GBS.
2 
The CDC 
recommends that laboratories report GBS results in concentrations of  104 colony forming 
units/ml from urine specimens of pure or mixed organism cultures. However, many labs report 
GBS at lower concentrations. For example, the University of Iowa Clinical Microbiology Lab 
reports any GBS isolate in urine culture in any reproductive age woman regardless of colony 
count according to recommendations from the American Society for Microbiology. Any urine 
culture reported as GBS positive, regardless of the colony count, should be considered positive 
as any positive urine culture is considered a marker of heavy GBS colonization.  Therefore, any 
GBS positive urine culture regardless of colony count should be considered GBS positive for the 
entire pregnancy and the pregnant woman should receive intrapartum antibiotic prophylaxis.
3
  
 
Antibiotic sensitivities should be performed on any GBS isolate from urine or rectovaginal swab 
if the patient is known to be allergic to penicillin and is at high risk of anaphylaxis. The CDC 
2010 guidelines clearly define “high risk of anaphylaxis” as: a history of anaphylaxis, 
angioedema, respiratory distress or urticaria following the administration of penicillin or a 
cephalosporin. 
  
Susceptibility testing must include testing for inducible clindamycin resistance, such as a D zone 
test.  In the “D zone test,” or double-disk diffusion method, a clindamycin disk is away from the 
edge of an erythromycin disk. The sample is incubated overnight and strains that have inducible 
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resistance will show flattening of the clindamycin zone in the area next to the erythromycin disc 
“D zone.”  
  
While the 2010 guidelines acknowledge some of the limitations of identification of GBS by PCR 
based nucleic acid amplification tests (NAAT), including test complexity, costs, availability, and 
staffing requirements, the updated guidelines do expand the options for the laboratory to include 
NAAT.  NAAT directly from the swab may be used for women at term with an unknown GBS 
status who have no other risk factors. If GBS is identified by NAAT, then intrapartum antibiotic 
prophylaxis (IAP) should be given. However, if a patient develops any risk factor, then IAP 
should be given regardless of the NAAT results. For prenatal NAAT tests, the test must be done 
from an enrichment broth. Availability for this testing in the state of Iowa is limited. At the 
University of Iowa, a rapid PCR technique to detect GBS is limited and is only available as a 
mail out assay.   
 
Screening and Treatment Algorithm (Figure 1 on page 43) 
In regards to screening, all pregnant women should be screened at 35-37 weeks’ gestation. The 
only exceptions are women who had GBS isolated from urine at any time in the current 
pregnancy or who had a previous infant with invasive GBS disease. As previously stated, a 
pregnant woman with a urine culture positive for GBS regardless of the colony count and 
gestational age of collection should be considered GBS colonized. While these women do not 
need third trimester screening, they should receive intrapartum antibiotic prophylaxis. IAP 
should be given to these GBS bacteremic patients even if repeat urine cultures are negative.   
  
With regard to GBS urinary tract infection (UTI), primary treatment for GBS UTI should occur 
if the colony count is greater than 10,000 colony forming units/mL. If the patient is 
asymptomatic and has a colony count less than 10,000 colony forming units/mL, then they do 
not need to be primarily treated for the GBS UTI. Women should also be screened if they 
experience preterm labor or PPROM. Any woman, who screens positive for GBS, should be 
given IAP with the exception of women who are having a cesarean section performed prior to the 
onset of labor and rupture of membranes. Although a risk does exist for transmission of GBS 
from a colonized mother to her infant during a planned cesarean delivery performed before onset 
of labor in a woman with intact amniotic membranes, it is extremely low, based on a 
retrospective study at a single hospital and a review of CDC active, population-based 
surveillance data from the 1990s. Thus, in this specific circumstance, in which the risk for 
disease is extremely low, the individual risks to a mother and her infant from receiving 
intrapartum antibiotic prophylaxis may balance or outweigh the benefits. Intrapartum antibiotic 
prophylaxis to prevent perinatal GBS disease is, therefore, not recommended as a routine 
practice for women undergoing planned cesarean deliveries. Patients expected to undergo 
planned cesarean deliveries should nonetheless still undergo routine vaginal and rectal screening 
for GBS at 35--37 weeks because onset of labor or rupture of membranes may occur before the 
planned cesarean delivery. In rare situations in which patients or providers opt for intrapartum 
prophylaxis before planned cesarean deliveries, administration of antibiotics at the time of 
incision rather than at least 4 hours before delivery may be reasonable. Unless they have a 
urinary tract infection, these women should not be given be antibiotics to clear the GBS 
infection.  
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IAP is indicated if the GBS status is unknown at the onset of labor and at least one of the 
following occur: delivery will occur <37 weeks’ gestation, ROM  18 hours, intrapartum 
temperature  100.4oF, and/or a positive GBS result by intrapartum nucleic acid amplification 
tests. The new guidelines clearly highlight that GBS screening should be performed and that 
prophylaxis is indicated if these patients are likely to deliver and should be discontinued if it is 
decided that the woman is not in true labor. For women who experience PPROM, GBS screening 
should be performed and latency antibiotics should be given if they are not in labor. If they are in 
labor, then GBS prophylaxis should be administered. IAP is not indicated solely for the reason of 
colonization by GBS in a previous pregnancy or GBS bacteriuria in a previous pregnancy. 
Regardless of intrapartum risk factors, IAP is also not indicated if a negative rectovaginal 
screening culture was obtained in late gestation of the current pregnancy. A vaginal-rectal GBS 
screening result is valid for 5 weeks if done prior to 35 weeks’ gestation. After 35 weeks, GBS 
screening does not need to be repeated. 
 
 
Prophylaxis Regimens (Figure 2 on page 44) 
Penicillin G remains the drug of choice for IAP; an initial dose of 5 million units should be given 
IV, then 2.5 to 3.0 million units administered IV every 4 hours until delivery. This range 
provides flexibility based on what formulation is available. The same degree of protection is 
provided by this range. Ampicillin can also be given as an initial dose of 2 grams IV followed by 
1 gram IV every 4 hours until delivery. In the case of women who are allergic to penicillin and 
are not at high risk for anaphylaxis such as those who do not have a history of anaphylaxis, 
angioedema, respiratory distress syndrome, or urticaria with penicillin or cephalosporin 
administration, then cefazolin is the antibiotic of choice; an initial dose of 2 grams should be 
given IV, then 1 gram administered IV every 8 hours until delivery. Cefazolin has similar 
pharmacokinetics to penicillin and concentrates well in amniotic tissues. In contrast, clindamycin 
does not concentrate well in fetal tissue or amniotic fluid. If a woman is at high risk for 
anaphylaxis, then clindamycin should be used if their GBS is susceptible to clindamycin and 
erythromycin, and the D-zone test was negative if the isolate was erythromycin resistant. 
Clindamycin 900 mg should be given IV every 8 hours until delivery. Erythromycin is no longer 
listed as an alternative for penicillin-allergic women. For a penicillin-allergic, high anaphylaxis 
risk women with unknown GBS sensitivity results, then vancomycin, 1 gram should be 
administered IV every 12 hours until delivery. Vancomycin should be used prudently because it 
is not as effective for IAP as clindamycin and is a “drug of last resort” for gram positive bacterial 
infections.   
  
Regarding the duration of IAP with respect to delivery, there is insufficient data regarding the 
timing of intrapartum procedures, such as amniotomy for labor progression, and length of IAP 
administration. Ideally, IAP should be administered at least 4 hours before delivery. However, 
obstetrically necessary procedures, such as amniotomy for the placement of a fetal scalp 
electrode in the setting of nonreassuring fetal heart tones, should not be delayed to achieve the 4 
hours of IAP. 
 
The 2010 changes to the CDC guidelines are summarized in Table 1 on page 45. Overall, the 
incidence of early-onset invasive GBS disease in newborns is low. However, the rates of GBS 
colonization are unchanged and the maternal rates of resistance to clindamycin and erythromycin 
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are high. And, there is a higher rate of early-onset GBS disease in different racial populations. 
Therefore, obstetric and pediatric providers in Iowa must be vigilant in the implementation of 
these updated guidelines. 
 
1. Prevention of Perinatal Group B Streptococcal Disease -- Revised Guidelines from CDC, 2010. 
MMWR Recomm Rep. Nov 19 2010; 59(RR-10):1-36. 
2. National Center for Immunization and Respiratory Diseases, Divison of Bacterial Diseases. Q&As 
About Implementing the 2010 Guidelines for Laboratorians. 2010; Available at:  
http://www.cdc.gov/groupbstrep/lab/QAs-lab.html. Accessed June 11, 2013. 
3. National Center for Immunization and Respiratory Diseases, Division of Bacterial Diseases. 
Q&As About Implementing the 2010 Guidelines for Obstetric Providers. 2010. Available at: 
http://www.cdc.gov/groupbstrep/clinicians/QAs-obstetric.html. Accessed June 5, 2013. 
 
 
 
Figure 1: GBS Screening and Treatment Algorithm 
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Figure 2:  Intrapartum Antibiotic Prophylaxis Regimen Algorithm 
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Table 1:  2010 CDC Updates to the 2002 CDC Group B Strep Recommendations 
Category Key Updates to 2002 Recommendations 
Screening for GBS  Guidance regarding to cesarean delivery before labor 
and no ROM is applied to all gestational ages 
 New screening protocols with PCR (NAAT) based 
techniques 
Screening in the setting of threatened pre-
term labor 
 Separate algorithms for spontaneous preterm labor 
and PPROM 
 Discontinuation of GBS prophylaxis if not truly in 
labor 
 PPROM latency antibiotic regimens including 
Ampicillin x 48 hours are adequate for GBS 
prophylaxis.  Yet, oral antibiotics alone not adequate. 
GBS Specimen Processing  In clindamycin susceptible, erythromycin resistant 
GBS isolates, inducible clindamycin resistance (D-
Zone) testing should be performed. 
 If available, clarified use of PCR (NAAT) based 
techniques 
 Labs should report GBS in urine cultures in 
concentrations ≥ 104 cfu/mL 
Intrapartum Antibiotic Prophylaxis  Definition for high risk for anaphylaxis clarified as a 
history of anaphylaxis, angioedema, respiratory 
distress or urticaria after penicillin or a cephalosporin. 
 Dosing of penicillin G to be 2.5-3.0 million units IV 
every 4 hours for appropriate drug levels and allow 
flexibility in penicillin G formulations. 
 Erythromycin is NOT an alternative antibiotic in 
penicillin-allergic women. 
Secondary Prevention of GBS in Neonates  Recommendations apply to all newborns. 
 Adequate IAP strictly defined as ≥ 4 hours of IV 
penicillin, ampicillin, or cefazolin. 
 Well appearing infants with moms with indication for 
IAP, but did not receive IAP can be observed for ≥ 48 
hours unless < 37 weeks or  ≥ 18 hours of membrane 
rupture  limited evaluation and ≥ 48 hours 
observation 
 Well appearing infants born between 35-36 weeks 
and mothers received IAP do not require diagnostic 
evaluations. 
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Appendix 17. Male Newborn Circumcision 
 
Male circumcision, surgical removal of some or all of the foreskin (prepuce) from the penis is one 
of the most common surgical procedures in the world. In the United States, circumcision is most 
often performed in the newborn period. In 2007, the American Academy of Pediatrics (AAP) 
formed a multidisciplinary task force to evaluate the recent evidence regarding male circumcision. 
An updated policy statement was subsequently released on August 27, 2012. The Circumcision 
Policy Statement
1
 has been endorsed by the American College of Obstetricians and Gynecologists 
(ACOG). Findings from the systematic evaluation of the evidence are available in the 
accompanying Technical Report, “Male Circumcision.”2 
 
Preventive Health Benefits  
The AAP task force on circumcision evaluated English-language peer-reviewed literature from 
1995 through 2010. They concluded that the preventive health benefits of elective circumcision 
for male newborns outweigh the risks of the procedure. These benefits include prevention of 
urinary tract infections, penile cancer and transmission of some sexually transmitted diseases, 
including HIV. The procedure is well tolerated when performed by trained and competent 
professionals under sterile conditions with appropriate pain management.  
 
The preventive health benefits are not great enough to recommend routine circumcision for all 
male newborns. However, the benefits are sufficient to justify access to this procedure and third-
party reimbursement for the cost of the procedure if families choose to have their newborns 
circumcised. Clinicians should routinely inform parents of the potential benefits and risks of 
newborn circumcision in a nonbiased manner and make sure they understand that it is an elective 
procedure. Parents should weigh the medical information in the context of their own religious, 
ethical and cultural beliefs and practices. For some families, the medical benefits alone may not 
outweigh these other considerations. 
 
Potential Complications 
The true incidence of complications with newborn male circumcision is unknown due to differing 
definitions and standards for determining the timing of when a complication occurred. The AAP 
task force has grouped potential complications in terms of the timing of the procedure. “Acute” 
complications are defined as those present in the immediate post-procedural time frame. They are 
rare, occurring in approximately 1 in 500 newborn male circumcisions. The most common 
complication is bleeding. Other acute complications include infection, penile injury and an 
imperfect amount of tissue removed during circumcision. “Late” complications are still present 
during infancy but not in the immediate post-procedural period. Adhesions (natural and 
vascularized skin bridges) and meatal stenosis are the most common late complications. Other 
late complications with newborn circumcision include excessive residual skin (incomplete 
circumcision), excessive skin removal, phimosis and epithelial inclusion cysts. Circumcision of 
premature infants and infants with a prominent suprapubic fat pad or penoscrotal webbing is 
associated with an increased risk of later-occurring complications, including poor cosmesis, 
trapped/buried penis and adhesions. Male circumcision performed during the newborn period has 
significantly lower complication rates than circumcision performed later in life. After review of 
the current literature, the AAP task force concluded that male circumcision does not adversely 
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affect penile sexual function, sensitivity or satisfaction, regardless of how these factors are 
defined. 
 
Contraindications 
Newborn circumcision is contraindicated for the following infants: significantly premature 
infants; infants with blood dyscrasias or those who have a family history of bleeding disorders; 
infants with congenital abnormalities such as hypospadias or congenital chordee; and infants with 
deficient shaft skin such as penoscrotal fusion or congenital buried penis. 
 
Circumcision Procedure 
Circumcision is an elective procedure and should be performed only if the infant is stable and 
healthy. Practitioners should confirm that vitamin K has been administered prior to the procedure 
in accordance with the standard of newborn care.
3
 The three most common techniques used for 
male circumcision in the United States involve use of  the Gomco clamp, the Plastibell device or 
the Mogen clamp. There is no significant difference in the risk of complications between the 
specific techniques. All three involve the following steps: 1) estimation of the amount of external 
skin to be removed; 2) dilation of the preputial orifice so the glans can be visualized to ensure that 
the glans itself is normal; 3) bluntly freeing the inner preputial epithelium from the epithelium of 
the glans; 4) placing the device; 5) leaving the device in place long enough to produce 
hemostasis; and 6) surgical removal of the foreskin. 
 
Gomco clamp: 
 Device specifically designed for performing circumcisions 
 Procedure: The foreskin is cut lengthwise through the stretched tissue (dorsal slit) to allow 
space to insert the device; the bell of the Gomco clamp is placed over the glans and the 
foreskin is pulled over the bell; the base of the Gomco clamp is then placed over the bell 
and the arm of the clamp is fitted; after confirming correct fitting and placement of the 
clamp and the amount of foreskin to be excised, the surgeon tightens the nut on the 
Gomco clamp; the clamp is left in place for 3-5 minutes to allow for hemostasis; then the 
foreskin is removed using a scalpel and the Gomco base and bell are removed.
4
  
 
Plastibell device: 
 Procedure: A plastic ring is inserted under the foreskin and a tie is placed over the ring to 
provide hemostasis; the ring remains on the penis for several days until the tissue necroses 
and the ring falls off spontaneously. 
 
Mogen clamp: 
 Device consisting of 2 flat blades that have a limited (slit-like) space between them and a 
mechanism that draws the blades together and locks them into place  
 Slit is limited to 3mm to allow the foreskin, but not the glans to cross the opening 
 Procedure: The preputial adhesions are taken down gently using a probe and the glans is 
pushed downward, protecting it from the blades; the prepuce distal to the glans is drawn 
into the slit between the blades and positioned; the blades are locked together, crushing the 
skin and creating hemostasis; the skin is excised from above the clamp; then the clamp is 
removed and the skin is pushed proximally into proper position. 
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Analgesia and Anesthesia 
Adequate analgesia/anesthesia should be provided whenever newborn circumcision is performed. 
The AAP recommends both nonpharmacologic and pharmacologic techniques for reducing the 
procedural pain associated with newborn circumcision. Nonpharmacologic techniques 
(positioning, sucrose pacifier) are not recommended as the sole method of analgesia during 
circumcision as they do not prevent procedural or post-procedural pain. They should be used as 
analgesic adjuncts to improve comfort during the procedure. The administration of oral 
Acetaminophen has been demonstrated to reduce postoperative pain scores 6 hours after the 
procedure.
5
 However, there is no evidence that the newborn experiences persistent pain after the 
local pre-procedure anesthetic wears off.  
 
 
Nonpharmacologic techniques: 
 Physiologic positioning of the infant (swaddling upper extremities) in a padded 
environment may decrease distress during circumcision. 
 Nonnutritive sucking on a pacifier dipped in sucrose has been demonstrated to decrease 
crying during circumcision. 
 
Penile nerve block techniques are highly effective in reducing the behavioral and physiologic 
indicators of pain caused by male newborn circumcision. The most commonly used method is the 
dorsal penile nerve block (DPNB). With this technique systemic lidocaine levels reach peak 
concentrations about 60 minutes after injection and are generally well below toxic ranges.
6 
Minor 
complications may include bruising and hematomas at the injection site which do not require any 
change in management. The subcutaneous circumferential ring block is also effective in relieving 
the procedural and post procedural pain of newborn circumcision. No complications have been 
reported with this technique. There is evidence that both the DPNB and subcutaneous ring block 
are superior to EMLA cream in relieving pain during and after circumcision.
7
 For newborns the 
maximum dose of 1% lidocaine without epinephrine is 4.5-5 mg/kg/dose in a 2-hour period (1% 
lidocaine equals 10 mg/ml).
8 
 
Nerve blocks: 
 Dorsal penile nerve block (DPNB): Consists of two subcutaneous injections of 0.4 ml of 
1% lidocaine without epinephrine administered below Buck’s fascia at the 10 and 2 
o’clock positions, 0.5 to 1 cm distal to the base of the penis using a 27-gauge needle 
 Subcutaneous ring block: Consists of one subcutaneous injection of 0.8 ml of 1% 
lidocaine without epinephrine administered at the base or midshaft of the penis and 
infiltrated in a band or ring around the penis using a 27-gauge needle 
 
Topical anesthetic preparations require the use of an occlusive dressing or plastic wrap to keep the 
cream in place prior to the procedure. Infrequent complications such as erythema, swelling and 
blistering have been associated with the use of topical anesthetics. These occur more commonly 
with lidocaine-prilocaine cream (EMLA) than 4% lidocaine cream (LMX4). LMX4 cream has the 
advantage of faster onset to anesthesia when compared to EMLA cream. Topical anesthetics may 
cause more skin irritation in low birth weight infants, and penile nerve block techniques are 
preferred for these infants. There have been no reports in the literature of systemic toxicity such 
as seizures or cardiovascular instability with the use of these products for newborn circumcision. 
Appendix 17 
Guidelines for Perinatal Services, Eighth Edition, Appendices Updated August 2013  47 
There have been isolated case reports of clinically significant methemoglobinemia with EMLA 
cream that involved prolonged application time or use in premature infants. EMLA should not be 
used in neonates who are receiving other drugs known to induce methemoglobinemia.
9 
There is 
no risk of methemoglobinemia with the use of LMX4 cream.  
 
Topical local anesthetics: 
 Eutectic mixture of 2.5% lidocaine & 2.5% prilocaine (EMLA cream): 1-2g applied 60-90 
minutes before circumcision 
 Topical 4% lidocaine (LMX4 cream): 2g applied 30 minutes before circumcision  
 
Discharge Instructions 
Parents of newborn boys should be instructed in the care of the penis at the time of hospital 
discharge, whether the newborn is circumcised or not.  The uncircumcised penis should be 
washed with soap and water. The foreskin should not be forcibly retracted. Adhesions present at 
birth usually disappear by age 2 to 4 months. When the adhesions have resolved the foreskin can 
be easily retracted, and the whole penis can be washed with soap and water. The circumcised 
penis should be washed gently without aggressive pulling back of the skin. 
1. American Academy of Pediatrics, Task Force on Circumcision. Circumcision Policy Statement. 
Pediatrics. 2012; 130(3):585-586. Available at: 
http://pediatrics.aappublications.org/content/130/3/585. Accessed June 4, 2013. 
2. American Academy of Pediatrics, Task Force on Circumcision. Technical Report—Male 
Circumcision. Pediatrics. 2012; 130(3):e756-e785. Available at: 
http://pediatrics.aappublications.org/content/130/3/e756. Accessed June 4, 2013. 
3. American Academy of Pediatrics, Committee on Fetus and Newborn. Controversies concerning 
vitamin K and the newborn. Pediatrics. 2003; 112(1 pt 1):191-192. Available at: 
http://pediatrics.aappublications.org/content/112/1/191.  Accessed November 28, 2012. 
4. Wikipedia. Gomco clamp. Available at: http://en.wikipedia.org/wiki/Gomco_clamp#cite_note-8. 
Accessed January 8, 2013.  
5. Howard CR, Howard FM, Weitzman ML. Acetaminophen analgesia in neonatal circumcision: the 
effect on pain. Pediatrics. 1994;93(4):641-46 
6. Maxwell LG, Yaster M, Wetzel RC, Niebyl JR. Penile nerve block for newborn circumcision. 
Obstet Gynecol. 1987; 70(3 pt 1):415-19.   
7. Lander J, Brady-Fryer B, Metcalfe JB, Nazarali S, Muttitt S. Comparison of ring block, dorsal 
penile nerve block, and topical anesthesia for neonatal circumcision: a randomized controlled trial. 
JAMA. 1997; 278:2157-62. 
8. Gunn VL, Nechyba C. The Harriet Lane Handbook: A Manual for Pediatric House Officers. 16th 
ed. Philadelphia, PA: Mosby, Inc; 2002:734-35. 
9. American Academy of Pediatrics, Circumcision Policy Statement. Pediatrics. 1999; 103(3):686-
93. 
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Appendix 18.    Managing Newborn Hyperbilirubinemia and Preventing 
Kernicterus 
 
Bilirubin is the yellow breakdown product created from the destruction of hemoglobin in 
circulating red blood cells. Red cells have a shortened lifespan in the newborn. Approximately 35 
mg of unconjugated bilirubin is formed from each gram of hemoglobin, and newborns produce up 
to 10 mg/dl/day.   Bilirubin production is elevated in the first 24-48 hours of life. Unconjugated 
bilirubin is lipid-soluble and must be transported to the liver in plasma, reversibly bound to 
albumin. In the liver, bilirubin is transported across hepatic cell membranes where it is bound to 
ligand for conjugation. A liver enzyme conjugates bilirubin, converting it to water-soluble 
bilirubin pigments that can be excreted into the bile and urine. It is eliminated from the body via 
the intestines and to a lesser degree through the renal system. Bilirubin pigments that are not 
eliminated can be reabsorbed into the circulation as unconjugated bilirubin, a process called 
enterohepatic recirculation. In term newborns, conjugation is delayed during the first hours after 
birth but increases by about 24 hours of age. Hemolysis or bruising at birth can increase the 
bilirubin load. Elimination of bilirubin is often delayed in preterm infants. Other factors can 
impair its elimination, such as poor feeding, bowel obstruction or immature liver conjugation. 
Breastfed babies typically have higher bilirubin levels than formula fed infants. 
 
Babies with 
reduced conjugation or elimination of bilirubin are at risk for hyperbilirubinemia.  
 
Definitions 
Total serum bilirubin (TSB):   bilirubin is the catabolic product of heme metabolism, which is 
formed by the breakdown of heme present in hemoglobin, myoglobin, cytochromes, catalase, 
peroxidase, and tryptophan pyrrolase. Several laboratory techniques have been developed for 
measuring the serum bilirubin concentration. The specific technique used has implications for the 
interpretation of serum values. 
 
Direct or conjugated bilirubin: concentration of bilirubin conjugated with glucuronic acid.  
 
Indirect or unconjugated bilirubin: the lipid-soluble form of bilirubin that circulates in loose 
association with the plasma proteins. 
 
Transcutaneous bilirubin (TcB): noninvasive measure of the yellow color of blanched skin and 
subcutaneous tissue; used as screening tool to help determine whether the TSB should be 
measured; provides an estimate of the TSB value expressed in mg/dl; measurements can be 
plotted on the same nomogram as TSB measurements 
 
Hyperbilirubinemia: TSB level of <13 mg/dl or a TSB rise of <0.5 mg/dl/hour; results in 
physiologic jaundice 
 
Physiologic jaundice: yellow color in skin and sclera that appears as bilirubin levels increase; 
begins cephalically, usually seen in face first and progresses caudally to trunk and extremities 
 
Severe hyperbilirubinemia: TSB above the 95
th
 percentile for age in hours; requires treatment 
with phototherapy 
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Phototherapy: visible light delivered in measurable doses; causes photoisomerization whereby 
bilirubin present in superficial capillaries and interstitial spaces of the skin and subcutaneous 
tissues is converted to water-soluble isomers that are excretable without further metabolism by the 
liver 
  
Intensive phototherapy: implies irradiance in the blue-green spectrum (wavelength band of 
approximately 430-490 nm) of at least 30 µW/cm
2
 per nm (measured at the infant’s skin directly 
below the center of the phototherapy unit) 
and delivered to as much of the infant’s surface area as possible; the most efficient units 
positioned for maximum skin coverage can lower TSB by as much as 5 mg/dl/hour  
 
“Bronze baby syndrome”: complication of phototherapy where a grayish-brown discoloration of 
the skin occurs; seen exclusively in infants with an elevated direct-reacting or conjugated 
bilirubin level (cholestatic jaundice) 
 
Acute bilirubin encephalopathy (ABE): acute and reversible clinical manifestations of bilirubin 
neurotoxicity caused by an accumulation of unconjugated bilirubin in the brain; seen in the first 
weeks after birth; presenting signs are subtle and nonspecific; early signs include lethargy, 
hypotonia and poor suck; intermediate phase is characterized by moderate stupor, irritability and 
hypertonia manifested by backward arching of the neck (retrocollis) and trunk (opisthotonos); 
infant may develop fever and high-pitched cry which alternates with drowsiness and hypotonia; 
advanced phase may be irreversible and is characterized by pronounced retrocollis-opisthotonos, 
shrill cry, no feeding, apnea, fever, deep stupor to coma, possible seizures and death 
 
Kernicterus: yellow staining of specific areas of brain tissue caused by an accumulation of 
unconjugated bilirubin in the brain; results in bilirubin neurotoxicity and chronic bilirubin 
encephalopathy 
 
Chronic bilirubin encephalopathy: chronic and irreversible clinical neurologic sequelae 
associated with bilirubin neurotoxicity, including severe choreoathetoid cerebral palsy, 
sensorineural hearing loss, dental- enamel dysplasia, paralysis of upward gaze and intellectual 
deficits   
 
Background and Scope of the Problem 
More than 60% of healthy full term and late preterm infants will develop hyperbilirubinemia 
during the first week of life. Most are discharged from their birth hospital before the peak of TSB 
occurs, usually at 72-120 hours of age.  Hyperbilirubinemia typically resolves by 7-10 days of 
life. Approximately 5-11% of infants will develop severe hyperbilirubinemia. Without 
intervention, TSB levels can progress to values greater than 25 or 30 mg/dl (above the 99
th
 
percentile for age in hours) which puts the infant at risk for acute bilirubin encephalopathy and 
kernicterus. It is estimated that about one in seven infants with TSB levels greater than 30 mg/dl 
will develop kernicterus, resulting in chronic bilirubin encephalopathy.
1,2
 The relationship 
between extremely high TSB levels and bilirubin neurotoxicity is not known because routine 
surveillance is not available. Cases of extremely high levels of serum bilirubin in infants with no 
apparent sequelae have been reported. Conversely, infants without documented high serum 
bilirubin levels have been found to have kernicterus.
3
 The critical level in otherwise healthy 
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newborns is likely influenced by postnatal age, maturity, duration of hyperbilirubinemia and rate 
of TSB rise.
 
 
In April 2001, The Joint Commission (formerly known as the Joint Commission on Accreditation 
of Hospitals, JCAHO) issued a sentinel event alert notifying hospitals and healthcare providers 
that recent cases of kernicterus in otherwise healthy newborns had been reported.
4
 One registry 
includes 90 cases in the United States from 1984 to 2001.
5
 Studies suggest that several factors 
contributed to the resurgence of kernicterus in the US, including early discharge, an increase in 
home births and an increase in exclusive breastfeeding. A warning on the danger of kernicterus 
was also issued by the Centers for Disease Control and Prevention (CDC).
6 
In 2002, the National 
Quality Forum declared kernicterus and TSB concentrations greater than 30 mg/dl to be “never 
events” or preventable, adverse medical occurrences that should never happen.7  
 
The current incidence of bilirubin encephalopathy in the US is unknown; however, kernicterus is 
still being reported. The majority of these affected infants are term and late-preterm infants who 
are discharged from 
the hospital as healthy newborns, yet subsequently develop extreme hyperbilirubinemia and the 
neurodevelopmental findings associated with kernicterus. 
 
Current Guidelines for Management and Follow-Up After Discharge 
In July 2004, the American Academy of Pediatrics (AAP) released a clinical practice guideline, 
“Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation.”8 
The focus of this guideline was to reduce the incidence of severe hyperbilirubinemia and bilirubin 
encephalopathy while minimizing the risks of unintended harm, such as maternal anxiety, 
decreased breastfeeding and unnecessary costs and treatment through appropriate identification, 
follow-up and therapy.  
 
The key elements of the AAP guideline are summarized in the following recommendations: 
1. Promote and support successful breastfeeding. 
2. Establish nursery protocols for the identification and evaluation of hyperbilirubinemia. 
3. Measure the total serum bilirubin (TSB) or transcutaneous bilirubin (TcB) level on infants 
jaundiced in the first 24 hours. 
4. Recognize that visual estimation of the degree of jaundice can lead to errors, particularly 
in darkly pigmented infants. 
5. Interpret all bilirubin levels according to the infant’s age in hours. (Figure 1) 
6. Recognize that infants less than 38 weeks’ gestation, particularly those who are breastfed, 
are at higher risk of developing hyperbilirubinemia and require closer surveillance and 
monitoring. 
7. Perform a systematic assessment on all infants before discharge for the risk of severe 
hyperbilirubinemia. (Table 1) 
8. Provide parents with written and verbal information about newborn jaundice. 
9. Provide appropriate follow-up based on the time of discharge and the risk assessment. 
10. Treat newborns, when indicated, with phototherapy or exchange transfusion. (Figure 2, 3)  
 
In 2009, a panel of experts reviewed the relevant literature including the report on screening for 
neonatal hyperbilirubinemia by the Tufts-New England Medical Center Evidence-Based Practice 
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Center
9 
and the current report by the US Preventive Services Task Force.
3 
New evidence suggests 
that combining a predischarge measurement of TSB or TcB with clinical risk factors including 
gestational age might improve the prediction of the risk of subsequent hyperbilirubinemia. In 
October 2009, Maisels et al published their commentary article, “Hyperbilirubinemia in the 
Newborn Infant >35 Weeks’ Gestation: An Update With Clarifications.”10 In addition to 
clarifying several areas addressed in the 2004 AAP guideline, the authors introduced new 
recommendations for management and follow-up testing, according to predischarge screening. 
Their recommendations are summarized in Figure 4.
10
 The gestational age and the predischarge 
TSB or TcB level are the most important factors that help to predict the risk of 
hyperbilirubinemia. The risk increases with each decreasing week of gestation from 42-35 weeks.  
 
TcB Measurement 
TcB or transcutaneous bilirubin measurement is being performed more frequently in hospitals and 
outpatient settings. This noninvasive screening tool provides a good estimate of the TSB 
expressed in mg/dl and helps to determine whether the TSB should be measured. As with any 
point-of-care testing, regular monitoring for quality assurance by comparing TcB measurements 
with the TSB is necessary. Studies in term and late preterm infants have indicated that the TcB 
tends to underestimate the TSB, particularly at higher TSB levels. In the 2009 updated guidelines, 
Maisels et al provide specific evidence-based strategies for determining when TSB measurement 
is indicated.  
 
Measurement of the TSB should be performed if: 
 The TcB value is at 70% of the TSB level recommended for the use of phototherapy11 
 The TcB value is above the 75th percentile on the Bhutani nomogram (Fig 1) or the 95th 
percentile on a TcB nomogram
12 
 
 At follow-up after discharge, the TcB value is >13mg/dl (222µmol/L)13  
 
Treatment 
In 2011, the AAP published a technical report to standardize the use of phototherapy in the 
management of hyperbilirubinemia, “Phototherapy to Prevent Severe Neonatal 
Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation.” 14 The most 
important intervention for infants with severe hyperbilirubinemia is to initiate phototherapy 
without delay. The clinical response to phototherapy depends on the efficacy of the phototherapy 
device, as well as the infant’s rates of bilirubin production and elimination. The following 
characteristics contribute to the effectiveness of the phototherapy device: emission of light in the 
blue-to-green range that overlaps the in vivo plasma bilirubin absorption spectrum (~460-490 
nm); irradiance of at least 30 µW/cm
2
 per nm (confirmed with an appropriate irradiance meter 
calibrated over the appropriate wavelength range); illumination of maximal body surface; and 
demonstration of a decrease in total bilirubin concentrations during the first 4 to 6 hours of 
exposure. Serial measurements of bilirubin concentrations are recommended to monitor the 
effectiveness of phototherapy treatment.  
 
The efficacy of commercial neonatal phototherapy devices varies widely. These devices can be 
categorized according to their light source as follows: gallium nitride light-emitting diodes (LED), 
halogen spot lights (metal halide bulbs), fiberoptic blankets and fluorescent tube devices. The 
performance characteristics of the most commonly used phototherapy devices are summarized in 
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14 
The AAP has recommended that the irradiance for intensive phototherapy be at least 30 
µW/cm
2
 per nm over the wavelength band interval of 460-490 nm.
8 
Devices that emit lower 
irradiance may be supplemented with auxiliary devices. The AAP further recommends that “All 
nurseries and services treating infants should have the necessary equipment to provide 
intensive phototherapy.”8  
 
The AAP recommendations for exchange transfusion are summarized in Figure 3, “Guidelines for 
exchange transfusion in infants 35 or more weeks” gestation.”8 During birth hospitalization, 
exchange transfusion is recommended if the TSB rises to these levels despite intensive 
phototherapy. The following guidelines are provided for infants readmitted to the hospital with 
severe hyperbilirubinemia: if the TSB concentration is above the exchange level, repeat TSB 
measurement every 2 to 3 hours and consider exchange transfusion if the TSB remains above the 
levels indicated after intensive phototherapy for 6 hours. Immediate exchange transfusion is 
recommended if the infant with hyperbilirubinemia shows signs of acute bilirubin 
encephalopathy: hypertonia, arching, retrocollis, opisthotonos, fever, high-pitched cry. 
 
In cases of isoimmune hemolytic disease, the AAP recommends administration of 
immunoglobulin (IgG, 0.5-1.0 g/kg over 2 hours) if the TSB is rising despite intensive 
phototherapy or the TSB level is within 2 to 3 mg/dl (34-51 µmol/L) of the exchange level (Fig 
3). If necessary, this dose can be repeated in 12 hours.
8
  
 
Several pharmaceutical agents have been investigated for their ability to prevent or treat neonatal 
hyperbilirubinemia. Tin mesoporphyrin, a potent inhibitor of heme oxygenase, has been shown to 
effectively reduce TSB levels in term and preterm infants.  It is currently being investigated for 
use in infants with severe hyperbilirubinemia.
16
 
 
 
Parent Education and Resources 
Before the infant is discharged from the hospital, parents should be given both written and verbal 
information about newborn jaundice, including risk factors, identification and treatment. As part 
of their Safe and Healthy Beginnings program, the AAP offers a resource toolkit for hospitals and 
providers. “Safe & Healthy Beginnings: A Resource Toolkit for Hospital and Physician’s 
Offices” is based on the key aspects of the revised AAP hyperbilirubinemia guideline, including 
1) the assessment of a newborn’s risk for severe hyperbilirubinemia, 2) support for breastfeeding 
mother, and 3) coordination of care between newborn nursery and primary care practice. It is 
available for purchase at the AAP Bookstore. This on-line resource includes tools for clinicians 
and parent handouts.  An on-line demo is available at, 
http://www2.aap.org/pubserv/shb/index.html, accessed June 26, 2013. 
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Table 1: Risk Factors for the Development of Severe Hyperbilirubinemia in Infants of 35 or More 
Weeks’ Gestation (In Approximate Order of Importance).  
Reprinted with permission from the American Academy of Pediatrics
8 
Major Risk Factors 
   Predischarge TSB or TcB level in the high-risk zone (Fig 2)
25,31
 
   Jaundice observed in the first 24 h
30
 
   Blood group incompatibility with positive direct antiglobulin test, other known hemolytic disease (eg, G6PD deficiency), elevated 
ETCOc 
   Gestational age 35-36 wk
39,40
 
   Previous sibling received phototherapy
40,41
 
   Cephalhematoma or significant bruising
39
 
   Exclusive breastfeeding, particularly if nursing is not going well and weight loss is excessive
39,40
 
   East Asian race
39
* 
Minor Risk Factors 
   Predischarge TSB or TcB level in the high intermediate-risk zone
25,31
 
   Gestational age 37-38 wk
39,40
 
   Jaundice observed before discharge
40
 
   Previous sibling with jaundice
40,41
 
   Macrosomic infant of a diabetic mother
42,43
 
   Maternal age >25 y
39
 
   Male gender
39,40
 
Decreased Risk (these factors are associated with decreased risk of significant jaundice, listed in order of decreasing importance) 
   TSB or TcB level in the low-risk zone (Fig 2)
25,31
 
   Gestational age >41 wk
39
 
   Exclusive bottle feeding
39,40
 
   Black race
38
* 
   Discharge from hospital after 72 h
40,44
 
* Race as defined by mother’s description. 
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Figure 1: Nomogram for Designation of Risk. Reprinted with permission from the American Academy 
of Pediatrics
8
 
Nomogram for designation of risk in 2840 well newborns at 36 or more weeks’ gestational age with birth weight of 
2000 g or more or 35 or more weeks’ gestational age and birth weight of 2500 g or more based on the hour-specific 
serum bilirubin values. The serum bilirubin level was obtained before discharge, and the zone in which the value fell 
predicted the likelihood of a subsequent bilirubin level exceeding the 95th percentile (high-risk zone) as shown in 
Appendix 1, Table 4. Used with permission from Bhutani et al.
31
 See Appendix 1 for additional information about 
this nomogram, which should not be used to represent the natural history of neonatal hyperbilirubinemia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Guidelines for phototherapy in hospitalized infants of 35 or more weeks’ gestation. 
Reprinted with permission from the American Academy of Pediatrics
8 
   Note: These guidelines are based on limited evidence and the levels shown are approximations. The guidelines refer 
to the use of intensive phototherapy which should be used when the TSB exceeds the line indicated for each category. 
Infants are designated as “higher risk” because of the potential negative effects of the conditions listed on albumin 
binding of bilirubin, 
45-47 
the blood brain barrier,
48
 and the susceptibility of the brain cells to damage by bilirubin.
48
 
   “Intensive phototherapy” implies irradiance in the blue-green spectrum (wavelengths of approximately430-490 nm) 
of at least 30µW/cm
2
 per nm (measured at the infant’s skin directly below the center of the phototherapy unit) and 
delivered to as much of the infant’s surface area as possible. Note that irradiance measured below the center of the 
light source is much greater than that measured at the periphery. Measurements should be made with a radiometer 
specified by the manufacturer of the phototherapy system. 
   See Appendix 2 for additional information on measuring the dose of phototherapy, a description of intensive 
phototherapy, and of light sources used. If total serum bilirubin levels approach or exceed the exchange transfusion 
line (Fig 4), the sides of the bassinet, incubator, or warmer should be lined with aluminum foil or white material.
50
 
This will increase the surface area of the infant exposed and increase the efficacy of  phototherapy.
51
 
   If the total serum bilirubin does not decrease or continues to rise in an infant who is receiving intensive 
phototherapy, this strongly suggests the presence of hemolysis. 
   Infants who receive phototherapy and have an elevated direct-reacting conjugated bilirubin level (cholestatic 
jaundice) may develop the bronze-baby syndrome. See Appendix 2 for the use of phototherapy in these infants.
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Figure 3: Guidelines for exchange transfusion in infants 35 or more weeks’ gestation. Reprinted with 
permission from the American Academy of Pediatrics
8 
   Note that these suggested levels represent a consensus of most of the committee but are based on limited evidence, 
and the levels shown are approximations. See ref. 3 for risks and complications of exchange transfusion. During birth 
hospitalization, exchange transfusion is recommended if the TSB rises to these levels despite intensive phototherapy. 
For readmitted infants, if the TSB level is above the exchange level, repeat TSB measurement every 2 to 3 hours and 
consider exchange if the TSB remains above the levels indicated after intensive phototherapy for 6 hours. 
   The following B/A ratios can be used together with but not in lieu of the TSB level as an additional factor in 
determining the need for exchange transfusion
52
: 
 
Risk Category B/A Ratio at Which Exchange Transfusion 
Should be Considered 
TSB mg/dl/Alb, g/dl TSB µmol/L/Alb, µmol/L 
Infants  >38 0/7 wk 
Infants 35 0/7-36 6/7 wk and well or >38 
0/7 wk 
   if higher risk or isoimmune hemolytic 
disease 
   or G6PD deficiency 
Infants 35 0/7-37 6/7 wk if higher risk or 
   isoimmune hemolytic disease or G6PD 
deficiency  
8.0 
7.2 
 
 
6.8 
0.94 
0.84 
 
 
0.80 
If the TSB is at or approaching the exchange level, send blood for immediate type and crossmatch. Blood for exchange transfusion 
is modified whole blood (red cells and plasma) crossmatched against the mother and compatible with the infant.53 
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Figure 4: Algorithm providing recommendations for management and follow-up according to 
predischarge bilirubin measurements, gestation, and risk factors for subsequent hyperbilirubinemia. 
Reprinted with permission from the American Academy of Pediatrics
10 
 Provide lactation evaluation and support for all breastfeeding mothers. 
 Recommendation for timing of repeat TSB measurement depends on age at measurement and how far 
the TSB level is above the 95th percentile (Fig 2). Higher and earlier initial TSB levels require an earlier 
repeat TSB measurement. 
 Perform standard clinical evaluation at all follow-up visits. 
 For evaluation of jaundice see 2004 AAP guideline.1 
 Table 3.b Fig 2.c Fig 1.d In hospital or as outpatient.e Follow-up recommendations can be modified 
according to level of risk for hyperbilirubinemia; depending on the circumstances in infants at low risk, 
later follow-up can be considered.
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Table 2: Phototherapy Devices Commonly Used in the United States and Their Performance Characteristics.  
Reprinted with permission from the American Academy of Pediatrics
14 
Device Manufacturer Distance 
to 
Patient 
(cm) 
Footprint Area 
(Length x  
Width, cm2) 
% 
Treatable 
BSA 
Spectrum, 
Total 
(nm) 
*Band-  
width 
(nm) 
Peak 
(nm) 
Footprint Irradiance 
(µW/cm2/nm) 
Min Max Mean 
±SD 
Light Emitting 
Diodes [LED] 
   neoBLUE 
    
   PortaBed 
 
Fluorescent 
   BiliLite CW/BB 
    
   BiliLite BB 
   
   BiliLite TL52 
    
   BiliBed 
Halogen 
   MiniBiliLite 
    
   Phototherapy Lite 
 
Halogen fiberoptic 
   BiliBlanket 
   Wallaby II  
      Preterm 
   Wallaby II Term 
    
   SpotLight 1000 
    
   PEP Model 2000 
   Bili Soft 
 
 
Natus Medical, San 
Carlos, CA 
Stanford University, 
Stanford, CA 
 
Olympic Medical, San 
Carlos, CA 
Olympic Medical, San 
Carlos, CA 
Olympic Medical, San 
Carlos, CA 
Medela, McHenry, IL 
 
Olympic Medical, San 
Carlos, CA 
Philips Inc, Andover, 
MA 
 
Ohmeda, Fairfield, CT 
Philips, Inc, Andover, 
MA 
Philips, Inc, Andover, 
MA 
Philips, Inc, Andover, 
MA 
PEP, Fryeburg, ME 
GE Healthcare, Laurel, 
MD 
 
 
30 
 
>5 
 
 
45 
 
45 
 
45 
 
0 
 
45 
 
45 
 
 
0 
0 
 
0 
 
45 
 
23 
0 
 
 
1152 (48 × 24) 
 
1740 (30 × 58) 
 
 
2928 (48 × 61) 
 
2928 (48 × 61) 
 
2928 (48 × 61) 
 
693 (21 × 33) 
 
490 (25 diam) 
 
490 (25 diam) 
 
 
150 (10 × 15) 
117 (9 × 13) 
 
280 (8 × 35) 
 
490 (25 diam) 
 
1530 (30 × 51) 
825 (25 × 33) 
 
 
100 
 
100 
 
 
100 
 
100 
 
100 
 
71 
 
54 
 
54 
 
 
24 
19 
 
53 
 
54 
 
100 
71 
 
 
420–540 
 
425–540 
 
 
380–720 
 
400–550 
 
400–626 
 
400–560 
 
350–800 
 
370–850 
 
 
390–600 
400–560 
 
400–560 
 
400–560 
 
400–717 
400–670 
 
 
20 
 
27 
 
 
69 
 
35 
 
69 
 
80 
 
190 
 
200 
 
 
70 
45 
 
45 
 
45 
 
63 
40 
 
 
462 
 
463 
 
 
578 
 
445 
 
437 
 
450 
 
580 
 
590 
 
 
533 
513 
 
513 
 
513 
 
445 
453 
 
 
12 
 
40 
 
 
6 
 
11 
 
13 
 
14 
 
<1 
 
<1 
 
 
9 
8 
 
6 
 
1 
 
12 
1 
 
 
37 
 
76 
 
 
10 
 
22 
 
23 
 
59 
 
19 
 
17 
 
 
31 
30 
 
11 
 
11 
 
49 
52 
 
 
30 ± 7 
 
67 ± 8 
 
 
8 ± 1 
 
17 ± 2 
 
19 ± 3 
 
36 ± 2 
 
7 ± 5 
 
5 ± 5 
 
 
20 ± 6 
16 ± 6 
 
8 ± 1 
 
6 ± 3 
 
28 ± 11 
25 ± 16 
Data in Table 1 are expanded and updated from that previously reported by Vreman et al.15 The definitions and standards for device assessment are explained below.                                                                                                                                                                                                             
EMISSION SPECTRAL QUALITIES: Measured data of the light delivered by each of the light sources are presented as the minimum, maximum and range. Light source emission 
spectra within the range of 300–700 nm were recorded after the device had reached stable light emission, using a miniature fiberoptic radiometer (IRRAD2000, Ocean Optics, Inc, 
Dunedin, FL). For precision based device assessment, the spectral bandwidth (*), which is defined as the width of the emission spectrum in nm at 50% of peak light intensity, is 
the preferred method to distinguish and compare instead of the total range emission spectrum (data usually provided by manufacturers). Emission peak values are also used to 
characterize the quality of light emitted by a given light source.                                                                                                                                                                                                     
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IRRADIANCE: Measured data are presented as mean ± standard deviation (SD), representing the irradiance of blue light (including spectral bandwidth), for each device's light 
footprint at the manufacturer-recommended distance. To compare diverse devices, the spectral irradiance (μW/cm2/nm) measurements were made using calibrated BiliBlanket 
Meters I and II (Ohmeda, GE Healthcare, Fairfield, CT), which were found to yield identical results with stable output phototherapy devices. This type of meter was selected from 
the several devices with different photonic characteristics that are commercially available, because it has a wide sensitivity range (400–520 nm with peak sensitivity at 450 nm), 
which overlaps the bilirubin absorption spectrum and which renders it suitable for the evaluation of narrow and broad wavelength band light sources. The devices have been found 
exceptionally stable during several years of use and agree closely after each annual calibration.                                                                                                FOOTPRINT: The 
minimum and maximum irradiance measured (at the intervals provided or defined) in the given irradiance footprint of the device (length × width). The footprint of a device is that 
area which is occupied by a patient to receive phototherapy. The irradiance footprint has greater dimensions than the emission surface, which is measured at the point where the 
light exits a phototherapy device. The minimum and maximum values are shown to indicate the range of irradiances encountered with a device and can be used as an indication of 
the uniformity of the emitted light. Most devices conform to an international standard to deliver a minimum/maximum footprint light ratio of no lower than 0.4.                                                                                           
BSA: BODY SURFACE AREA refers to percent (%) exposure of either the ventral or dorsal planar surface exposed to light and Irradiance measurements are accurate to ±0.5.                                                                                                                                                                                         
All of the reported devices are marketed in the United States except the PortaBed, which is a non-licensed Stanford-developed research device and the Dutch Crigler-Najjar 
Association (used by Crigler-Najjar patients).
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Appendix 19. Perinatal Illicit Substance Exposure in Infants and 
Pregnant Women 
 
Scope of the problem 
The National Survey on Drug Use and Health (NSDUH) reports that in 2002 and 2003, 4.3 
percent of pregnant women aged 15 to 44 had used illicit drugs including opiates, marijuana, 
cocaine, hallucinogens, inhalants, tranquilizers, stimulants, and sedatives in the past month. Also 
4.1 percent reported binge alcohol use and 18.0 percent reported smoking cigarettes.
1
 The rate of 
drug use for pregnant teenagers was approximately 15 percent. 
2
 The NSDUH data also suggest 
that women increased their substance use during the year after giving birth.   
 
Illicit substance use/abuse (and legal substance use/abuse including alcohol and tobacco) may 
impact a pregnant woman’s health, the course of her pregnancy, and the development of her 
fetus. Fetal effects of illicit substances include teratogenesis, intrauterine growth retardation, 
prematurity, low birth weight, birth complications, and central nervous system damage. Exposed 
newborns are at risk for neonatal abstinence effects and developmental and behavioral 
abnormalities.  
 
Increasing rates of substance abuse during pregnancy translate into higher numbers of drug-
exposed infants.  In 2004 and 2005 DHS confirmed in utero drug exposure on 549 and 306 
newborns, respectively, in Iowa.
5 
However, this number is lower than the expected 1500-1750 
newborns based on ~ 37,000 infants being delivered in Iowa annually. This discrepancy is 
mainly due to poor screening/testing practices. The unrecognized infants are discharged to their 
homes where mothers are likely to continue to use/abuse illegal substances. These infants 
continue to be exposed to illegal substances and the associated chaotic life style, health 
degradation, violence, child abuse and neglect, and family dysfunction.  
 
Research shows that intervention works. Treatment for substance abuse during pregnancy is 
significantly more effective than at other times in a woman’s life.  Treatment also has a positive 
effect on fetal outcome (fewer intensive care admissions due to greater gestational age and birth 
weight).
6 
Early recognition, early intervention, timely entry into treatment, and a sustained, long-
term treatment regimen minimize the fetal impacts of perinatal maternal illicit drug use and 
improve a woman’s prognosis for successful, ongoing recovery from addiction. A screening and 
intervention protocol developed by a panel of experts from across Iowa will help medical care 
providers to make objective decisions regarding their screening/testing/intervention practices for 
substance abuse in women during pregnancy and for their offspring.
7,8
 
 
Purpose  
 Develop a community practice guideline for perinatal illicit substance use screening and 
testing 
 Identify illicit substance using patients during pregnancy and their exposed infants 
 Provide a screening tool to identify the patients and infants at risk for use and exposure  
 Provide guidelines for referral and intervention both for the mother and the infant 
 Increase secondary and tertiary prevention efforts to reduce pregnancy related illicit drug 
use/abuse 
 
Appendix 19 
Guidelines for Perinatal Services, Eighth Edition, Appendices Updated August 2013  61 
The sole goal of identification is to provide early access to assessment and treatment for the 
mother/infant dyads without application of punitive measures. Identification efforts should start 
at the first prenatal visit. Screening for maternal substance abuse must begin with a thorough but 
non-judgmental and compassionate interview. History taking should include questions about the 
pregnant woman’s and her immediate family members’ use of prescribed and un-prescribed 
drugs, tobacco, and alcohol.   
 
Consent for Testing  
Specific consent should be sought from the pregnant woman to perform urine toxicology testing 
if any risk factor is recognized via risk assessment form. Urine testing history including testing 
offer dates, maternal responses (consented versus declined), test dates, results, and positive 
testing drug(s) should be documented in the chart. Any concerning result should be shared with 
the hospital social worker and the pediatric team. 
 
Maternal consent is not needed to test a newborn as long as one or more of the risk indicators 
related to maternal and infant history or presentation are present; if the risk factors equate to the 
conditions stated in Iowa law that is “if a health practitioner discovers in a child physical or 
behavioral symptoms of the effect of exposure to cocaine, heroin, amphetamine, 
methamphetamine, or other illegal drugs including marijuana, or combination or derivatives that 
were not prescribed by a health practitioner or if the health  practitioner has determined through 
examination of the natural mother of the child that the child was exposed in-utero.” However, the 
mother should be informed of the decision to test the newborn. Urine/meconium or umbilical 
cord testing with testing dates and results should be documented in the chart. 
 
Risk assessment in Prenatal Clinic, Labor & Delivery, and Neonatal Units 
This tool consists of two assessments; one to assess the risk status of the pregnant/delivering 
woman, the other of the infant.   
 Prenatal clinic/delivery room risk assessment form: Prenatal clinic and labor and delivery 
staff will fill out this form. This risk assessment should take place at the first encounter with 
the pregnant woman and at delivery.  At other encounters the staff should document that the 
pregnant woman continues to be abstinent.   
 Neonatal risk assessment form: This form will be filled out by the newborn staff who will 
also review the above listed form and maternal drug testing results.  
 Labor and delivery staff should share the maternal risk assessment and testing results with 
the medical team providing care to the newborn. If prenatal care and delivery take place at 
different hospitals, the delivery hospital should request maternal consent to obtain the 
prenatal records from where prenatal care was obtained.   
 Each hospital is encouraged to either adopt these attached forms or develop a system to 
incorporate the risk assessment forms into the prenatal/neonatal records. Prenatal clinic/labor 
and delivery staff, hospital substance abuse management team, hospital social worker(s), 
psychiatry staff, and pediatric team should review these forms in their assessment of their 
client (infant and/or the mother).   
 
Test specimens 
 Urine: 10 ml urine; if submission to the lab is to be delayed it should be kept refrigerated 
until testing. 
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 Umbilical Cord: 6-8 inch segment; cord blood should be drained from the cord segment and 
discarded, rinse exterior with normal saline, place cord segment in specimen container; 
sample is shipped to testing laboratory without preservative at room temperature.   
 Meconium: 5 grams of meconium is necessary. It may be refrigerated up to 48 hours after 
collection.   
 Urine is the test of choice for the mother; either umbilical cord testing OR urine and 
meconium testing should be done to test the newborn.  
 Every institution should have a procedure for documentation according to their policies and 
procedures in handling all specimens obtained for the purpose of newborn toxicology testing.   
 
Institutional response to addiction in Prenatal Clinic/Labor & Delivery Unit 
Hospitals are recommended to establish an in-house team to respond to the needs of pregnant 
women using illicit drugs. This team may include staff from prenatal clinic, newborn unit, 
hospital social services, hospital/community chemical dependency unit/agency, and psychiatry 
department. Staff becoming aware of substance abuse or positive test results should have this 
team or the hospital social worker involved to improve the referral process for treatment at any 
time during pregnancy. Information on referral centers for substance abuse treatment can be 
found at, www.idph/state.ia.us under Bureau of Substance Abuse/Online Resources/Licensed 
Substance Abuse Treatment Programs.   
 
Notification Guidelines 
Any staff becoming aware of an infant testing positive for illicit substances as defined in Iowa 
code is required by law to file a report with DHS for “Presence of Illegal Drugs.” Any staff 
becoming aware of maternal substance abuse, positive test result and/or multiplicity of risk 
indicators for perinatal illicit substance exposure should have the hospital social worker get 
involved to assess for a need to file a report for “denial of critical care” with DHS for child 
protection.  
 
 
Resources 
National Institute on Drug Abuse (NIDA): Commonly Abused Drugs Chart (revised 
March 2011)  
 Lists substances of abuse, including tobacco, alcohol, illicit and prescription drugs; 
Provides information  on their common and street names, how they are generally administered 
and their potentially harmful  health effects; Website available at:  
 http://www.drugabuse.gov/drugs-abuse/commonly-abused-drugs/commonly-abused-
drugs-chart, accessed  June 4, 2013. 
 
Iowa Substance Abuse Information Center (ISAIC)  
 Provides information for parents, teens, college students, educators and health 
professionals on substance  abuse prevention and recovery; Provides specific age-appropriate 
information on club drugs,  Crack/Cocaine, Heroin/opiates, inhalants, Marijuana, 
Methamphetamine, prescription and OTC drugs,  steroids, synthetic drugs (K2, Bath Salts) 
and Tobacco; Provides contact information for prevention and  treatment programs in Iowa 
to anyone seeking a referral; Website available at:  http://www.drugfreeinfo.org/drugs/, 
accessed June 4, 2013. Helpline is staffed 24/7, (866) 242-4111. 
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SAMPLE--Perinatal Illicit Substance Exposure Risk Assessment Tool* 
 
A. Obstetrics Clinic and Labor and Delivery Unit 
►Risk Factors Related to Current Pregnancy 
Maternal urine drug screen positive  .......................................................................Yes No 
Maternal report of illicit drug use ...........................................................................Yes No 
No prenatal care or late prenatal care (> 16 weeks gestation) ................................Yes No 
Poor prenatal care (≤ 4 prenatal visits) ...................................................................Yes No 
Abruptio placenta ....................................................................................................Yes No 
Unexplained premature delivery .............................................................................Yes No 
Unanticipated out-of-hospital delivery ...................................................................Yes No 
Unexplained discrepancy between delivery/prenatal care facilities (hospital hopping) 
.................................................................................................................................Yes No 
Presented at hospital in second stage of labor ........................................................Yes No 
Precipitous labor (<3 hours) ...................................................................................Yes No 
Unexplained episode of acute hypertension (≥140/90 mmHg) ..............................Yes No 
Unexplained seizures, stroke, or myocardial infarction..........................................Yes No 
Tobacco/Alcohol use or prescription drug (i.e. Vicodin, Oxycotin) abuse ............Yes No 
Physical attributes suggesting illicit drug use such as IV track marks, visible  
   tooth decay, sores on face, arms or legs…………………………………….......Yes No 
Altered mental status suggesting influence/withdrawal from illicit drugs .............Yes No 
Unexplained stillbirth..............................................................................................Yes No 
 
►Risk Factors Related to Maternal Medical History 
Unexplained hepatitis B or C, syphilis or HIV within the last 3 years ...................Yes No 
Untreated maternal depression or major psychiatric illness within the last 3 yearsYes No 
Ever used illegal drugs during any pregnancy ........................................................Yes No 
Ever delivered an infant who tested positive for illicit drugs .................................Yes No 
 
►Risk Factors Related to Maternal Social History 
History of illicit drug use by mother or partner within the last 3 years ..................Yes No 
History of illicit drug rehabilitation by mother or partner within the last 3 years ..Yes No 
History of domestic violence by partner within the last 3 years .............................Yes No 
History of child abuse, neglect, or court ordered placement of children outside of home 
 ..................................................................................................................Yes No 
 
 _______________________________________ _________________________ 
Physician/CNM/Nurse Signature    Date 
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This risk assessment should take place at the first encounter with the pregnant woman and 
at delivery.  At other encounters the staff should document that the pregnant woman 
continues to be abstinent.  If any of the above questions is answered with a YES, please do 
the following: 
 Request informed consent from the mother to order urine screening for illicit drugs 
 Contact the unit social worker to initiate detailed psychosocial assessment  
 Request Chemical Dependency Services consult if the social worker and the physician 
believe it is warranted 
 Request Psychiatry consult if mental health problems recognized 
 Communicate the risk status with Newborn Nursery or NICU staff verbally (for L&D staff) 
 Attach copy of this form to Labor and Delivery Form and send to the Newborn Nursery or 
NICU along with the baby 
 
B.  Newborn Nursery/NICU (please review maternal risk assessment from L&D unit) 
 ►Risk Factors Related to Newborn Assessment 
 Maternal risk factor(s) present ................................................................................Yes No 
 Mother was tested during this pregnancy or labor for illicit drugs .........................Yes No 
 Mother tested positive for illicit drugs during this pregnancy ................................Yes No 
 Gestation ≤37 weeks from unexplained preterm delivery ......................................Yes No 
 Unexplained birth weight less than 10
th
 percentile for gestational age ..................Yes No 
 Unexplained head circumference less than 10
th
 percentile for gestational age ......Yes No 
 Unexplained seizures, stroke, or brain infarction ...................................................Yes No 
 Unexplained symptoms that may suggest drug withdrawal/intoxication: high pitched  
  cry, irritability, hypertonia, lethargy, disorganized sleep, sneezing, hiccoughs,  
  drooling, diarrhea, feeding problems, or respiratory distress………….. ............Yes No 
 Unexplained congenital malformations involving genitourinary tract, abdominal  
  wall, or gastrointestinal systems ..........................................................................Yes No 
 
 ______________________________________             ___________________________ 
 Physician/Nurse Practitioner Signature                                        Date 
 
►Staff should order meconium and urine screening tests for illicit drugs if the answer is 
Yes to one or more questions under the Risk Assessment Tool parts A or B.  
 
 
*Tool developed by task force of statewide perinatal experts in collaboration with the Iowa Perinatal Care 
Program
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EFFECTS OF MATERNAL SUBSTANCE ABUSE ON THE FETUS/NEONATE
9 
SUBSTANCE PREGNANCY EFFECTS  NEONATAL EFFECTS  WITHDRAWAL SYMPTOMS 
Cocaine 
Amphetamines 
Methamphetamine 
Spontaneous abortion 
Abruptio placenta 
Stillbirth 
Premature delivery  
     (most common effect) 
Growth:                                                            
Low birth weight                             Prematurity 
Smaller head circumference            Intrauterine growth restriction 
 
Malformations: 
Urogenital                                        Brain 
Ocular                                              Cardiac 
Vascular disruption (limb reduction, intestinal atresia) 
Skull defect, encephaloceles 
Midline defects (agenesis of corpus callosum, septo-optic dysplasia)                
 
Neurodevelopmental: 
Hypertonia                                       Seizures 
Tremulous                                       Strokes 
Porencephaly                                   SIDS 
Impaired organizational state          Brainstem conduction delays 
Onset:  At birth or a few days thereafter 
 
Neurobehavioral: 
Depressed state occurring immediately after birth and 
lasting 3-4 days 
Late-emerging hyperirritable phase (onset 3-30 days) 
Abnormal crying, sleeping, and feeding patterns 
Possible seizures 
 
Other symptoms: 
Tachycardia, tachypnea, and apnea 
Elevated cardiac output, stroke volume, mean arterial 
blood pressure, and cerebral artery flow velocity 
resolving by day 2 
 
Opiates (heroin, 
opium, morphine) 
Appetite suppression 
Iron-deficiency anemia 
Spontaneous abortion 
Premature delivery 
Preterm labor 
Abruptio placenta 
Chorioamnionitis 
Fetal distress 
Fetal loss 
Increased C/S related to  
   breech presentation 
Growth: 
Intrauterine growth restriction 
Smaller head circumference 
 
Other effects: 
Longer duration of membrane rupture 
Increased rates of meconium staining 
Lower Apgar scores 
Increased incidence of syphilis and HIV infection at birth   
Onset:  At birth 
NEONATAL WITHDRAWAL SYNDROME 
Central Nervous System: 
Irritable, excessive crying     Hyperactive reflexes 
Jittery, tremulous                   Sleep disturbances 
Increased tone                        Seizures 
Autonomic Dysfunction: 
Excessive sweating                Hyperthermia 
Hypertension                          Mottling 
Respiratory Symptoms:            
Nasal stuffiness                      Tachypnea 
Gastrointestinal and Feeding Disturbances: 
Diarrhea         Hyperphagia          Excessive sucking 
Hallucinogens 
(PCP) 
Precipitous delivery 
Out of hospital delivery 
Growth: 
Small for gestational age 
Onset:  At birth or shortly after birth 
PCP-ASSOCIATED SYNDROME 
Neurological: 
Severe hypertonicity         Severe hyperreflexia     
Sudden episodes of agitation 
Fluctuating levels of consciousness 
Early alterations in state lability and consolability 
Spontaneous clonus persisting for several weeks 
Gastrointestinal: 
Abdominal distention       Vomiting       Diarrhea 
Marijuana  Growth:  Intrauterine growth restriction Neurological:  Hypertonicity   Irritability   Jitteriness 
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Appendix 20. Hepatitis B  
 
Maternal Hepatitis B Surface Antigen (HBsAg) Testing 
All pregnant women should be tested routinely for HBsAg during an early prenatal visit (e.g., 
first trimester) in each pregnancy, even if they have been previously vaccinated or tested. Women 
who were not screened prenatally, those who engage in behaviors that put them at high risk for 
infection and those with clinical hepatitis should be tested at the time of admission to the hospital 
for delivery. 
 
If the woman has a positive HBsAg, the case must be reported to the Iowa Department of Public 
Health, Center for Acute Disease Epidemiology (EPI) within one week per Iowa Administrative 
Code 614 Chapter 1.  The case may be reported by phone (1-800-362-2763), by secure fax (515-
281-5698), or in writing. The form for reporting a Hepatitis B case is located in the EPI Manual, 
Hepatitis B section, available at: 
http://www.idph.state.ia.us/idph_universalhelp/main.aspx?system=IdphEpiManual, accessed 
June 6, 2013. 
 
Vaccination of Infants at Birth 
Birth Dose:  Only single-antigen hepatitis B vaccine should be used for the birth dose. 
 
For all medically stable infants weighing >2,000 g at birth and born to HBsAg negative mothers, 
the first dose of vaccine should be administered before hospital discharge. On a case-by-case 
basis and only in rare circumstances, the first dose may be delayed until after hospital discharge 
for an infant who weighs >2,000 g and whose mother is HBsAg negative. When such a decision 
is made by the physician to withhold the birth dose and a copy of the original laboratory report 
indicating that the mother was HBsAg negative during this pregnancy should be placed in the 
infant’s medical record. 
 
Infants born to mothers who are HBsAg positive should receive hepatitis B vaccine and hepatitis 
B immune globulin (HBIG) <12 hours of birth. 
 
Infants born to mothers whose HBsAg status is unknown should receive hepatitis B vaccine <12 
hours of birth.  The mother should have blood drawn as soon as possible to determine her 
HBsAg status; if she is HBsAg positive, the infant should receive HBIG as soon as possible (no 
later than one week of age). 
 
Preterm infants weighing <2,000 g and born to HBsAg negative mothers should have their first 
vaccine dose delayed until one month after birth or hospital discharge. For these infants, a copy 
of the original laboratory report indicating that the mother was HBsAg negative during this 
pregnancy should be placed in the infant’s medical record. 
 
Preterm infants weighing <2,000 g and born to HBsAg positive mothers should receive hepatitis 
B vaccine and hepatitis B immune globulin (HBIG) <12 hours of birth. The initial vaccine dose 
(birth dose) should not be counted as part of the vaccine series because of the potentially reduced 
immunogenicity of hepatitis B vaccine in these infants; three additional doses of vaccine (for a 
total of four doses) should be administered beginning when the infant reaches one month of age.  
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After the Birth Dose—Completion of Vaccine  
All infants should complete the hepatitis B vaccine series with either single-antigen vaccine or 
combination vaccine, according to the recommended vaccination schedule.  
 
Administration of four doses of hepatitis B vaccine to infants is permissible in certain situations 
(e.g., when combination vaccines are administered after the birth dose). 
 
Post-vaccination Testing 
For infants born to mothers who are HBsAg positive, post-vaccination testing for anti-HBs and 
HBsAg should be performed after completion of the vaccine series, at age 9–18 months 
(generally at the next well-child visit). Testing should not be performed before age 9 months to 
avoid detection of anti-HBs from HBIG administered during infancy and to maximize the 
likelihood of detecting late HBV infection. Anti-HBc testing of infants is not recommended 
because passively acquired maternal anti-HBc might be detected in infants less than 24 months 
of age born to HBV infected mothers.  
 
Resource 
Maternal Hepatitis B Coordinator 
Bureau of Disease Prevention & Immunization  
Iowa Department of Public Health  
321 East 12th Street 
Des Moines, IA  50319 
Phone: (515) 281-7228 
Fax: (800) 831-6292 
 
1. Iowa Department of Public Health. The Epi Manual: Guide to Surveillance, Investigation, and 
Reporting. Available at: 
http://www.idph.state.ia.us/idph_universalhelp/main.aspx?system=IdphEpiManual. Accessed 
June 6, 2013. 
2. Iowa Department of Public Health. Bureau of HIV, STD, and Hepatitis: Hepatitis Program. 
Available at: 
http://www.idph.state.ia.us/HivStdHep/Hepatitis.aspx?prog=Hep&pg=HepResources. 
Accessed June 6, 2013. 
3. Centers for Disease Control and Prevention (CDC). MMWR, December 23, 2005. Vol.54/ No. RR-
16. A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus 
Infection in the United States. Available at: 
 http://www.cdc.gov/mmwr/PDF/rr/rr5416.pdf. Accessed June 6, 2013. 
4. Immunization Action Coalition. Available at: http://www.immunize.org/. Accessed June 6, 2013. 
5. Centers for Disease Control and Prevention: Viral Hepatits. Available at: 
http://www.cdc.gov/ncidod/diseases/hepatitis/b/. Accessed June 6, 2013. 
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Appendix 21. Induced Therapeutic Hypothermia for Newborns with 
Moderate to Severe Hypoxic Ischemic Encephalopathy 
 
Hypoxic ischemic encephalopathy (HIE), also known as birth asphyxia, is the most common 
cause of brain injury in the newborn. In the United States, perinatal asphyxia and resulting 
hypoxic ischemic encephalopathy occurs in 1 to3 per 1,000 births. HIE is defined as acute brain 
injury that is evidenced by clinical signs of encephalopathy and laboratory findings indicating 
fetal acidemia. The clinical criteria for defining moderate and severe encephalopathy are 
described in Table 1. Brain injury occurs as the result of an  intrapartum event that disrupts 
cerebral blood flow and leads to decreased oxygenation in the brain, most often in term or late 
preterm infants. Events that may lead to HIE include uterine rupture, abruptio placenta, cord 
prolapse, cord rupture, maternal trauma, hemorrhage, shoulder dystocia, maternal hypotension 
and fetal heart rate decelerations. Accumulating evidence supports the thinking that this is an 
evolving process of brain injury which begins with the initial hypoxic-ischemic insult, but then 
extends into the recovery period. After resuscitation where cerebral perfusion and oxygenation are 
restored, a secondary reperfusion injury occurs from 6 to 48 hours after the initial event. This 
second phase of injury involves irreversible cell death. About half of all neonates with severe HIE 
will die in the newborn period, and most of the survivors experience significant disability. 
Table 1 
Category Moderate Encephalopathy Severe Encephalopathy 
1. Spontaneous Activity Decreased activity No activity 
2. Posture Distal flexion or complete extension Decerebrate 
3. Autonomic System: 
    Pupils 
    Heart Rate 
    Respirations 
 
Constricted 
Bradycardia 
Periodic breathing 
 
Skew deviation/dilated/NR 
Variable heart rate 
Apnea 
4. Tone Hypotonia (focal or general) Flaccid 
5. Primitive Reflexes: 
    Suck 
    Moro 
 
Weak 
Incomplete 
 
Absent 
Absent 
6. Level of Consciousness Lethargic Stupor or coma 
 
Induced Therapeutic Hypothermia 
Until recently, treatment for neonates with hypoxic-ischemic encephalopathy has been limited to 
supportive care and treatment of seizures. However, research has emerged with new treatment 
options that have great potential for  improving outcomes. Induced hypothermia, therapy aimed 
at minimizing the secondary reperfusion injury associated with HIE has been shown to reduce 
the incidence of death and disability for infants with moderate to severe encephalopathy. Brain 
cooling has a favorable effect on multiple pathways contributing to ischemic brain injury. 
Studies suggest that cooling the deep regions of the brain can provide some neuro protection for 
the newborn at risk for severe brain injury. The Neonatal Resuscitation Program, 6
th
 Edition 
guidelines recommend that infants born at >36 weeks gestation with evolving moderate to severe 
hypoxic ischemic encephalopathy should be offered therapeutic hypothermia.
2 
Treatment should 
be initiated within 6 hours of birth using an  established study protocol in a tertiary facility that 
is capable of managing the adverse effects of cooling. The  potential adverse effects of induced 
hypothermia include hypoglycemia, decreased myocardial contractility, ventilation-perfusion 
mismatch, increased blood viscosity, acid-base and electrolyte imbalances, and an increased risk 
for infection. The cooling process should continue for 72 hours followed by slow rewarming 
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over at least 4  hours. Cooling centers must have the capability for multidisciplinary care and 
longitudinal follow-up. 
 
  
 Cooling Techniques 
Induced hypothermia has been studied using two methods of treatment: selective head cooling 
and whole-body cooling.  Selective head cooling is accomplished using a cooling cap. For 
whole-body cooling, the infant is placed on a cooling blanket. Both methods have been 
associated with a reduction in brain injury following a hypoxic-ischemic event. Although 
selective head cooling has been associated with fewer systemic effects of hypothermia, it has not 
been proven effective in cooling the deep regions of the brain where the greatest potential for 
neuro protection exists. Whole-body cooling involves lowering the core body temperature and is 
associated with more adverse systemic effects. But, this method provides more consistent 
regulation of the brain temperature and more effective cooling of the deep brain structures.
3 
It is 
important to note that clinical trials for both cooling techniques are ongoing.  
 
Induced Whole-Body Cooling in Iowa 
Induced whole-body cooling for infants with moderate to severe hypoxic ischemic 
encephalopathy is currently available at the following perinatal centers in Iowa:  
 
 University of Iowa Children’s Hospital, Iowa City 
 NICU, Bay 1: (319) 356-1671  
 Mercy Medical Center, Des Moines 
 NICU: (515) 358-4000  
 Blank Children’s Hospital, Des Moines 
 NICU: (515) 241-4490 
 St. Luke’s Hospital, Cedar Rapids 
 NICU: (319) 369-7247  
 
Practitioners have collaborated in these centers to develop a treatment protocol that mirrors the 
original NICHD Neonatal Research Network randomized trial comparing whole-body cooling 
and usual care (control) for term infants with hypoxic-ischemic encephalopathy.
4
 Potential 
candidates for cooling must be <6 hours of age, > 36 weeks gestation, and have a birth weight 
that is >1800 grams. There must be physiologic evidence of acute perinatal depression: a cord 
blood gas or first postnatal blood gas indicating severe acidemia, pH <7.0 or base deficit >16 
mmol/L. In cases where a blood gas is not obtained or there is moderate acidemia, pH 7.01-7.15 
or base deficit 10-15.9 mmol/L, infants will be considered for treatment if their 10-minute Apgar 
score is <5 or they require prolonged resuscitation with intubation and ventilation for more than 
10 minutes. Neurologic criteria for cooling include the presence of seizures or an abnormal 
neurological exam that is defined by the presence of signs in 3 of 6 categories from Table 1. The 
general guidelines for identifying potential candidates for induced hypothermia treatment are 
outlined in the attached algorithm (Figure 1), “Whole Body Cooling for Hypoxic Ischemic 
Encephalopathy.” Eligible patients may be excluded from treatment if cooling therapy 
cannot be initiated by 6 hours of life. So, it is imperative that practitioners identify potential 
candidates for cooling soon after birth and initiate transfer to a cooling center.  
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Clinical trials supported by the Neonatal Research Network are ongoing at the University of 
Iowa, information is available at: https://neonatal.rti.org/, accessed June 26, 2013. Practitioners 
are encouraged to contact a cooling center to discuss the care of any infant at risk for HIE, even 
those who fail to meet the general guidelines for cooling. 
 
 
 
Temperature Management Prior to Cooling 
In an observational study within the NICHD trial, Laptook et al
5
 demonstrated that an elevated 
body temperature is associated with worse outcomes among term infants with hypoxic ischemic 
encephalopathy. The risk of death or moderate/severe disability was increased with the duration 
and total time of elevated esophageal temperatures >38.0°C. Death or moderate/severe disability 
was also associated with the longest duration of skin temperatures >37.5°C. More research is 
needed to determine the implications for passive cooling prior to induced hypothermia treatment. 
For newborns with suspected HIE, frequent monitoring of axillary temperatures prior to transfer 
is recommended. The goal for managing these patients prior to cooling is to maintain a normal 
temperature, 36.0-37.0°C (96.8-98.6°F) and avoid hyperthermia, temperature >37.5°C (99.5°F). 
 
 
1. Shankaran S, Laptook A, Wright LL, et al. Whole body hypothermia for neonatal encephalopathy: 
animal observations as a basis for a randomized, controlled pilot study in term infants.  Pediatrics. 
2002; 110(2):377-85. Available at: http://pediatrics.aappublications.org/content/110/2/377. 
Accessed November 19, 2012. 
2. American Academy of Pediatrics, Task Force on Sudden Infant Death Syndrome. Policy statement—
SIDS and Other Sleep-Related Infant Deaths: Expansion of Recommendations for a Safe Infant 
Sleeping Environment. Pediatrics. 2011; 128(5):1030-1039. Available at: 
http://pediatrics.aappublications.org/content/early/2011/10/12/peds.2011-2284. Accessed 
November, 19, 2012. 
3. Laptook AR, Shalak L, Corbett RJT. Differences in brain temperature and cerebral blood flow during 
selective head versus whole-body cooling. Pediatrics. 2001; 108(5):1103-10. Available at: 
http://pediatrics.aappublications.org/content/108/5/1103. Accessed November 19, 2012.  
4. Shankaran S, Laptook AR, Ehrenkranz RA, Tyson JE, McDonald SA, Donovan EF, Fanaroff AA, 
Poole WK, Wright LL, Higgins RD, Finer NN, Carlo WA, Duara S, Oh W, Cotten M, Stevenson 
DK, Stoll BJ, Lemons JA, Guillet R, Jobe AH. Whole-body hypothermia for neonates with 
hypoxic-ischemic encephalopathy.  N Engl J Med. 2005; 353:1574-84. Available at: 
http://www.nejm.org/doi/full/10.1056/NEJMcps050929. Accessed November 19, 2012.    
5. Laptook A, Tyson J, Shankaran S, McDonald S, Ehrenkranz, Fanaroff A, Donovan E, Goldberg R, 
O’Shea TM, Higgins RD, Poole WK. Elevated temperature after hypoxic-ischemic 
encephalopathy: risk factor for adverse outcome. Pediatrics. 2008; 122(3):491-99. Available at: 
http://pediatrics.aappublications.org/content/122/3/491. Accessed November 19, 2012. 
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Figure 1.    Whole Body Cooling for Hypoxic Ischemic Encephalopathy 
Clinical trials supported by the Neonatal Research Network are ongoing at the University of Iowa,  
https://neonatal.rti.org/. Practitioners are encouraged to contact a cooling center to discuss the care of any 
infant at risk for HIE, even those who fail to meet the general guidelines for cooling.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contributing author: D. Ellsbury MD, Mercy Medical Center, Des Moines, IA; Adapted from: Shankaran, N Engl J Med 2005;353:1574 
YES
NO 
NO 
YES 
YES NO 
NO 
YES 
≥36 weeks gestation, ≥ 1800 grams, < 6 hours old NOT ELIGIBLE 
FOR COOLING 
Blood gas pH of 7.0 or less 
-Cord gas (venous/arterial) OR  
-Any postnatal blood gas (ABG, 
VBG, or Capillary BG) in the first 
hour of life 
     OR 
Base deficit of 16 mEq/L or 
more 
-On cord gas or any postnatal blood 
gas in the first hour of life 
MAY BE ELIGIBLE 
FOR COOLING         
pH of 7.01 to 7.15 
 
              OR  
 
Base deficit of 10 to 15.9 
History of an acute perinatal event  
Examples: Abruptio placenta, cord prolapse, severe 
FHR abnormality (variable or late decelerations) 
 
         AND EITHER 
 
10 minute Apgar score of 5 or less 
 
               OR 
Ventilation initiated at birth and 
continued for at least 10 minutes 
 
  Seizures  
        ? 
TRANSFER BABY 
TO COOLING 
CENTER 
  
Maintain Normal Axillary              
Temperature: 
36.0°C – 37.0°C 
(96.8°F – 98.6 °F) 
 
AVOID HYPERTHERMIA 
Cooling Centers in Iowa: 
 
         University of Iowa Children’s Hospital             Mercy Medical Center 
    Iowa City                           Des Moines 
         NICU, Bay 1: (319) 356-1671            NICU: (515) 358-4000 
 
    Blank Children’s Hospital                         St. Luke’s Hospital 
         Des Moines                        Cedar Rapids 
      NICU: (515) 241-4490                        NICU: (319) 369-7247 
     YES    
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Appendix 22. Progesterone Therapy to Prevent Preterm Birth 
 
Women with a history of preterm delivery are at two to three times greater risk of having a 
recurrent preterm delivery. For these women, there is one option available to decrease their risk 
of prematurity—17 alpha-hydroxyprogesterone caproate (17-P). The exact mechanism by which 
17-P works is not clearly understood, but it is thought to be related to a reduction of gap junction 
formation and therefore decreased uterine contractions.
1
 It has recently been proposed that the 
effect of 17-P may also be anti-inflammatory in nature and that it may preserve cervical integrity. 
Initially studied as a 250mg weekly injection, 17-P was found to decrease the rate of preterm 
delivery (less than 37 weeks) from 55% in the placebo group to 36% in the treatment group.2 In 
addition, infants of the treatment group were significantly less likely to have necrotizing 
enterocolitis, intraventricular hemorrhage, or need supplemental oxygen. Administration of 17-P 
was initiated a 16-20 weeks gestation in the initial study. However, the optimal timing to initiate 
therapy has not been well established. 
 
Follow-up studies have evaluated the use of 17-P with different routes of administration and 
study populations. Since many women would like to avoid injections, other routes of 
administration have been investigated. 17-P is not widely marketed by any particular 
pharmaceutical company. Prophylactic administration of progesterone in the form of a vaginal 
suppository, 100mg administered every night at bedtime was found to significantly reduce the 
risk of prematurity (by approximately 50%) in women with a prior preterm delivery.3 Although 
this may be a more convenient form for patients due to self-administration, the vaginal 
suppository is not widely available and must be formulated by individual pharmacies. 
 
A study is currently underway to evaluate the use of vaginal progesterone suppositories in 
women with a history of prior preterm birth, but with normal cervical lengths during the current 
pregnancy. For women with no history of a preterm birth, but a shortened (≤15 mm) cervix, it 
appears that progesterone suppositories may be beneficial.
4 
As for twin gestations, treatment with 
prophylactic 17-P does not seem to reduce the risk of preterm delivery.
5
 This is likely due to the 
different mechanism, possibly uterine over distension which many twin premature deliveries are 
thought to be attributed. 
 
Currently, the American College of Obstetricians and Gynecologists (ACOG) recommends that 
the use of progesterone supplementation in pregnancy to prevent preterm birth be restricted to 
women with a history of a prior spontaneous preterm delivery.
6 
However, the ideal population, 
route and timing of progesterone therapy are yet to be determined. 
 
On January 3, 2013 the Iowa Department of Human Services, Iowa Medicaid Enterprise (IME) 
sent Informational Letter No. 1203 to Iowa Medicaid physicians, nurse practitioners, nurse 
midwives, hospitals, clinics, maternal health centers and family planning agencies. It provides 
information regarding Medicaid coverage of 17HP. It is available at, 
http://secureapp.dhs.state.ia.us/IMPA/Information/ViewDocument.aspx?viewdocument=af825d92-12fc-
4284-af1b-aa75d053f819, accessed June 26, 2013. For questions about filing claims, please contact the 
IME Provider Services Unit at 1-800-338-7909, or locally in Des Moines at 515-256-4609 or email at, 
imeproviderservices@dhs.state.ia.us.  
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Appendix 23. Preventing Shaken Baby Syndrome and Abusive Head 
Trauma 
 
Shaken Baby Syndrome is a highly preventable form of child abuse which occurs when an infant 
or young child is violently shaken or slammed into a surface. It is usually triggered by 
inconsolable infant crying. An infant’s neck muscles are very weak and his head is 
disproportionally large for his body. So, when shaken, the head will violently rotate in a figure 
eight pattern, causing blood vessels to tear and brain damage to occur.  
Background and Scope of Problem                                                                                                                     
From 1995 – 2007, 51 Iowa infants died from Shaken Baby Syndrome (SBS). Many more 
survived with injuries, some of them life-altering. Immediate effects of SBS may include 
vomiting, seizures, breathing difficulties, lethargy, limpness or stiffness of arms and legs, and 
bleeding in the eye. Long-term effects may include cognitive and learning disabilities, paralysis, 
speech impairments, hearing loss, vision problems, and behavior disorders. In approximately 
20% of cases the victim dies.   
The Iowa Prevent SBS Team, comprised of representatives from Iowa Department of Public 
Health, Prevent Child Abuse Iowa, Iowa Department of Management and Blank Children’s 
Hospital worked collaboratively to plan and implement a statewide program to prevent Shaken 
Baby Syndrome. Through a scholarship opportunity, the team attended the PREVENT Institute 
for Child Maltreatment at University of North Carolina to receive six days of training by experts 
in the field and coaching toward the development of a five-year plan for Shaken Baby Prevention 
in Iowa.   
Efforts by child abuse prevention advocates and victims’ families led to the passage and signing 
of a bill during the 2009 legislative session, directing the Iowa Department of Public Health to 
develop and implement a statewide SBS prevention plan. With work from the PREVENT 
Institute as a foundation, the plan was developed and is currently in the implementation phase. 
Funds received through Heartland Area Education Agency (American Recovery and 
Reinvestment Act) have allowed for a pilot SBS prevention program to serve birthing hospitals 
in a 12-county region in central Iowa. Additional hospitals throughout the state were supported 
though grant funds from the University of Iowa Children’s Hospital. Prevent Child Abuse Iowa 
received funding from other donors. Many Iowa hospitals have located independent funding and 
implemented the program as well.  
Period of PUPLE Crying
® 
                                                                                                                                   
The educational program selected for use is the Period of PURPLE Crying
®
, the only SBS 
prevention program having undergone randomized, clinical trials to measure its effectiveness. 
Program development drew from more than 25 years of research on normal infant crying. Using 
a child development education approach, the Period of PURPLE Crying
®
 program helps parents 
and caregivers understand the features of crying in normal infants that can lead to shaking or 
abuse. The program teaches these crying characteristics in a 10-minute DVD which is available 
in ten languages. Education is provided to new parents by nurses at the time of discharge from 
the hospital. The word PURPLE is an acronym representing the prominent characteristics of 
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inconsolable infant crying: Peaks at 2 months; Unexpected; Resists soothing; Pain-like face; 
Long lasting; Evening (baby may cry more in late afternoon or evening) Figure 1.   
   
      Figure 1 
 
Behavioral Component 
There are 3 action steps outlined in the Period of PURPLE Crying® program. They guide the 
caregiver to respond in a way that reduces crying as much as possible while preventing shaking 
and abuse. These action steps are: 
 
1. Caregivers should respond to their baby with “Comfort, carry, walk and talk” 
behaviors. This encourages caregivers first to increase contact with their infant to reduce 
some of the fussing, to attend to their infant’s needs, and to not neglect them. 
 
2. It is “OK to walk away” if and when the crying becomes too frustrating. When this 
happens, caregivers should put the baby in a safe place and then walk away. 
 
3. It is “Never OK to shake or hurt” your baby to stop his crying under any 
circumstances. 
 
The Period of PURPLE Crying
®
 program is unique because: 
 It approaches prevention through educating parents and the community about normal 
infant development, specifically that crying for infants is normal. The program focuses 
on education and coping skills, rather than on the negative consequences of shaking. 
 It uses highly attractive, positive messages for caregivers rather than negative warnings 
about bad consequences. 
 It aims to bring about a cultural change in our understanding of infant crying both for 
caregivers and the general public. 
 It is designed to increase program “penetration rates” to new parents and be widely 
acceptable to health care professionals and groups disseminating the intervention. 
 Each family of a new baby gets their own set of materials so they can review it as needed 
and relevant. They can also share it with others who care for their baby. 
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Minimum Requirements for Hospital Implementation 
1.  Each Family Needs to Receive Their Own Set of Materials  
The tested model requires that each parent of a new infant receives both the PURPLE program 
DVD and booklet to take home with them. Parents may not realize how relevant the material is 
until baby is a few months old.  People learn in different ways; some learn best through reading 
the brochure, and others learn through viewing the DVD. Families are encouraged to share the 
information with all caregivers.   
 
 
2. Consistent Messages and Fidelity of the Program  
It is critically important that consistent, clear and correct (evidence-based) messages are given to 
the parents and the public.  
 
3. Triple Dose Strategy  
Dose One: Birthing Hospitals   
The PURPLE program is given to families of new babies, both mothers and fathers, in the 
hospital after the birth of their baby. Maternity nurses are trained and provided with a script to 
use when presenting the materials to families of new babies. Each family receives from the nurse 
the 10-minute DVD and 11-page full color booklet about PURPLE Crying to take home with 
them. When possible, the parents should watch the DVD in the hospital and be able to ask the 
nurse questions. Additionally, the nurse should give the DVD/Booklet to the parent, have them 
open it and read the booklet at the hospital before they leave. It is very important that the parents 
receive the program from a person in a position of authority or influence, like a maternity nurse, 
doctor, midwife or health educator. It is equally important that the person delivering the 
PURPLE program encourages parents to review the materials and encourages them to share the 
materials with other caregivers of their baby. Users of the program can add a certificate or 
commitment statement if they wish. These are also available at no cost from the NCSBS.  
 
Dose Two: Prenatal and Postnatal Primary Health Care Units or Public Health Visiting Nurses  
Public health nurse home visitors, pediatricians, family doctors or public health clinics should 
reinforce the message by talking to parents about the concepts taught in the Period of PURPLE 
Crying
®
 program.  
 
Dose Three: Public Education and Media Campaign  
A public education campaign provides this information to everyone, especially to those who did 
not receive it through the previous two methods. This is an important part of bringing about a 
cultural change in our understanding of the normality of early increased crying.  It is important to 
educate grandmothers, temporary caregivers, boyfriends, neighbors and relatives about the 
PURPLE program. Understanding of the Period of PURPLE Crying
®
 among the general 
population can help ease the stress, and even criticism, of parents dealing with the inconsolable 
crying of their babies. It also enables mothers and fathers to receive support and reinforcement 
from those who understand the Period of PURPLE Crying
®
 concept. 
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Resources 
For more information on the Period of PURPLE Crying
®
, visit: www.purplecrying.info. 
 
The program has undergone several years of randomized controlled trials in the United States and Canada. Refer to 
Randomized Controlled Trials and Research accepted for publication at: 
http://www.dontshake.org/sbs.php?topNavID=4&subNavID=32&navID=345. Accessed June 6, 2013. 
 
The program is also based on over three decades of research on normal infant crying. Refer to the SBS and Infant 
Crying Bibliography attributed to this program, available at: 
http://www.dontshake.org/sbs.php?topNavID=4&subNavID=32&navID=332. Accessed June 6, 2013. 
 
For more information about the PURPLE program, contact the National Center on Shaken Baby Syndrome 
(NCSBS) by email at: purple@dontshake.org; Visit the website at: www.dontshake.org; Call the center at (801) 
447-9360) or write to: 1433 North 1075 West, Suite #110, Farmington, Utah 84025.  
 
The Period of PURPLE Crying® is a registered trademark and all content is copyright protected. All Rights Reserved, Ronald G. 
Barr, MDCM and the National Center on Shaken Baby Syndrome (2004–2009). 
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Appendix 24. Sudden Unexpected Infant Death and Sudden Infant Death 
Syndrome  
 
Sudden unexpected infant death (SUID), also known as sudden unexpected death in infancy 
(SUDI), is a term used to describe any sudden and unexpected death in infants less than 1 year of 
age, where the cause of death is not immediately obvious prior to investigation. With a thorough 
case investigation, many of these sudden, unexpected infant deaths can be explained. 
Explainable causes for SUID include poisoning, metabolic disorders, hyper or hypothermia, 
suffocation, neglect and homicide (Fig.1).1 When cases of SUID 
remain unexplained after a complete autopsy, examination of the 
death scene and review of the clinical history the death is 
classified as sudden infant death syndrome (SIDS). Ninety 
percent of SIDS deaths occur before 6 months of age, and the 
peak incidence occurs between 1 and 4 months. SIDS is 
uncommon after 8 months of age. It is the leading cause of death 
in infants from one month to one year of age. Historically, SIDS 
deaths were observed more often in the colder months of the 
year, but a pattern of seasonality is no longer apparent. 
 
Background and Scope of the Problem 
In the United States there are approximately 4600 SUID cases 
every year. Of those deaths, about 2300 are classified as SIDS. In 
2006, the latest year from which data are available, 2327 infants 
died of SIDS.2 There is a higher incidence among African American 
infants (99 per 100 000 live births) and American Indian/Alaskan 
Native infants (112 per 100 000 live births) than non-Hispanic white infants (55 per 100 000 live 
births).3 However, no ethnic, religious or socioeconomic group is immune to SIDS. 
 
 
In their annual report to the governor and general assembly, Iowa’s Child Death Review Team 
reported 91 sleep-related infant deaths (death of a child 1 year of age or less) for the years 2008 
and 2009.3 A sub-committee was formed to explore and analyze data from those 2008 and 2009 
deaths. Of those 91 deaths, 22 infants died of SIDS, 42 deaths were classified as SUID, 25 
infants died of asphyxia and in 2 cases the cause of death was undetermined. In a majority of 
these cases the sub-committee found identifiable risk factors in the baby’s sleep environment that 
increased the risk of SIDS and accidental death. The two most common sleep surfaces were adult 
beds and couches (28/91 and 21/91). Other significant factors included soft bedding (65/91), 
prone sleep position (34/91 placed prone to sleep and 48/91 found deceased in prone position), 
co-sleeping with adults or older children (40/91), exposure to tobacco products (53/91) and 
exposure to alcohol or illicit drugs either in utero, environmentally or their caretakers at the time 
of death were under the influence of these substances (45/91).    
 
In 1992, the American Academy of Pediatrics (AAP) first recommended that infants be placed in 
a non-prone position for sleep as a strategy to reduce the risk of SIDS.4 The “Back to Sleep” 
campaign was initiated in 1994.5 Subsequently, the incidence of SIDS in the US declined from 
120 deaths per 100 000 live births in 1992 to 56 deaths per 100 000 live births in 2001, a 
decrease of 53% over 10 years (Fig.2)1 However, in recent years that decline has plateaued.  
Figure 1.  Possible causes of SUID
1 
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Figure 2: Trends in SIDS and other SUID mortality: United States 1990-2006. UNK indicates ill-defined or 
unspecified deaths.
1 
 
 
In 2005, the AAP published a policy statement on SIDS.6 Since then, sleep-related infant deaths 
due to suffocation, asphyxia, entrapment and other ill-defined or unspecified causes of death 
have increased. In October 2011, the AAP expanded its recommendations regarding SIDS to 
focus on a safe sleep environment to reduce the risk of all sleep-related infant deaths. These 
recommendations are published in their policy statement, “Sudden Infant Death Syndrome and 
Other Sleep-Related Infant Deaths: Expansion of Recommendations for a Safe Infant Sleeping 
Environment.”7 The background literature review and data analyses on which this policy 
statement is based are included in the accompanying technical report.8 Case-control studies are 
the standard regarding SIDS and other sleep-related deaths as there have been no randomized 
controlled trials. 
 
The AAP recommendations were developed to reduce the risk of SIDS and sleep-related 
suffocation, asphyxia and entrapment among infants in the general population. They are intended 
for parents, health care providers and others who care for infants. Some recommendations are 
directed toward women who are pregnant or may become pregnant. Most of the epidemiologic 
studies that established the risk factors for SIDS/SUID include infants up to one year of age. 
Therefore, the AAP recommendations for sleep position and sleep environment should be used 
consistently for infants throughout the first year of life.  
   
 
Summary of Evidence and AAP Recommendations for Reducing the Risk of SIDS/SUID
8, 9
  
Back to sleep for every sleep.  
 Infants should be placed supine, wholly on their back for every sleep until one year of age. 
Once an infant is able to independently roll from supine to prone he can remain in whatever 
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sleep position he assumes. Supine sleeping does not increase the risk of choking and 
aspiration, even in infants with gastroesohageal reflux. The rare exception is the infant with 
an upper airway disorder where protective mechanisms are impaired.  
 Side sleeping increases the infant’s risk of rebreathing expired gases, resulting in 
hypercapnia and hypoxia. Recent studies have found the risk of SIDS with side sleeping to be 
similar to prone sleeping. 
 Prone sleeping puts the infant at high risk for SIDS. It increases the risk of rebreathing 
expired gases and overheating. A recent study suggests that prone sleeping alters the 
autonomic control of the infant’s cardiovascular system during sleep which can result in 
decreased cerebral oxygenation. Compared to back sleepers, babies who sleep on their 
stomach experience less movement, higher arousal thresholds and longer periods of deep 
sleep. For unaccustomed stomach sleepers (babies who usually sleep supine), their risk of 
SIDS when placed prone to sleep is increased by 20%. 
 Elevating the head of the crib is not recommended. This is not effective in reducing 
gastroesophageal reflux and might result in the infant sliding to the foot of the crib into a 
position that compromises respiration. 
 Preterm infants and other infants in the NICU should be placed supine for sleep as soon as 
they are “medically stable and significantly before the infant’s anticipated discharge, by 32 
weeks’ postmenstrual age.” 
 
Use a firm sleep surface.  
 Appropriate sleep surfaces include a crib, bassinet or portable crib/play yard that conforms to 
the current safety standards.* The crib mattress should be firm and maintain its shape so that 
there are no gaps between the mattress and the side of the crib, bassinet or play yard. Soft 
materials such as pillows, cushions, quilts, comforters or sheepskins should not be placed 
under the infant. The mattress should be covered only with a fitted sheet. 
 Sitting devices such as car safety seats, strollers, swings and infant carriers are not 
recommended for routine sleep in the hospital or at home. If an infant falls asleep in a sitting 
device, he should be moved from the seat to a crib or other appropriate flat surface as soon as 
is practical. 
  In 2010, the Consumer Product Safety Commission (CPSC) issued a statement warning 
consumers about the suffocation hazard to infants, particularly those younger than 4 months, 
who are carried in an infant sling. When using a sling or cloth carrier, the baby’s head should 
be up and above the fabric so that his face is visible and the nose and mouth are not 
obstructed. 
 
*Beginning June 28, 2011 the Consumer Product Safety Commission requires that all cribs 
manufactured and sold in the US (including resale) must comply with new and improved federal 
safety standards. The new rules, which apply to full-size and non-full-size cribs, prohibit the 
manufacture or sale of traditional drop-side rail cribs, strengthen crib slats and mattress supports, 
improve the quality of hardware, and require more rigorous testing. The details of the rule are 
available on the CPSC website at, http://www.cpsc.gov/info/cribs/index.html, accessed June 26, 
2013. By December 28, 2012, child care centers must use only compliant cribs that meet the new 
federal safety standards.  
 
Room-sharing without bed-sharing is recommended. 
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 In 2011, a meta-analysis of 11 studies confirmed that bed sharing, an infant sleeping on the 
same surface with another person, is a significant risk factor for SIDS. Bed-sharing, puts the 
baby at risk for accidental injury and death from suffocation, asphyxia, entrapment, falls and 
strangulation. Younger infants <12 weeks old and those born prematurely or with low birth 
weight are at greatest risk for SIDS while bed-sharing, possibly because they lack the motor 
skills to escape potential danger in their sleep environment. The risk of SIDS is higher, the 
longer the duration of bed-sharing during the night. There is a higher risk of SIDS when the 
infant is bed-sharing with someone who is not a parent and when there are multiple bed 
sharers. Epidemiologic studies have not found bed-sharing to be protective of SIDS for any 
subgroup of the US population. This includes the subgroup of breastfeeding mothers who do 
not smoke and have not consumed alcohol, drugs or arousal-altering medications. 
  The AAP recommends that infants sleep on a separate sleep surface (crib, bassinet, play 
yard) in the parents’ bedroom close to their bed. This arrangement is safer than bed-sharing 
or solitary sleeping (infant sleeping in a separate room), and it decreases the risk of SIDS by 
as much as 50%. Room-sharing allows the parents to sleep in close proximity to their infant 
which facilitates feeding, comforting and nurturing. 
 Devices promoted to make bed-sharing “safe” are not recommended (eg, in-bed co-sleeper). 
 Multiple studies have demonstrated an extremely high risk of SIDS and suffocation for 
infants sleeping with adults on couches and armchairs. The AAP recommends that infants not 
be held for feeding on a couch or armchair when there is a high risk that the parent might fall 
asleep. 
 Co-bedding twins and higher order multiples is not recommended in the hospital or at home. 
 
Keep soft objects and loose bedding out of the crib to reduce the risk of SIDS, suffocation, 
entrapment and strangulation. 
 Pillows, quilts, comforters, sheepskins, soft toys and loose blankets in the baby’s sleep 
environment are hazardous and increase the risk of suffocation and rebreathing exhaled 
gases. In many SIDS cases, the infant was found with his head covered by loose bedding. 
These objects should be kept out of the crib. 
 As an alternative to loose blankets, parents should consider using wearable blankets or sleep 
sacks. 
 Bumper pads and similar products are not recommended. 
 
Pregnant women should receive prenatal care. 
 Several epidemiologic studies have demonstrated a lower risk of SIDS for infants whose 
mothers obtained early and regular prenatal care. 
 
Avoid smoke exposure during pregnancy and after birth. 
 Maternal smoking before, during and after pregnancy continues to be a major risk factor for 
SIDS in many epidemiologic studies. Exposure to second-hand tobacco smoke adversely 
affects infant arousal and increases the risk for SIDS in a dose-dependent manner. Third-
hand smoke refers to residual contamination after the cigarette has been extinguished. There 
has been no research to date that demonstrates a risk for SIDS with third-hand smoke. In 
2010, Dietz et al estimated that one third of SIDS deaths could be prevented if all maternal 
smoking during pregnancy was eliminated. 
 Mothers should not smoke during pregnancy or after birth. 
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 Families are encouraged to set strict rules for smoke-free homes and cars to prevent exposure 
of infants and children to second-hand tobacco smoke.   
 
Avoid alcohol and illicit drug use during pregnancy and after birth. 
 Several studies have demonstrated an increased risk of SIDS with prenatal and postnatal 
exposure to alcohol and illicit drugs. In 50% of SIDS cases in Iowa in 2008 and 2009 
(45/91), the infant was exposed to drugs in utero, environmentally or was being cared for by 
someone under the influence of drugs or alcohol at the time of death. 
 Mothers should not use alcohol or illicit drugs before and during pregnancy. 
  Parents should be advised that alcohol and/or illicit drug use in combination with bed-
sharing places the infant at particularly high risk of SIDS.  
 
Breastfeeding is recommended. 
 Several recent studies support the protective role of breastfeeding for SIDS; however, they do 
not distinguish between nursing and feeding expressed human milk. In 2011, researchers 
reported that any breastfeeding was more protective of SIDS than no breastfeeding. And, the 
protective effect is increased with exclusivity for any duration. In the largest and most recent 
case-control study of SIDS, German researchers found that exclusive breastfeeding at 1 
month of age halved the risk of SIDS.  At all ages, the SIDS rate was lower for breastfed 
infants, partially or exclusively breastfed. 
 If possible, infants should be exclusively fed breast milk (breastfeeding or feeding expressed 
human milk) for the first 6 months of life. 
Consider offering a pacifier at nap time and bedtime. 
 Several studies have demonstrated a protective effect of pacifier use on the incidence of 
SIDS. In two meta-analyses the risk of SIDS was decreased by 50-60%. Even when the 
pacifier falls out of the baby’s mouth the protective effect continues throughout that sleep 
period. The mechanism of protection is unclear, but the following theories have been 
proposed: lowered arousal thresholds, favorable modification of autonomic control during 
sleep, and maintaining airway patency during sleep. 
 The AAP recommends that a pacifier be offered when placing the infant down to sleep. Once 
he falls asleep, it is not necessary to reinsert the pacifier. If the baby refuses the pacifier, he 
should not be forced to take it. 
 Pacifiers should not be attached to clothing or stuffed toys when the infant is sleeping as this 
may pose a strangulation or suffocation risk. 
 To avoid disruption in breastfeeding, pacifier introduction can be delayed until breastfeeding 
is well established, usually by 3-4 weeks of age. 
 There is currently no evidence that thumb-sucking or finger-sucking is protective for SIDS. 
 
Avoid overheating. 
 Studies have shown an increased risk of SIDS with overheating, but the definition of 
overheating varies. 
 Infants should be dressed appropriately for the environment, with no more than 1 layer more 
than an adult would wear to be comfortable. 
 Over-bundling and covering the infant’s face and head should be avoided. Caregivers should 
watch for signs of overheating, such as sweating or the baby’s chest feeling hot to the touch. 
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 It has been suggested that improving/increasing room ventilation with a floor fan or ceiling 
fan may decrease the risk of SIDS. However, after reviewing the current data the AAP task 
force concluded that there is insufficient evidence to recommend the use of fans as a strategy 
to reduce the risk of SIDS. 
 
Infants should be immunized in accordance with recommendations of the AAP and the 
Centers for Disease Control and Prevention. 
 There is no evidence of a causal relationship between immunizations and SIDS. And, recent 
evidence suggests that immunizations may have a protective effect against SIDS. In a 2007 
meta-analysis researchers found the risk of SIDS to be halved for those infants who were 
immunized. 
Avoid commercial devices marketed to reduce the risk of SIDS. 
 In September 2010, the FDA and CPSC issued a joint press release urging parents and 
caregivers to stop using infant sleep positioners because of the risk of suffocation with their 
use, www.fda.gov/medicaldevices/safety/alertsandnotices/ucm227301.htm, accessed June 26, 
2013. They reported 12 infant deaths related to these devices in the past 13 years. Sleep 
positioners are devices intended to keep a baby in a desired position during sleep. The two 
most common types of positioners are the sleeping bolster (Fig. 4) and the wedge-style 
positioner (Fig. 5). There is no evidence that any benefits of these devices outweigh the risk 
of suffocation.  
.                                   
                   Figure 4. Sleeping bolster                         Figure 5. Wedge-style positioner  
 
 Commercial devices including wedges, positioners, special mattresses, and special sleep 
surfaces should be avoided as there is no evidence that these devices are safe or reduce the 
risk of SIDS. 
 
Do not use home cardiorespiratory monitors as a strategy to reduce the risk of SIDS. 
 Home cardiorespiratory monitors can be useful for detecting apnea or bradycardia in cases 
where the infant has had an apparent life-threatening event. However, there is no evidence 
that home monitors are effective for preventing SIDS.  
 
Supervised, awake tummy time is recommended to facilitate development and to minimize 
development of positional plagiocephaly. 
 Positional plagiocephaly refers to the persistent flat spot that develops on the back or one 
side of a baby’s head when he sleeps in the same position repeatedly.  
 Supervised, awake tummy time is recommended for infants on a daily basis, beginning as 
early as possible to promote motor development and minimize the risk of positional 
plagiocephaly. 
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 Other preventive strategies include routinely changing the baby’s orientation in the crib and 
avoiding excess time spent in sitting devices. 
 For detailed information regarding diagnosis, management and prevention strategies see the 
recent AAP clinical report, “Prevention and management of positional skull deformities in 
infants.”10 
 
Health care professionals, staff in newborn nurseries and neonatal intensive care nurseries, 
and child care providers should endorse the SIDS risk-reduction recommendations as soon 
at the infant is clinically stable and significantly before anticipated discharge. 
 Healthcare providers in neonatal intensive care units and newborn nurseries are encouraged 
to implement and model all of the recommendations to reduce the risk of SIDS. 
 All physicians, nurses, other health professionals and child care providers should receive 
education on safe infant sleep practices. 
 Child care providers should implement these safe sleep practices, and it is preferable that 
they have a written safe sleep policy.   
 
Media and manufacturers should follow safe sleep guidelines in their messaging and 
advertising. 
 In a recent study, investigators examined magazines targeted toward child-bearing women. 
They found that one-third of the sleeping infants pictured and two-thirds of the sleeping 
environments portrayed unsafe sleep positions and sleep environments. 
 “Safe sleep messages should be reviewed, revised and reissued every 5 years to address the 
next generation of new parents and products on the market.”   
 
The AAP recommends that the national campaign to reduce the risks of SIDS be expanded to 
include a major focus on the safe sleep environment and ways to reduce the risks of all sleep-
related infant deaths, including SIDS, suffocation, and other accidental deaths. Pediatricians, 
family physicians, and other primary care providers should actively participate in this campaign. 
 
Resources 
Iowa SIDS Foundation, a statewide, nonprofit, voluntary health organization dedicated to 
providing emotional support to SIDS and SUID families residing in Iowa, educating 
professionals and the general public about  SIDS and risk reduction, and funding medical 
research into the causes of SIDS. Visit website at: www.iowasids.org; Call toll free at, (866) 
480-4741. 
First Candle, a national nonprofit organization dedicated to eliminating stillbirth, SIDS and other 
sudden unexpected infant deaths. Visit website at: http://www.firstcandle.org/.  
 
National Institutes of Health, Safe to Sleep® Public Education Campaign. Information and 
materials available at: http://www.nichd.nih.gov/sids/, accessed June 26, 2013; Call toll free at: 
(800) 505-CRIB (2742). 
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Appendix 25. Cocooning for Pertussis  
 
Diseases do not have age limits. Vaccines are not just for kids, adults need protection too. 
Parents of newborns need to ensure their vaccinations are up to date to keep themselves healthy 
and to prevent spreading disease to their infants.  
 
One important vaccine is Tdap (tetanus, diphtheria and acellular pertussis) which protects adults 
from contracting pertussis and spreading it to others.
1
 Infants are at greatest risk of having severe 
complications from getting pertussis, including death. 
 
Pertussis, also known as whooping cough, is a highly contagious and vaccine-preventable 
disease that has made a startling comeback in recent years. Immunity from childhood pertussis 
vaccinations wanes over time, therefore the pertussis immunizations most adults received as 
children may no longer fully protect them.  In infants younger than 1 year of age who get 
pertussis, more than half must be hospitalized. The younger the infant, the more likely treatment 
in the hospital will be needed. Of those infants who were hospitalized with pertussis from 2000-
2004, approximately 1 in 4 developed pneumonia and 1 in 100 died.
1 
 
In Iowa, according to the Iowa Department of Public Health, there are approximately 502% more 
persons with pertussis disease in calendar  year 2012 compared to the average of the past five 
years (the five year average is 179 and 1121 cases have been reported as of Sept 14, 2012). 
Historically, pertussis activity has been cyclical with increased activity observed every three to 
five years; therefore the current activity is not unexpected. High levels of activity last occurred in 
2004 (1066 cases reported) and 2005 (1106 cases reported), and the number of cases also 
increased moderately in 2010.
  
 
The Advisory Committee on Immunization Practices (ACIP) voted in October of 2012 to 
recommend that health care professional should administer a dose of Tdap during each 
pregnancy irrespective of the patient’s prior history of receiving Tdap. This is done to maximize 
the maternal antibody response and passive antibody transfer to the infant.  The optimal timeing 
for Tdap administration is between 27 and 36 weeks gestation. For women not previously 
vaccinated with Tdap, if Tdap was not administer during pregnancy, Tdap should be 
administered immediately postpartum3.  
 
The strategy of protecting infants from pertussis by vaccinating those in close contact with them 
(e.g. parents, siblings, grandparents, caregivers, etc.) is known as “cocooning.” ACIP has 
recommended cocooning with Tdap vaccine since 2005 and continues to recommend this 
strategy for all those with expected close contact with newborns. Cocooning enhances maternal 
vaccination to provide maximum protection to the infant.
4 
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Appendix 26. Breastfeeding Term & Late Preterm Infants  
 
According to the Centers for Disease Control and Prevention (CDC), Breastfeeding is a priority 
because we know that this is one way we can positively affect the health of mothers and babies. 
Evidence shows that several specific practices in medical care settings can significantly affect 
rates of breastfeeding initiation and duration among women. Birth facility policies and practices 
that create a supportive environment for breastfeeding should begin prenatally and continue 
through discharge.  
In an effort to improve breastfeeding policy and practice in hospitals, with the goal of increasing 
the number of babies breastfed in Iowa, the Department of Public Health has implemented a 
statewide breastfeeding initiative, “6 Steps 4 Success.” The Initiative includes face-to-face 
meetings with key maternity staff in birthing hospitals to identify and evaluate current 
breastfeeding policy and offer resources to promote development and improvement of policies. 
Also, training on basic breastfeeding support and management for staff directly assisting mothers 
and babies with breastfeeding is offered to all birthing hospitals. To date, there have been face-
to-face meetings with key maternity staff in 65 birthing hospitals and 34 staff trainings have been 
conducted.  
The Academy of Breastfeeding Medicine, Protocol #7: Model Breastfeeding Policy (Revision 
2010) is included as an addendum to these guidelines. This model breastfeeding protocol 
provides guidelines for the care of breastfeeding mothers and infants at term.  It includes the 
“Ten Steps to Successful Breastfeeding” as defined by the Baby-Friendly Hospital Initiative. 
Guidance for each step can be found at, http://www.babyfriendlyusa.org, accessed June 26, 2013. 
The Academy of Breastfeeding Medicine, Protocol #10: Breastfeeding the Late Preterm Infant 
(34
0/7
 to 36
6/7
 Weeks Gestation), revised June 2011 provides guidelines specific to the late 
preterm infant.
8
  
 
WHO/UNICEF Ten Steps to Successful Breastfeeding 
1. Have a written breastfeeding policy that is routinely communicated to all health care staff. 
2. Train all health care staff in the skills necessary to implement this policy. 
3. Inform all pregnant women about the benefits and management of breastfeeding. 
4. Help mothers initiate breastfeeding within the first hour of birth. 
5. Show mothers how to breastfeed and how to maintain lactation even if they are separated 
from their infants. 
6. Give newborn infants no food or drink other than breast milk, unless medically indicated. 
7. Practice rooming-in (allow mothers and infants to remain together) 24 hours a day. 
8. Encourage breastfeeding on demand. 
9. Give no artificial nipples or pacifiers to breastfeeding infants.* 
10. Foster the establishment of breastfeeding support groups and refer mothers to them on 
discharge from the hospital.  
  
Professional Counseling Guides 
Counseling Guides for Health Care Professionals, developed by the Iowa Breastfeeding 
Coalition, are one-page guidelines intended for use by health care professionals when counseling 
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mothers. The following guidelines are available on the Iowa Department of Public Health 
website, http://www.idph.state.ia.us/wic/Breastfeeding.aspx:  
 Prenatal Breastfeeding Promotion 
 Breastfeeding in the 1st Week (included in these guidelines) 
 Breastfeeding at 2 Weeks 
 Breastfeeding at 4 Months 
 Breastfeeding at 6 Months 
 Breastfeeding at 9 Months 
 
Breastfeeding in the 1st Week 
A Counseling Guide for Health Care Professionals 
 
Counseling Message for Mothers  Background for Professionals  
It is important to hold your baby skin-to-skin 
after birth and breastfeed within the first hour.  
There are many benefits to breastfeeding skin-to-
skin for several weeks.  It has been shown to 
increase breastfeeding duration, enhance growth 
and development, and builds your confidence.   
Skin-to-skin contact (i.e., no clothing or bedding between 
mother and baby) helps baby transition to extrauterine life, 
stabilizes baby and facilitates the first feeding. Routine 
medications and the initial weight can be delayed for an hour.  
Offer the breast at least 8-12 times every 24 
hours and let your baby feed until baby is 
satisfied, falls asleep and releases the breast.  
  
Babies have been fed continuously in utero and 
therefore need to learn the sensation of hunger 
and be able to communicate this to you. Feeding 
cues may include:  
 
 
-to-mouth activity  
 
-cry facial grimaces   
 
Crying is a late signal of needing to be fed and 
babies cry for many other reasons beside hunger.  
Colostrum, the first milk, is available in small amounts.  
Colostrum provides everything healthy newborns need.  
Newborns need to nurse often because their stomachs are small 
and breastmilk is quickly digested.  Frequent feeding and skin-
to-skin contact also helps to prevent hypoglycemia, minimize 
jaundice, and stimulate milk supply.  Limited and scheduled 
feedings may prevent establishment of a good milk supply.  By 
day 3, babies are more alert and have longer periods of 
wakefulness.  Babies usually nurse every 1½ to 3 hours for a 
total of at least 8-12 feedings every 24 hours.  If baby 
breastfeeds less than 8 times per day, evaluate the feeding 
pattern to make sure baby is feeding often enough.  Information 
on appropriate intake and weight gain on the other side.  
Proper position and latch helps get breastfeeding 
off to a good start.  The following steps tell how:  
 
 
baby’s nose and chin close to your breast.  
your nipple (pillow or folded blanket may help). 
your nipple so baby will open mouth. Your baby 
may not open wide enough if both lips are 
touched as the same time.  
wide open baby can latch on.  
 
Both mother and baby should be comfortable during feedings.  
Encourage mothers to support their breasts during feeding.  
Hold the breast with the thumb across from baby’s nose and 
four fingers below the breast and behind the areola.  
  
Help mothers to learn several feeding positions:  side-lying, 
laid-back, cradle, cross-cradle and football.  
  
Many mothers experience gentle tugging or tenderness during 
the early days.  However, breastfeeding should not hurt. Pain 
that causes a woman to question whether to continue 
breastfeeding is not normal and she should be referred to an 
individual who has been trained to help mothers with 
breastfeeding problems.  
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Most prescriptions and over the counter 
medicines can be taken during breastfeeding.   
 
your baby’s) before taking anything.  
 
breastfeeding is to you and ask them to help you 
continue.     
 
The Infant Risk Center at 806-352-2519 takes 
calls from parents and professionals on questions 
about medicines and herbs. The website, 
www.infantrisk.org is a good resource as well. 
Prescribe medications that will expose the baby to the least 
amount of drug; i.e., those with the shortest half life, lowest 
dose possible and time the dose related to the baby’s typical 
feeding schedule.    
  
Check credible resources like Thomas Hale’s book, 
Medications and Mother’s Milk and the website Lactmed. If 
temporary weaning is necessary, provide instructions about 
how to maintain a full milk supply with a quality electric breast 
pump.    
Counseling Message for Mothers 
Avoid pacifiers and bottles for the first month of 
your baby’s life.*  
Background for Professionals 
Breastmilk is all that healthy babies need.  It takes some 
practice for breastfeeding to go smoothly.  Encourage mothers 
to wait until milk supply is established before introducing 
bottles or pacifiers.  Babies suck differently on bottle nipples 
and pacifiers which may make it hard for baby to go back to the 
breast.  Early supplemental feedings decrease mother’s milk 
supply and negatively affect baby’s intestinal flora.  
Look for signs that baby is getting enough:  
 
 
 
 
  
The minimum number of wet and dirty diapers 
per day for the first week is listed below.  
Day       Wets       Stools  
1           1              1 dark color  
2           2              2 dark to greenish-brown  
3-4        3+           1-2 greenish-brown to yellow  
5-7        6+           3-4 yellow  
  
Teach mothers to evaluate how baby is feeding.  
 
soft “ka, ka” sound as baby swallows.  
 
breastmilk baby is getting.  The stool changes in color and 
consistency as mature milk replaces colostrum.  Once the 
meconium is eliminated, stools will be loose and unformed, 
with a consistency of seedy mustard.  After 4 weeks of age, 
stooling patterns change.  The volume of stool usually increases 
and the frequency decreases, however, each baby is different.  
 
Have your baby’s weight checked at 3 to 5 days 
of age by one of the following:  
 
Baby’s health care provider  
 
 
 
 
 
 
An early weight check gives a new mother confidence in her 
ability to produce enough milk and an opportunity for you to 
answer questions and provide support.  Babies discharged with 
a weight loss >7% should be seen by their health care provider 
within 2 days of discharge.  
  
Babies lose weight the first 4 days after birth.  Then most 
breastfed babies begin gaining weight at the rate of ½ to 1 ounce 
per day.  By 2 weeks of age, babies should be at or over birth 
weight.  If not, careful assessment is needed and a referral to 
someone knowledgeable on breastfeeding management.  For 
further information see the Academy of Breastfeeding 
Medicine’s clinical protocol #3 on supplementation, at 
www.bfmed.org. 
The only thing your baby needs other than 
breastmilk is vitamin D.  
All healthy newborn breastfed infants should receive 400 IU of 
vitamin D per day beginning in the first few days of life to 
prevent rickets and vitamin D deficiency.  
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Questions?  Call one of the following:  
ing educator/counselor  
 
 
 
 
 
 
Mothers and babies are not born knowing how to breastfeed.  It 
takes patience and practice to learn and recognize each other’s 
signals.  Identify sources of support from family, friends, and 
the community.  Encourage mothers to call with questions or for 
advice.   
Developed by the Iowa Breastfeeding Coalition, Distributed by the Iowa WIC Program, Revised 2011
6 
 
*In their 2011 Policy Statement on SIDS and other sleep-related infant deaths, the American Academy of Pediatrics 
makes the following recommendation: “Consider offering a pacifier at nap time and bedtime. Although the 
mechanism is yet unclear, studies have reported a protective effect of pacifiers on the incidence of SIDS…For 
breastfed infants, delay pacifier introduction until breastfeeding has been firmly established, usually by 3 to 4 weeks 
of age.”9 
 
 
Contraindications to Breastfeeding10 
Medical Conditions: 
-Conditions where the mother should not breastfeed OR feed expressed breast milk: 
 Mother is HIV positive 
 Mother is positive for human T-cell lymphotrophic virus type I or II (HTLV-1 or HTLV-
2) 
 Mother has untreated brucellosis  
 Infant has classic galactosemia 
-Conditions where the mother may partially breastfeed or partially feed expressed breast milk: 
 Infant has phenylketonuria (PKU): may alternate breastfeeding with special protein-free 
or modified formula, provided that appropriate blood monitoring is available 
-Conditions where the mother should not breastfeed, but can feed expressed breast milk: 
 Mother has active (infectious) untreated tuberculosis: can resume breastfeeding after 
treated for minimum of  2 weeks and documented that mother is no longer infectious  
 Mother has active herpes simplex lesions on her breast: may breastfeed using other breast 
if not affected 
 Mother develops varicella in period of 5 days before through 2 days after delivery: 
mother should be separated from infant, but expressed milk can be used for feeding 
 Mother is acutely infected with H1N1 influenza: mother should be separated from infant 
until she is afebrile 
  
Maternal Medications: 
 There are a limited number of agents that are contraindicated with breastfeeding, and 
usually an appropriate substitute can be found.  
 LactMed, an internet resource published by the National Library of Medicine/ National 
Institutes of Health is the most comprehensive, up-to-date source of information 
regarding the safety of maternal medications when the mother is breastfeeding.11 This 
resource is available at, http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT, accessed 
June 26, 2013.  
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 Breastfeeding is not recommended when the mother is receiving medication from the 
following classes of drugs: amphetamines, chemotherapy agents, ergotamines, and 
statins.   
 
Maternal Substance Abuse: Drugs, Alcohol, Tobacco 
 Narcotic-dependent mothers can be encouraged to breastfeed if they are enrolled in a 
supervised methadone maintenance program and have negative screening for HIV and 
illicit drugs.  
 Breastfeeding is contraindicated with use of the following street drugs: PCP 
(phencyclidine), cocaine, and cannabis. 
 Alcoholic beverages should be limited to an occasional intake but no more than 0.5g 
alcohol per kg body weight, which for a 60kg mother is approximately 2oz liquor, 8oz 
wine, or 2 beers.12 
 Nursing should take place 2 hours or longer after the mother consumes alcohol to 
minimize its concentration in the breast milk. 
 Maternal smoking is not an absolute contraindication to breastfeeding, but should be 
strongly discouraged as it is associated with an increased incidence of infant respiratory 
allergy and SIDS. 
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This protocol was reprinted with the permission of the Academy of Breastfeeding Medicine  
www.bfmed.org 
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Appendix 27. Tobacco Cessation  
 
Women should not initiate smoking cigarettes, and current smokers should pursue smoking 
cessation.  There is no known level of smoking that is considered a safe consumption level. 
Parents who smoke often expose their children to secondhand smoke, with associated adverse 
health consequences and economic costs, and model smoking behavior to their children, 
potentially increasing the likelihood that their children will become smokers 
 
Background  
In 2011, approximately 2,800 Iowa deaths were directly attributable to tobacco use. Another 
1,600 deaths were identified as likely being due to tobacco use. Estimated annual health care 
costs in Iowa directly related to tobacco use now total $1 billion. 
Cigarette smoking is the leading cause of preventable death and poses one of the most significant 
threats to public health in the United States. Approximately 173,940 women died in the U.S. 
during 2000-2004 due to smoking. The CDC estimates that 18.1% of adult U.S. women aged 18 
years or older are current cigarette smokers (CDC 2009).  
 
Smoking and Childbearing  
Smoking is harmful to the health of pregnant women and their fetuses. However, despite 
evidence of these harmful effects, Iowa Vital Records data for 2011 indicate that 12.7% of 
pregnant women in their third trimester of pregnancy stated that they were smokers. Iowa 
women on Medicaid were more than four times as likely to smoke in the last 3 months of 
pregnancy when compared to women with private insurance. Smoking during pregnancy 
presents major, avoidable health risks to both the woman and her fetus. Smoking has been linked 
to doubling a woman’s risk of having a low birth-weight baby, slowing fetal growth, and 
increasing the risk of preterm delivery. Compared to babies of nonsmokers, babies whose 
mothers smoked during pregnancy are up to three times more likely to die from sudden infant 
death syndrome (March of Dimes, 2009).  
 
Health Care Professional 
Health care professionals should educate all women about the risks of tobacco use and second-
hand smoke, screen women for tobacco use, and support cessation efforts. Focusing attention on 
these efforts before, during and after pregnancy is critically important because of the harmful 
effects of smoking and exposure to second hand smoke on the fetus and newborn. See ACOG’s 
2011 Smoking Cessation During Pregnancy – A Clinician’s Guide to Helping Pregnant Women 
Quite Smoking at the following link: 
http://www.acog.org/About_ACOG/News_Room/~/media/Departments/Tobacco%20Alcohol%2
0and%20Substance%20Abuse/SCDP.pdf, accessed June 26, 2013. 
 
One evidence based model for brief tobacco cessation intervention is “2 A’s and a R”. This 
model was developed by the American Dental Hygienists Association visit, 
www.askadviserefer.org, accessed June 26, 2013. 
 
Providers are encouraged to talk to each patient about quitting, but the time to perform this 
intervention is limited so this intervention is very brief. Providers are educated to ask about 
tobacco use as well as identify and document tobacco use status for each patient at every visit.  
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1. Ask about tobacco use. Ideally health care practitioners should implement an office-
wide system that ensures that tobacco use status is queried and documented at each 
visit 
2. Advise to quit. In a clear strong and personalized manner, urge ever tobacco user to 
quit. The provider should emphasize the importance of quitting before health problem 
arise.  
Once the patient has been advised to quit, the provider is encouraged to ask probing 
questions to determine readiness to quit before making a fax referral. This could be as 
simple as asking the patient, “How do you feel about quitting” or “Have you ever 
tried quitting before?” “How did it go?”  
3. Refer patient to Quitline Iowa. If a patient expresses and interest in quitting, the 
provider recommends participation with Quitline Iowa. The provider’s is then 
encourage to ask the patient to sign a fax referral form, making sure the patient fills in 
contact information and preferred call-back times.  
 
Quitline Iowa will provide cessation assistance including helping patient set a quit date and 
develop a plan to quit. Quitline counselors will help identify strategies for coping with cravings, 
withdrawal symptoms, smoking triggers, and other challenges, including providing information 
about pharmacotherapy. A variety of printed materials covering health information, quit tips, 
relaxation techniques, and other helpful advice can also be mailed to patients. In addition, 
Quitline counselors will identify and refer patients to other resources, such as community support 
groups or smoking cessation classes, for those patients who would prefer such services. 
 
Smoking Cessation Coverage Available to Medicaid Members  
When providers are working with Medicaid eligible women a helpful tool is located on the Iowa 
Department of Public Health’s website. It has tips on making a fax referral to the Quitline, 
Nicotine Replacement Therapy (Medicaid Prior Authorization form) and Cessation Medication 
Fax referral form, available at:  
http://www.idph.state.ia.us/TUPAC/Cessation.aspx, accessed June 26, 2013.  
 
Iowa Medicaid Enterprise has an Informational Letter no. 1048 released in 2011 to assist you. It 
is available at the following link: 
http://www.ime.state.ia.us/docs/1048_SmokingCessationCoverageAvailabletoMedicaidMembers
.pdf, accessed June 26, 2013. 
 
For Clients  
 
Quitline IOWA 
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Quitting is about more than just not smoking. When patients join the Quitline program, a Quit 
Coach® will help them become an expert in living without tobacco using "The 4 Essential 
Practices to Quit For Life," based on 25 years of research and experience helping people quit 
tobacco. 
Web Coach 
Another new option from the Iowa Department of Public Health the “Web Coach” is an 
interactive online program that provides each participant with a personalized experience. The 
Web Coach focuses on four essential practices to enable smokers to quit for life: 
 Quit at their own pace  
 Conquer urges to smoke  
 Use medications so they really work  
 Don’t just quit; become a non-smoker  
 
Each of these practice areas includes articles, videos, e-lessons and interactive worksheets to 
help participants successfully quit tobacco. Progress toward that goal includes a spending 
calculator, to help a participant compare the cost of tobacco vs. the cost of medication; a tobacco 
usage tracker, which allows a participant to track when and where they smoke to identify 
patterns and triggers; and discussion forums and online groups for more personalized social 
support. After quitting, participants can track how long they’ve been tobacco-free and see how 
much money they’ve saved and time that has been added back to their daily life since quitting 
tobacco. For more information about Web Coach, call Quitline Iowa 1-800-784-8669 or visit, 
www.quitlineiowa.org.  
 
1. Center for Disease Control and Prevention (CDC). (2009). Smoking and Tobacco Use. Available at: 
http://www.cdc.gov/tobacco/data_statistics/fact_sheets/populations/women.  
2. Centers for Disease Control and Prevention. (2009a). Smoking-attributable mortality, years of potential 
life lost, and productivity losses, United States, 2000-2004. Journal of the American Medical 
Association, 301, 593-594.  
3. Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz N, Curry SJ, Wewers ME. (2009). Treating 
tobacco use and dependence: 2008 update. Quick reference guide for clinicians. Rockville, MD: 
U.S. Department of Health and Human Services. 
4. Institute of Medicine, Board on Population Health and Public Health Practice. Consensus Report, 
October 15, 2009.  Secondhand Smoke Exposure and Cardiovascular Effects: Making Sense of the 
Evidence. Available at: http://www.iom.edu/~/media/Files/Report%20Files/2009/Secondhand-
Smoke-Exposure-and-Cardiovascular-. Accessed June 6, 2013. 
5. March of Dimes. (2009) Professionals and research, quick reference: fact sheets smoking during 
pregnancy. Retrieved from: http://www.marchofdimes.com/professionals/14332_1171.asp. 
Accessed June 6, 2013.
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Appendix 28. Influenza Immunization for Pregnant Women & Health 
Care Workers 
 
Influenza is a highly contagious viral infection that affects mainly the nose, throat, chest and 
lungs. Influenza may cause mild to severe illness, and may even lead to death. In the very young, 
the elderly, and those with other serious medical conditions, infection can lead to severe 
complications such as pneumonia.  
Everyone unless contraindicated, 6 months and older should get a influenza vaccine each year. 
This recommendation has been in place since February 24, 2010 when CDC’s Advisory 
Committee on Immunization Practices (ACIP) voted for “universal” influenza vaccination in the 
U.S. to expand protection against influenza to more people. While everyone should get a vaccine 
each influenza season, it’s especially important that those at high risk of having serious 
influenza-related complications and for those who live with or care for people at high risk for 
developing influenza-related complications. Those in greatest need of being vaccinated include: 
 Pregnant women  
 Children younger than 5, but especially children younger than 2 years old  
 People 50 years of age and older  
 People of any age with certain chronic medical conditions  
 People who live in nursing homes and other long-term care facilities  
 People who live with or care for those at high risk for complications from flu, including 
Health care workers, Household contacts of persons at high risk for complications from 
the flu, Household contacts and out of home caregivers of children less than 6 months of 
age (these children are too young to be vaccinated).
1
 
Receiving an influenza vaccine is the first and most important step in protecting against 
influenza. When given during pregnancy, the influenza vaccine has been shown to protect both 
the mother and her baby (up to 6 months old) from influenza. Influenza is more likely to cause 
severe illness in pregnant women than in women who are not pregnant. Changes in the immune 
system, heart, and lungs during pregnancy make pregnant women more prone to severe illness 
from influenza as well as hospitalizations and even death. Pregnant women with influenza also 
have a greater chance for serious problems for their unborn babies, including premature labor 
and delivery.
2 
To prevent influenza and complications in pregnant women, in 2004 the Centers for Disease 
Control and Prevention’s (CDC) Advisory Committee for Immunization Practices (ACIP) began 
recommending routine immunization of pregnant women with the influenza vaccine at any stage 
of pregnancy. The nasal spray vaccine is not recommended for use in pregnant women. Influenza 
vaccine will protect pregnant women, their unborn babies, and protect the baby after birth.
3 
In 2010 the American Academy of Pediatrics released a policy statement to recommend 
implementation of a mandatory influenza immunization policy for all health care workers. 
Immunization rates of health care workers are unacceptably low and health care associated 
influenza outbreaks are common. Employees of health care institutions have both ethical and 
professional obligation to act in the best interests of the health of their patients. Medical and 
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religious exceptions can be granted on an individual basis. Hospitals should develop policies 
regarding influenza immunization policy for all health care workers to ensure patient and staff 
safety. 
1. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: 
recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2010; 
59(No. RR-8). 
2. Centers for Disease Control and Prevention (CDC). Disease Information: Influenza: Pregnant Women 
and Influenza (Flu). http://www.cdc.gov/flu/protect/vaccine/pregnant.htm. Accessed June 6, 2013.  
3. Centers for Disease Control and Prevention (CDC). Disease Information: Influenza: Pregnancy and 
Influenza Vaccine Safety.  http://www.cdc.gov/vaccinesafety/Concerns/pregnancy_influenza.html. 
Accessed June 6, 2013.  
4. American Academy of Pediatrics. Bernstein HH, Starke JR, Committee on Infectious Diseases. Policy 
Statement—Recommendations for Mandatory Influenza Immunization of All Health Care 
Personnel. Pediatrics. 2010; 126(4):809-815. Available at: 
http://pediatrics.aappublications.org/content/126/4/809. Accessed June 6, 2013.
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Appendix 29. Eliminating Elective Delivery Prior to 39 Weeks Gestation 
 
Despite long standing recommendations from the American College of Obstetricians and 
Gynecologist (ACOG), the practice of elective inductions at less than 39 weeks of gestation is 
common practice in the United States and may account for 10-15% of all deliveries.1 This 
practice is associated with more unplanned cesarean births, operative vaginal deliveries, longer 
length of stay in labor and delivery and significant newborn morbidity. Newborn morbidity, 
caused by iatrogenic prematurity, is significant enough of an issue to warrant inclusion as a 
national perinatal quality benchmark both by the National Quality Form and the Joint 
Commission.1   
  
Following the ACOG recommendations for no elective inductions, primary or repeat cesarean 
births prior to 39 0/7 weeks is a practice where obstetric providers may intervene to decrease the 
rate of prematurity. Infants born between 37-39 weeks gestation are at increased risk for 
temperature instability, feeding problems and infection. Significant brain and neurologic 
development continues to occur in the last month of pregnancy, with the fetal brain nearly 
doubling in weight.2 The confirmation of fetal lung maturity through amniocentesis can 
minimize the risk of respiratory distress syndrome but, fetal lung maturity testing does not assess 
for any other risk of prematurity. 
  
ACOG practice bulletin #107 (2009) on induction of labor has prescribed indications and 
contraindications for induction of labor before 39 weeks (Table 1).
3
 With adequate surveillance 
and treatment, both chronic hypertension and diabetes can often be managed until 39 weeks 
gestation. Repeat cesarean sections should be completed 39 weeks or after, unless a prior 
classical cesarean section was performed. 2 A woman with contractions prior to 39 weeks should 
clearly be in labor (cervical change with contractions), prior to proceeding to a repeat cesarean 
section. 
  
Table 1 
Examples of Indications and Contraindications for Induction of Labor 
Indications Contraindications 
Abruptio Placenta 
Chorioamnionitis 
Fetal Demise 
Gestational Hypertension 
Preeclampsia, eclampsia 
Postterm Pregnancy 
Maternal medical conditions( diabetes mellitus, renal 
disease, chronic pulmonary disease, chronic 
hypertension, antiphospholipid syndrome) 
Fetal compromise ( severe IUGR, isoimmunization. 
Oligohydramnios) 
 
Vasa previa or complete previa 
Transverse fetal lie 
Umbilical cord prolapse 
Pervious classical cesarean delivery 
Active genital herpes infection 
Previous myomectomy entering the endometrial cavity 
Confirmation of Term Gestation 
 Ultrasound measurement at less than 20 weeks of gestation supports gestational age of 39 weeks or greater. 
 Fetal heart tones have been documented as present for 30 by Doppler ultrasonography. 
 It has been 36 weeks since a positive serum or urine human chorionic gonadotropin pregnancy test result. 
From ACOG Bulletin # 107, 20093 
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One of the principles of quality process improvement is that process uniformity will generally 
improve outcomes. Therefore, a checklist based protocol for the management of induction of 
labor is recommended for standardization and patient safety. An example of a checklist from 
ACOG is included in this hard copy of the appendix. Please check the ACOG website if viewing 
this appendix online as well as for frequently for updates on checklist and other bulletins at the 
link below. 
http://www.acog.org/~/media/Patient%20Safety%20Checklists/psc002.pdf?dmc=1&ts=2013030
7T1011029875. Accessed June 6, 2013. 
 
 
1. Clark S, Frye D, Meyers J, Belfort M, Dildy G, Kofford S, Perlin. Reduction in elective delivery at 
<39 weeks of gestation: comparative effectiveness of 3 approaches to change and the impact on 
neonatal intensive care admission and stillbirth. American Journal of Obstetrics & Gynecology. 
2010; 203(5):449.e1-6. 
2. Day L, Hunter S (2008). The rising pre-term delivery rate in Iowa—Three things we can do now. The 
Perinatal Letter, XXIX (1), pp.1-6. 
3. American College of Obstetricians and Gynecologists, Practice Bulletin. Induction of Labor. Vol.114, 
No.2, Part 1, August 2009. 
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Appendix 30. Intimate Partner Violence  
 
Homicide is an infrequent event, but it is the leading cause of death for women of reproductive 
age. In Iowa, between the years of 2000 and 2003, there was an average of 12.2 deaths yearly 
due to domestic violence.
1
 Each year, more than 6 million American women become pregnant; 
unfortunately, pregnancy does not exempt women from being victims of homicide.
2
 For every 
100,000 live births in the United States during 1991 through 1999, there were at least 2 women 
who died as a result of homicide during pregnancy or within one year of pregnancy.
2
 Of the 6-
8% of women (20-25% of pregnant adolescents) who experience abuse during pregnancy, 
intimate partners have been the perpetrators. Intimate Partner Violence (IPV) is a not just a social 
problem anymore; it has gradually been acknowledged as one of the most severe threats to a 
woman’s health. Preventing violence against women was listed as one of the top priority health 
issues for the United States in the Department of Health and Human Services’ campaign, 
“Healthy People 2010.” 
 
All nurses who provide care to women will inevitably encounter a patient affected by IPV.  This 
gives nurses and other health care providers a unique opportunity to have discussions about IVP 
and for referrals and possible interventions. Violence during pregnancy may be more common 
than some conditions (gestational diabetes, placenta previa or pre-eclampsia.) for which most 
pregnant women are routinely screened. Along with screening for risk factors such as smoking 
and alcohol use, screening for intimate partner violence could be incorporated into routine 
prenatal care.  
 
Nurses and other clinicians need to be aware of Iowa’s Mandatory reporting statutes. Iowa Code 
147.111 mandates “that any person who administers any treatment to persons suffering from a 
gunshot, stab wound, or other bodily injury, which may have resulted from a criminal offense, 
must be reported to a law enforcement agency.” Iowa code 135B.7 requires each hospital to 
establish protocols for treating victims. Under the Iowa Administration Code (IAC 481.51.7), 
hospitals must interview victims in privacy, ensure confidentially, educate emergency 
department staff to identify victims of domestic violence. It also specifies certain information 
that must be included in the victim’s medical record as well as giving out referral information. 
 
Definitions 
 Intimate Partner Violence (IPV) has been defined as a pattern of coercive behavior 
designed to exert power and control over a partner (or ex- partner) in an intimate 
relationship through the use of intimidating, threatening, harmful, or harassing behavior.
4
 
IPV takes on many forms, ranging from serious physical injury and sexual assault to 
progressive social isolation, emotional abuse, humiliation, intimidation, economic abuse 
and progressive coercion and control. IPV occurs in all cultures, races, ages, sexes, 
educational levels and socioeconomic groups. 
 Physical violence is the intentional use of force with the potential to cause injury, harm, 
or death. Physical violence can be actual or threatened. It includes, but is not limited to, 
these acts: slapping, pushing, shaking, biting, scratching, choking, burning, hitting, and 
using a knife, gun or other weapon against another person.  
 Sexual violence is the actual or threatened use of physical force to compel a person to 
engage in a sexual act against her/his will. An attempted or completed act with a person 
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who is unable to avoid participation, communicate unwillingness or understand the nature 
of the act. Examples of abusive sexual contact include unwanted touching, fondling or 
other sexual contact that does not necessarily involve intercourse. 
 Forms of emotional abuse may be as effective at controlling a victim as a physical injury. 
There are many behaviors that may be perceived by the victim as emotionally abusive 
including, but not limited to: humiliating name calling, deliberately embarrassing the 
victim, especially in public, controlling the victim’s movements and activities, isolating 
victims from friends and family, and/or controlling financial resources. 
 
 
Intimate Partner Violence and Pregnancy 
IPV may vary throughout a relationship. It may occur only prior to conception or during 
pregnancy; but, most often, it is continuous. The strongest predictor of IPV during pregnancy is 
IPV before pregnancy. However, pregnancy is in itself an especially high risk time for IPV to 
begin or reoccur. The physical, emotional and financial changes associated with pregnancy often 
provide an opportunity for an abusive partner to establish power and control over the woman. 
Similarly, women who experience IPV during the postpartum period are likely to have 
experienced it during pregnancy.  
 
Abuse during pregnancy is responsible for poor perinatal outcomes. Violence during pregnancy 
may result in miscarriage, poor maternal weight gain, anemia, second and third trimester 
bleeding, and abruption.  Controlling partners may prevent or prohibit prenatal care; therefore, 
abused women may start prenatal care late in the pregnancy or have frequent missed 
appointments. This behavior has two effects:  the woman (1) may find it difficult to fulfill the 
basic prenatal care requirements, such as taking prescribed supplements, screenings for sexually 
transmitted diseases, diabetes, and pre-eclampsia and (2) may have limited access to referral and 
follow-up care.  In an attempt to deal with the stress of physical or emotional abuse in her life, 
the woman may continue to smoke or self-medicate by using alcohol or other drugs during her 
pregnancy. These behaviors may lead to preterm labor and/or preterm delivery, low birth weight 
term infants, intrauterine growth restriction and fetal alcohol syndrome.  
 
Abusive partners sometimes prohibit their partners from using birth control, take away her 
contraception or intentionally break or refuse to use condoms. This can lead to a large number of 
unwanted pregnancies, pregnancies in close intervals and transmission of sexually transmitted 
infections and HIV. 
 
Many women experiencing IPV may suffer from both anxiety and depression. Even when the 
pregnancies result in healthy birth outcomes, abused women may be at an increased risk for 
postpartum depression, especially because women who are abused during their pregnancy are 
likely to be abused after delivery as well.  Severe cases of physical abuse to a pregnant woman 
have direct effects on the fetus. For example, physical injury to fetus or fetal death associated 
with trauma to the mother. 
 
Caring for pregnant women experiencing IPV 
A study by Sharps et al in 2001 reported that within a year of her murder, 41% of women 
experiencing IVP had used health care agencies.
5
 Each contact with the healthcare system 
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represents an opportunity for intervention by health care providers to increase that woman’s 
awareness of her and her child’s risk of injury or death. It provides an opportunity to help the 
woman develop a safety plan and to receive services to address her personal needs.  Routine 
screening establishes that the problem of intimate partner violence is medically relevant. 
 
Screening should be done for all women, especially those of childbearing age. Steps in screening 
and interventions can be summarized in the acronym RADAR, which was developed by the 
Massachusetts Medical Society.  Routinely screen, Ask directly, Document your findings, 
Assess the patient’s safety and Review options and provide referrals. The steps of the RADAR 
process for screening/intervention are as follows: 
 
-Routinely screen for violence. Most women will not disclose violence in their relationships 
without being asked.  Screening should occur at various times over the course of the pregnancy, 
at the first prenatal visit, at least once per trimester and at postpartum checkup, as well as during 
the intranatal (labor) admission assessment. This is important because some women may need to 
be asked more than once about abuse and abuse may begin later in pregnancy. Many women will 
respond eventually if the questioning is sensitive and caring and the environment feels safe. 
Also, screen women and adolescents when they present to your unit with injuries (especially to 
breast, abdomen and genitals during pregnancy) that are not consistent with her explanation.  
 
-Ask about abuse in a non-judgmental way. It is important to ask about current as well as past 
relationships, because past events could have an effect on current situation. Partner control is a 
key factor in violence and abuse.  It is essential to ask questions in private, apart from the partner 
and apart from children, family and friends. The presence of a partner, who comes into the 
examining room with the patient and controls or dominates the interview, is overly solicitous and 
will not leave the patient alone with the provider, may be an indicator of abuse. 
 You may want to frame the questions about abuse by saying, for example, “because violence is 
so common in many people’s lives, I have begun to ask all my patients about it.” Ask direct 
questions:  
 “Are you in a relationship with a person who physically hurts or threatens you?” 
 “Within the last year, have you been hit, slapped, kicked or otherwise physically hurt by 
someone?” 
 “Since you’ve been pregnant, have you been hit slapped, kicked, or otherwise physically 
hurt by some one?” 
 “Within the last year, has anyone forced you to do something sexually that you didn’t 
want to do? 
 “Are you afraid of your partner or anyone else?” 
 
It is important to document the woman’s response, even when she says “no” and when you may 
suspect otherwise. When dealing with clear evidence of violence, even if denied, let a patient 
know that you and other staff are always available resources. Keep in mind that your questions 
about violence may help those who are experiencing violence move towards disclosure and help. 
Also a woman experiencing violence may be the best judge of her present situation and of her 
own and children’s safety. Other reasons for non-disclosure may include lack of trust in others, 
economic dependence on partner, desire to keep family together and fear of retaliation by violent 
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partner. When your patient confides that she is being abused, express support for her. Telling her 
that the abuse is not her fault and that no one deserves to be treated this way is a powerful short 
intervention. 
 
-Documentation of your findings is essential. Document your findings thoroughly in the 
patient’s chart, using the patient’s own words to describe the abuse. Use a body map to describe 
the locations of injuries. Ask her permission to take photographs of injuries. Documentation is 
one of the most important interventions for IPV. Medical records can be used by the woman to 
support charges of abuse is she chooses to do so. 
      
-Assess the safety of the woman and her children. Questions should focus on whether the 
violence or threat of violence has escalated recently and whether there are weapons in the home. 
If guns are present, threats to kill have been made, or violence has intensified, this is an 
emergency that requires the formulation of a safety plan before the patient is discharged.  
        
-Review options and provide referrals. This is the last step in the screening/intervention 
process. A team approach is helpful. Nurses are not, and don’t have to be, experts in all fields. 
Care will be more efficient if referrals were made to experts in the field of IPV.  Iowa’s rural 
conditions can contribute to make IPV more difficult to escape. The distance to and the 
unavailability of services, provides challenges to abuse women and to healthcare providers. 
Victim advocates, mental health services, social workers, trained clergy and legal services can 
help the woman think about her options: whether to stay with the abuser and develop a safety 
plan, remove the abuser through arrest or protective orders, or leave the relationship temporarily 
or permanently. Remember the woman alone is in the best position to determine what she should 
do. 
      
An indirect question during abuse assessment might be: “If a family member or friend was being 
hurt or threatened by a partner, do you know of resources that could help?” In our clinical 
settings, the staff should be provided with a list of local resources, shelters and hotlines. The 
National Domestic Violence hot line phone number is 1-800-799-SAFE (7233) Iowa State 
Hotline is 1-800-942-0333.  
      
Given the large numbers of women who are exposed to abuse, there will be many healthcare 
providers who are survivors or who may still be in an abusive relationship. Responding to 
women effectively requires taking care of ourselves; we may need to seek support within or 
outside our community. 
 
 
1. Healthy Iowa 2010 Mid- Course Revision on Violent and Abusive Behavior 
2. Chang, J, Berg, C., Saltzman, L. and Herndon, J.,” Homicide: A Leading Cause of Injury Deaths 
among Pregnant and Postpartum Women in the United States, 1991-1999”, American Journal of 
Public Health, Vol.95 No.3 March 2005 
3. Pluzzi and Houde-Quimby, “Domestic Violence. Implications for the American College of Nurse 
Midwives and its members. Journal of Midwifery and Women’s Health Vol. 41 No.6  Nov/Dec. 
1996 
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4. Espinosa and Osborne “Domestic Violence during Pregnancy: Implications for practice.” Journal 
of Midwifery and Women’s Health Vol. 47 No. 5 Sept/ Oct 2002 
5. Sharps et al,. “ Healthcare Providers’ Missed Opportunities for Preventing Femicide.”  Preventive 
Medicine Vol. 33 pp. 373-380, 2001 
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Appendix 31. Guidelines for Newborn Screening for Critical Congenital 
Heart Disease 
 
This guideline is intended for use by all individuals, including physicians, nurses, respiratory 
care practitioners, and clinical technicians involved in using pulse oximetry screening for critical 
congenital heart disease (CCHD) in newborns. The focus of this guideline is to provide guidance 
on the medical use of pulse oximetry devices for the sole intent of newborn screening for CCHD.  
 
Senate File 452 from the 85
th
 Iowa General Assembly was signed by the governor and went into 
effect July 1, 2013. Senate File 452 states:  
DIVISION VI 
NEWBORN CRITICAL CONGENITAL HEART DISEASE SCREENING 
 
Sec. 91. NEW SECTION. 136A.5A    Newborn critical congenital heart disease 
screening. 
1. Each newborn born in this state shall receive a critical congenital heart disease screening 
by pulse oximetry or other means as determined by rule, in conjunction with the 
metabolic screening required pursuant to section 136A.5. 
2. An attending health care provider shall ensure that every newborn under the provider's 
care receives the critical congenital heart disease screening. 
3. This section does not apply if a parent objects to the screening. If a parent objects to the 
screening of a newborn, the attending health care provider shall document the refusal in 
the newborn's medical record and shall obtain a written refusal from the parent and report 
the refusal to the department. 
4. Notwithstanding any provision to the contrary, the results of each newborn's critical 
congenital heart disease screening shall only be reported in a manner consistent with the 
reporting of the results of metabolic screenings pursuant to section 136A.5 if funding is 
available for implementation of the reporting requirement. 
This section shall be administered in accordance with rules adopted pursuant to section 136A.8. 
 
Sec. 92. NEWBORN CRITICAL CONGENITAL HEART DISEASE SCREENING.  
Notwithstanding any provision to the contrary relating to the newborn screening policy 
pursuant to 641 IAC 4.3(1), critical congenital heart disease screening shall be included in 
the state's newborn screening panel as included in the recommended uniform screening panel 
as approved by the United States secretary of health and human services. 
The center for congenital and inherited disorders advisory committee shall make 
recommendations regarding implementation of the screening and the center for congenital 
and inherited disorders shall adopt rules as necessary to implement the screening.
 However, reporting of the results of each newborn's critical congenital heart disease 
screening shall not be required unless funding is available for implementation of the 
reporting requirement. 
 
 
Introduction 
In September 2011, Department of Health and Human Services Secretary Kathleen Sebelius 
approved the addition of screening for critical congenital heart disease to each state’s newborn 
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screening panel. Screening for CCHD is accomplished by using pulse oximetry to estimate levels 
of arterial oxygen saturation in the newborn’s hand and foot.  
 
Pulse oximetry is a noninvasive method of estimating the arterial oxygen saturation and pulse 
rate (PR) from pulsatile absorption signals derived from a sensor placed on the skin. 
 
Pulse oximeters can be used for patients of all ages and are associated with minimal risk. Pulse 
oximetry should be performed by trained personnel who exercise sound judgment in selecting 
the site and sensor, interpreting the results, and formulating subsequent clinical decisions. 
 
Definitions 
Oxygen saturation: the amount of oxyhemoglobin in blood expressed as a percent fraction of 
amount of hemoglobin able to bind oxygen (oxyhemoglobin plus deoxyhemoglobin). 
 
Pulse rate: the pulse rate (PR) value is derived by a pulse oximeter and expressed in beats per 
minute (bpm). 
 
SaO2: oxygen saturation of arterial blood 
 
SpO2: in pulse oximetry, an estimate of the arterial oxygen saturation derived by measuring 
relative absorption of red and infrared light by pulsating arterial blood. 
 
Sensor: the part of the pulse oximeter applied to the patient that contains the light source(s) and 
detector(s); NOTE: this term is used interchangeably with the term “probe.” 
 
Indication for Use 
The fundamental purpose of pulse oximetry is to noninvasively assess the level of blood 
oxygenation to aid in the detection of hypoxemia or hyperoxemia. The most thorough assessment 
of a subject’s oxygenation status occurs via direct analysis of blood, which may include the 
measurement of arterial and mixed venous blood gases with laboratory oximetry. 
 
Newborn screening for critical congenital heart disease in well-baby and intermediate-care 
nurseries uses pulse oximetry to detect low blood oxygen saturation. 
 
Seven specific lesions are considered primary targets for screening: hypoplastic left heart 
syndrome, pulmonary atresia, tetralogy of Fallot, total anomalous pulmonary venous return, 
transposition of the great arteries, tricuspid atresia, and truncus arteriosis. This subset of lesions 
excludes those not usually associated with hypoxia, such as aortic valve stenosis. Although the 
primary goal of screening is identification of these seven specific lesions, other hypoxic cardiac 
or non-cardiac associated conditions (e.g., persistent pulmonary hypertension) may be detected 
(secondary targets). Tracking rates of detection of such secondary targets could lead to 
modifications of the screening guidelines. 
 
Pulse oximeters minimally display SpO2 as a percentage, an estimate of the functional arterial 
oxygen saturation (SaO2), and PR in bpm. Pulse oximeters do not require operator calibration 
and are non-invasive, making it a preferred method for screening for CCHD. 
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Environment of Use 
Pulse oximetry is prescribed by a physician or nurse practitioner, and its use should be medically 
supervised. The personnel directly responsible for its application should be trained and 
competent in the setup, short- and long-term use, the assessment of data reliability, and the 
limitations of the device. Perfusion and/or motion artifact can produce false-negative and false-
positive results. 
 
Newborn screening for CCHD will occur in well-baby and intermediate nurseries—those areas 
where newborns may appear healthy-looking and have shorter stays than an intensive care 
nursery. 
 
Instrument 
A pulse oximeter is composed of a sensor and a monitor, which may be combined in a single 
assembly. Most commonly, the photodetector is positioned opposite the light source. Pulse 
oximeters cannot be calibrated by the operator. The primary available method for determining 
the accuracy of an SpO2 reading is to compare it with measurements of arterial blood using a 
laboratory oximeter. 
 
The performance of a pulse oximeter can be adversely affected by the patient/sensor interface 
(i.e., the site selected and the type of sensor). It is essential to select a sensor that is appropriate 
for use on the newborn hand and foot, and that the sensor is correctly aligned and securely fitted 
to the patient. The site should also be well perfused and free of artifact sources (e.g., deep skin 
pigmentation, extraneous light, venous congestion, and motion. 
 
Screening should be done with motion-tolerant pulse oximeters that report functional oxygen 
saturation, have been validated in low perfusion conditions, have been cleared by the FDA for 
use in newborns, and have a 2 percent root-mean-square accuracy. A new guidance document of 
the safety and effectiveness of pulse oximeters is being developed by the FDA, and when the 
guidance document is finalized, any pulse oximeter used for screening should meet FDA 
recommendations. 
 
Pulse oximeters can be used with either disposable or reusable probes. Reusable probes can 
reduce the cost of screening, but must be appropriately cleaned between uses to minimize the 
risk of infection. Pulse oximeter probes may be a source of contamination. 
 
Standard precautions—universal precautions and body substance isolation practices—should be 
used as it is impossible to know what isolates or specimens might be infectious. 
 
The adhesives and materials used in the construction of disposable and reusable probes are 
generally latex-free but should be verified by the operator in conditions of known sensitivity. 
 
As with any patient monitoring device that uses wire leads, there can be a risk of entanglement. 
 
To prevent damage, soaking or immersing the pulse oximeter sensor in any liquid should be 
avoided. If the sensor is damaged in any way, it should be replaced immediately. 
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There is a need for ongoing assessment of the sensor site, type of sensor used, and device to limit 
the complications and optimize the performance of pulse oximetry. 
 
Site Selection and Preparation 
 Application of the sensor for newborn screening for CCHD should be on the right hand 
and either foot. In cases of poor perfusion, local rewarming of sensor sites may restore 
adequate signal quality. Covering the site with a nonrestrictive bootie can correct poor 
perfusion. 
 The site should be well perfused and completely cover the sensor’s detector. 
 The site should be cleaned of debris and dry before sensor placement. 
 In newborns, the palm of the hand and lateral aspect of the foot are the preferred sites. 
See diagram below. 
 
Preferred pulse oximetry sites for newborn screening for CCHD 
 
 The extremity should be free of a blood pressure cuff or IV or intra-arterial catheters. 
 In the presence of sources of bright light, covering the sensor site with an opaque material 
will minimize the potential for ambient light interference, which can cause inaccurate 
readings. 
 Probes with close coupling to skin (i.e., taped rather than clamped), will provide better 
performance, however care must be taken to not damage fragile newborn skin. Adhesive 
sensors should not be wrapped too tightly. 
 When applied to the selected area, the optical components must be properly aligned 
across a capillary bed. 
 Do not hold the sensor in place, as that interferes with the signal. 
 Anecdotal reports suggest that false positives are decreased if the infant is alert. In 
addition, timing the pulse oximetry screening around the time of the newborn hearing 
screening increases efficiency, assuming that the hearing screening is conducted at least 
24 hours after birth or immediately prior to discharge. 
 Use the same machine to test both the hand and foot to assure consistency of the 
readings. 
 Take the reading on the foot first—baby may get fussy when opening up the hand to get a 
reading - doing the foot first while the baby is calm will help get a good reading in the 
foot. 
 You may do the screen as the baby is nursing, just be sure the sensor is aligned properly. 
 Pulse oximeters are validated only with the specific probes recommended by the 
manufacturer; therefore, to optimize valid screening, manufacturer-recommended pulse 
oximeter-probe combinations should be used. Third-party reprocessed sensors should not 
be used unless the original manufacturers of the sensors and instruments have approved 
the reprocessed sensors for the intended applications. 
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Screening Criteria 
 Screening should not occur until 24 hours of life, or as late as possible if earlier discharge 
is planned, and be completed by the second day of life. Earlier screening can lead to false 
positive results because of the transition from fetal to neonatal circulation and 
stabilization of systemic oxygen saturation levels. Later screening can miss an 
opportunity for intervention before closing of the ductus arteriosus. 
 
 Screening is recommended in the right hand and either foot. See diagram for probe 
placement.  
 
 The pulse oximetry measure is complete once the waveform on the oximeter’s 
plethysmograph is stable or there is other indication that the device is appropriately 
tracking the baby’s pulse rate. 
 A screen would be considered positive when (1) any oxygen saturation measure is below 
90%; (2) oxygen saturation is below 95% in both extremities on three measures each 
separated by one hour; or (3) there is a greater than 3% absolute difference in oxygen 
saturation between the right hand and the foot on three different measures each separated 
by one hour. 
 Any screening that is higher than or equal to 95% in either extremity  with less than or 
equal to 3% absolute difference in oxygen saturation between the hand and foot would be 
considered a pass and CCHD screening would end. 
 
The screening protocol is described below. 
 
Follow up for the Positive Screen 
The newborn’s primary care physician (PCP) should be notified immediately of any abnormal 
screening results. The newborn should NOT be discharged. Support the newborn as per orders 
from the PCP. 
 
After evaluation by the PCP, if there is not a respiratory reason for the positive screen, the PCP 
should obtain a consultation with a pediatric cardiologist and neonatologist from the provider list 
for the area. 
 
If the birth facility has the capacity for pediatric echocardiography, prepare the infant for an 
echocardiogram, per physician orders. Transmit the results of the echocardiogram to the pediatric 
cardiologist, if they are off site. 
 
If the birth facility does not have the capacity to conduct a pediatric echocardiogram, arrange for 
transport to a perinatal center. 
 
Parent Education 
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Parents should be informed of the pulse oximetry screening prior to administration of the screen. 
Information may be provided at the same time the parents are informed of the other newborn 
screening procedures. A frequently asked question (FAQ) sheet is available from the Iowa 
Department of Public Health CCHD screening web page, available at 
http://www.idph.state.ia.us/genetics/newborn_screening.asp, accessed June 26, 2013.   
 
Parents should also receive communication and explanation of any abnormal screening results 
and the expected plan of care regarding the result. Parents may refuse the pulse oximetry 
screening. The health care provider should discuss this refusal with the parents to assure they 
understand the ramifications of a missed condition. The refusal should be documented in the 
baby’s medical record, and any waiver forms should be completed according to hospital policy 
and procedures. 
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Figure 1 
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Appendix 32. Management of Late-Preterm Infants  
 
Late-preterm refers to infants born at 34 0/7 through 36/6/7 weeks’ gestation. They are often 
managed in Level I nurseries because their size and weight may be similar to that of term infants. 
However, these infants are both physiologically and developmentally immature. This puts them 
at higher risk for developing medical complications that can result in higher rates of morbidity 
and mortality during and after their birth hospitalization. During their birth hospitalization, late-
preterm infants are at risk for respiratory distress, apnea, temperature instability, hypoglycemia, 
hyperbilirubinemia and poor feeding. During the first month after birth, they are more likely to 
be readmitted to the hospital for jaundice, feeding difficulties, dehydration and suspected sepsis. 
 
When late-preterm birth is necessary due to fetal or maternal complications in pregnancy, 
collaborative counseling by obstetric and neonatal clinicians about fetal, neonatal and maternal 
outcomes is warranted. Information regarding gestational age-specific outcomes can help to 
prepare families for the infant’s anticipated course in the nursery. Parents of late-preterm infants 
may also need additional guidance and education before discharge from the hospital. Infants who 
are first born or breastfed are particularly vulnerable to complications that may result in hospital 
readmission. It is important to educate first-time mothers on how to evaluate feeding success and 
recognize the signs of dehydration and jaundice. This education may necessitate a longer hospital 
stay. After discharge, late-preterm infants require closer follow-up with their medical care 
provider.  
 
In 2007, the American Academy of Pediatrics (AAP) published a clinical report, “Late-Preterm 
Infants: A Population at Risk,”1 available at: 
http://pediatrics.aappublications.org/content/120/6/1390.full, accessed June 26, 2013. The 
authors describe the characteristics of late-preterm infants that predispose them to a higher risk 
of morbidity and mortality than term infants and propose guidelines for the evaluation and 
management of these infants after birth. The AAP guideline includes minimum discharge criteria 
for late-preterm infants that are intended to reflect evidence of the following prior to discharge: 
physiologic maturity; feeding competency; thermoregulation; maternal education; assessment 
and planned interventions for medical, family, environmental, and social risk factors; and follow-
up arrangements.
 
Practitioners are encouraged to refer to these guidelines when caring for late-
preterm infants and their mothers. 
 
Resources 
 National Perinatal Association: “Multidisciplinary Guidelines for the Care of Late 
Preterm Infants” ©2007-2013 NPA; Available at: http://www.nationalperinatal.org/, 
accessed June 26, 2013. 
 
 Association of Women’s Health, Obstetric and Neonatal Nurses: “AWHONN Late 
Preterm Infant Assessment and Intervention Guide” ©2007 
 
 
1. American Academy of Pediatrics. Clinical Report—“Late-preterm” infants: a population at risk. 
Pediatrics. 2007; 120(6):1390-1401. Available at: 
http://pediatrics.aappublications.org/content/120/6/1390.full. Accessed May 2, 2013. 
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Appendix 33. Management of Newborns with Suspected Early-Onset 
Sepsis 
 
The 2010 updated CDC guidelines provide more guidance for the treatment of newborns and aim 
to reduce unnecessary evaluations.
1
 The current guidelines are based on the child’s clinical 
appearance and gestational age, as well as maternal factors such as chorioamnionitis, prolonged 
rupture of membranes, and adequacy of the IAP. The definition of adequate IAP has also been 
clarified; adequate IAP is defined as the administration of penicillin, ampicillin, or cefazolin for at 
least 4 hours prior to delivery. Any other agent or duration is considered inadequate.  
 
In 2012, the American Academy of Pediatrics (AAP) published a clinical report, “Management 
of Neonates With Suspected or Proven Early-Onset Bacterial Sepsis.”2 The authors identify three 
challenges that clinicians face: 1) identifying neonates with a high likelihood of sepsis promptly 
and initiating antimicrobial treatment; 2) distinguishing “high-risk” healthy-appearing infants or 
infants with clinical signs who do not require treatment; and 3) discontinuing antimicrobial 
therapy once sepsis is deemed unlikely. They provide the following guidelines. 
 
Guidelines for the newborn WITH signs of sepsis: 
 Newborns who have risk factors for infection should receive a full evaluation and broad-
spectrum antibiotic therapy should be initiated after cultures are obtained. 
 A full evaluation includes the following: a complete blood count (CBC) with differential 
and platelets; a blood culture; a chest radiograph if respiratory abnormalities are present; 
and a lumbar puncture if the infant can safely undergo the procedure; evaluation may 
include a C-reactive protein (CRP) obtained at birth and/or 6-12 hours of life. A follow-
up CBC with differential and CRP at 24-48 hours of life may be indicated. 
o One milliliter of blood drawn before initiating antibiotic therapy is needed to 
adequately detect bacteremia when using a pediatric culture bottle. 
o Lumbar puncture is also indicated if the infant: 1) has a positive blood culture; 2) 
is likely to become bacteremic (on the basis of clinical status or laboratory data); 
and 3) does not respond to antimicrobial therapy in the expected manner. 
o Cultures of superficial body sites, gastric aspirates, and urine are of no value in 
the diagnosis of early-onset sepsis. 
 Broad-spectrum antibiotic therapy should be directed toward the most common causes of 
neonatal sepsis, including ampicillin for GBS and coverage for other organisms 
(including Escherichia coli and other gram-negative pathogens). The optimal 
antimicrobial agents are ampicillin and an aminoglycoside, usually gentamicin.
2
 
o Once a pathogen is identified, antimicrobial therapy can be narrowed. 
o Antibiotic therapy should be discontinued at 48 hours in clinical situations where 
the probability of sepsis is low. 
o Third-generation cephalosporins: Studies have reported rapid development of 
resistance when cefotaxime was routinely used for the treatment of early-onset 
sepsis
3
 and extensive/prolonged use of third-generation cephalosporins is a risk 
factor for invasive candidiasis.
4
 
o Empirical or therapeutic use of cefotaxime should be restricted for use in infants 
with meningitis attributable to Gram-negative organisms.
2
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 “More mature newborns” without risk factors for infection with relatively mild findings 
(tachypnea with or without an oxygen requirement) who clinically improve over the first 
6 hours of life (eg, need for oxygen is decreasing and respiratory distress is resolving) 
may be observed without antibiotic therapy; any worsening of the infant’s condition 
should prompt a full evaluation and initiation of antibiotic therapy.
2
 
  
Guidelines for the newborn WITHOUT signs of sepsis: 
 If intrapartum antibiotic prophylaxis (IAP) is indicated for the mother without 
chorioamnionitis and she receives adequate IAP: The asymptomatic newborn requires 
only observation for at least 48 hours. 
o If the infant remains asymptomatic, no additional diagnostic testing is necessary.  
o If signs of sepsis develop, a full diagnostic evaluation should be performed and 
antibiotic therapy should be initiated.  
 If chorioamnionitis is diagnosed clinically: An infant born at  37 weeks’ gestation 
should receive a limited evaluation and broad-spectrum antibiotic therapy should be 
initiated. A limited evaluation includes a blood culture at birth and a CBC with 
differential at birth and/or 6-12 hours of life; evaluation may include a C-reactive protein 
(CRP) obtained at birth and/or 6-12 hours of life. A follow-up CBC with differential and 
CRP at 24-48 hours of life may be indicated. Consultation with obstetric providers is 
important to determine the level of clinical suspicion for chorioamnionitis.  
o If the blood culture is negative and laboratory data remain normal and the infant 
remains well, antibiotic therapy can be discontinued by 48 hours and the infant 
can be discharged from the hospital. 
o If the laboratory data are abnormal and the blood culture is negative, continue 
antibiotic therapy if the mother received antibiotics during labor and delivery. 
Consultation with a referral center may be needed. 
o If the blood culture is positive, continue antibiotic therapy and perform a lumbar 
puncture if possible. Consultation with a referral center should be considered. 
 If membranes are ruptured >18 hours or IAP is indicated but inadequate: An infant born 
at  37 weeks’ gestation should receive a CBC with differential at 6-12 hours of life; 
evaluation may include a C-reactive protein (CRP) obtained at 6-12 hours of life. No 
antibiotics are needed; observation is required for at least 48 hours. 
o If the laboratory data are normal and the infant remains well, he can be discharged 
by 48 hours. 
o If the laboratory data are abnormal, a blood culture should be performed; if the 
blood culture is negative and the infant remains well, he can be discharged by 48 
hours.  
o If the blood culture is positive, initiate antibiotic therapy and perform a lumbar 
puncture if possible. Consultation with a referral center should be considered. 
 If membranes are ruptured <18 hours and IAP are indicated but inadequate (no 
chorioamnionitis): An infant born at  37 weeks’ gestation requires only observation for 
at least 48 hours.  
o If the infant remains asymptomatic, no additional diagnostic testing is necessary.  
o Observation may occur at home after 24 hours if other discharge criteria have 
been met. Access to medical care must be readily available and a person who is 
able to comply fully with instructions for home observation should be present. If 
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any of these conditions are not met, the infant should be observed in the hospital 
for at least 48 hours and until discharge criteria are achieved. 
 If chorioamnionitis is diagnosed clinically or membranes are ruptured >18 hours or IAP 
is indicated but inadequate (regardless of timing of rupture of membranes): An infant 
born at <37 weeks’ gestation should receive a limited evaluation and broad-spectrum 
antibiotic therapy should be initiated. A limited evaluation includes a blood culture at 
birth and a CBC with differential at birth and/or 6-12 hours of life; evaluation may 
include a C-reactive protein (CRP) obtained at birth and/or 6-12 hours of life. A follow-
up CBC with differential and CRP at 24-48 hours of life may be indicated. Consultation 
with obstetric providers is important to determine the level of clinical suspicion for 
chorioamnionitis.  
o If the blood culture is negative and laboratory data remain normal and the infant 
remains well, antibiotic therapy can be discontinued by 48 hours. 
o If the blood culture is negative and the infant remains well, but laboratory data are 
abnormal continue antibiotic therapy if the mother received antibiotics during 
labor and delivery. Consultation with a referral center may be needed. 
o If the blood culture is positive, continue antibiotic therapy and perform a lumbar 
puncture if possible. Consultation with a referral center should be considered. 
 
1. Prevention of Perinatal Group B Streptococcal Disease -- Revised Guidelines from CDC, 2010. 
MMWR Recomm Rep. Nov 19 2010; 59(RR-10):1-36. 
2. American Academy of Pediatrics. Clinical Report—Management of neonates with suspected or 
proven early-onset bacterial sepsis. Pediatrics. 2012; 129(5):1006-1015. Available at: 
http://pediatrics.aappublications.org/content/129/5/1006.  Accessed June 4, 2013. 
3. Bryan CS, John JF, Jr, Pai MS, Austin TL. Gentamicin vs cefotaxime for therapy of neonatal 
sepsis. Relationship to drug resistance. Am J Dis Child. 1985;139(11):1086-1089. 
4. Manzoni P, Farina D, Leonessa M, et al. Risk factors for progression to invasive fungal infection 
in preterm neonates with fungal  colonization. Pediatrics. 2006;118(6):2359-2364. 
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Appendix 34. Neonatal Abstinence Syndrome 
 
Neonatal Abstinence Syndrome 
Neonatal Abstinence Syndrome (NAS) refers to the withdrawal symptoms a newborn 
experiences after birth when there has been intrauterine exposure to certain illicit or prescription 
drugs. NAS occurs in approximately 55-94% of drug-exposed infants and is most commonly 
seen with opioid exposure. However, exposure to sedatives, barbiturates, polysubstance abuse 
and occasionally alcohol exposure may cause NAS. The onset of withdrawal depends on the 
half-life of the drug, duration of the mother’s addiction, and time of the last maternal dose prior 
to delivery. On average, the observation period for withdrawal symptoms to appear is 3 days. 
Preterm infants may exhibit fewer signs of withdrawal than late preterm and term infants.  
 
NAS Scoring: 
The Finnegan Scoring System is the tool used most often to quantify the severity of NAS 
symptoms (Fig 1). Scoring should begin within the first 2 hours of life and continue every 4 
hours when symptoms are present. Pharmacologic therapy is indicated when 3 consecutive 
Finnegan scores are > 8 or when the sum of 3 consecutive Finnegan scores is > 24.  
 
Pharmacologic Therapy: 
Morphine is usually the first-line agent and mainstay of treatment. Phenobarbital is the first-line 
additional therapy for polysubstance exposure and may be used in combination with opioid 
therapy for NAS secondary to opiate withdrawal. Opioid dependency is likely seen after 
exposure to buprenorphine (Subutex), codeine, heroin, hydrocodone (Lortab, Vicodin), 
hydromorphone (Dilaudid), methadone, morphine, oxycodone (Percocet). Polysubstance-
dependency is likely seen with the above drugs as well as barbiturates, sedatives, SSRIs.  
 
Specific guidelines for pharmacologic management of NAS from the University of Iowa 
Children’s Hospital are available at: https://thepoint.healthcare.uiowa.edu/sites/Policies-
UIHCPolicies/neonateguidelines/default.aspx, accessed June 26, 2013.   
 
Non-Pharmacologic Interventions: 
 Swaddling 
 Rocking 
 Minimal sensory or environmental stimulation 
 Maintain temperature stability 
 Feed (consider alternating bottle and pacifier during feed to compensate for excessive sucking 
and possibly prevent emesis) 
 Breast milk feedings when appropriate can help reduce the need for pharmacological intervention 
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Figure 1: Modified Finnegan Scoring System
10 
System Symptoms Points Score 
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Excessive high pitched (or other) cry (< 5 min) 
Continuous high pitched (or other) cry (> 5 min) 
2 
3 
   
Sleep < 1 hour after feeding 
Sleep < 2 hours after feeding 
Sleep < 3 hours after feeding 
3 
2 
1 
   
Hyperactive Moro reflex 
Moderately hyperactive Moro reflex 
2 
3 
   
Mild tremors when disturbed 
Moderate-severe tremors when disturbed 
1 
2 
   
Mild tremors when undisturbed 
Moderate-severe tremors when undisturbed 
3 
4 
   
Increased muscle tone 1    
Excoriation (eg. Chin, knees, elbows, toes, nose) 1    
Myclonic jerks (twitching/jerking of limbs) 3    
Generalized convulsions 5    
M
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V
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R
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ry
 
Sweating 1    
Hyperthermia (37.2 – 38.2°C) 
Hyperthermia (≥ 38.4°C) 
1 
2 
   
Frequent yawning (>3-4/interval) 1    
Molting 1    
Nasal stuffiness 1    
Frequent sneezing (> 3-4/interval) 1    
Nasal flaring 2    
Respiratory rate > 60/min 
Respiratory rate > 60/min with retractions 
1 
2 
   
G
a
st
ro
-
in
te
st
in
a
l 
Excessive sucking 1    
Poor feeding (infrequent/uncoordinated suck) 2    
Regurgitation (≥2 times during/past feed) 
Projectile vomiting 
2 
3 
   
Loose stool  
Watery stool  
2 
3 
   
 TOTAL SCORE     
 
 
 
 
 
 
Appendix 34 
Guidelines for Perinatal Services, Eighth Edition, Appendices Updated August 2013  126 
1. American Academy of Pediatrics, Committee on Drugs. Neonatal drug withdrawal. 
Pediatrics. 1998; 101(6):1079-1088. 
2. Greene, CM and Goodman, MH. Neonatal abstinence syndrome: strategies for care of the 
drug-exposed infant. Neonatal Network. 2003; 22(4):15-25. 
3. Taeusch H, Ballard R, Gleason C. (2005) Avery’s Diseases of the Newborn (8th ed.). 
Philadelphia, PA: Elsevier, Saunders, pp.106-126. 
4. Finnegan LP. Neonatal abstinence syndrome: assessment and pharmacotherapy. In: Nelson N, 
editor. Current therapy in neonatal-perinatal medicine. 2 ed. Ontario: BC Decker; 1990. 
5. American Academy of Pediatrics, Hudak ML, Tan RC, Committee on Drugs, Committee on 
Fetus and Newborn. Neonatal Drug Withdrawal. Pediatrics. 2012; 129(2):540-560. 
6. Bio LL, Siu A, Poon CY. Update on the pharmacologic management of neonatal 
abstinence syndrome. J Perinatol. 2011; 31:692-701.  
 
 
 
